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Splicing of pre-messenger RNA (pre-mRNA) is catalyzed by the spliceosome, a 
multimegadalton ribonucleoprotein (RNP) comprising several small nuclear (sn) 
RNPs and numerous proteins. The spliceosome assembles on its pre-mRNA substrate 
in an ordered process that begins with recognition of the 5' end of the intron (5' splice 
site, 5'SS) by the U1 snRNP. Thereafter the U2 snRNP binds to the pre-mRNA's 
branch point sequence (BPS), forming complex A. Complex A then binds the pre-
formed U4/U6·U5 tri-snRNP to form complex B, which contains a full set of snRNAs 
in a pre-catalytic state. Complex B is then activated for catalysis by a major 
rearrangement of its RNA network and its overall structure; this remodeling includes 
dissociation of the U1 and U4 snRNAs and the formation of the activated spliceosome 
B
act
. In the catalytically activated complex (termed B*) step 1 catalysis takes place: 
the adenosine at the BPS attacks the 5'SS, generating a cleaved 5' exon and intron-3' 
exon intermediate. The resulting complex C then catalyzes step 2 catalysis, in which 
the intron is cleaved at the 3' splice site (3'SS) with concomitant ligation of the 5' and 
3' exons to form mature mRNA. Thus, the spliceosome is a particularly dynamic RNP 
machine that undergoes many changes in composition and conformation. The 
structural dynamics of the spliceosome are facilitated by the action of multiple 
DExD/H-box RNA helicases. Among these are Prp5 and Prp2, which are essential 
ATPase required prior to the first step of pre-mRNA splicing. Prp5 enables stable U2 
snRNP association with the branch site and Prp2 promotes a structural rearrangement 
that transforms the B
act 
into the catalytically activated B* complex.  
The pathway of spliceosome assembly and the main features of its catalytic chemistry 
appear to be conserved between metazoans and yeast. Thus, I set out to study isolated 
spliceosomal complexes from the lower eukaryote Saccharomyces cerevisiae as it 
was already known to possess a basic (constitutive) spliceosomal machinery similar to 
that of primates. Each new round of splicing generates a catalytic centre de novo 
during the transitions from complex B to B
act
 to B* and to the product of step 1 of 
splicing, complex C. Here, I focused on the isolation and characterization of complex 
B, the activated complex B
act
 and complex C. Each complex was stalled via truncation 
or modification of the actin pre-mRNA used during the splicing reaction or 
adjustment of the ATP concentration in the splicing reaction. Each complex was then 
 
 
isolated by centrifugation and affinity-selection, their proteomes determined by mass 
spectrometry (in collaboration with Prof. Henning Urlaub) and their structures 
examined by electron microscopy (in collaboration with Dr. Berthold Kastner and 
Prof. Holger Stark), for the first time. The analysis of the three stalled yeast 
spliceosomal “snapshots” isolated here has made it possible to pinpoint the window of 
function for important spliceosomal proteins. For instance, the number, characteristics 
and time of recruitment of evolutionarily conserved proteins involved in the formation 
and stabilization of the U2/U6/pre-mRNA network of the catalytic center in complex 
B
act 
remained so far elusive. The data revealed several evolutionarily conserved 
proteins recruited at the time of pre-catalytic activation (i.e. Cwc2, Cwc24, Yju2, 
Prp2 and Spp2) and also provided important hints for those proteins involved in 
promoting step 1 catalysis and the formation of complex C (i.e. Cwc25). Compared to 
metazoan spliceosomes the number of proteins associated with purified yeast 
spliceosomes at any stage is less than a half, yet more than 85% of these have 
evolutionarily conserved counterpart in humans. The less complex protein 
composition of yeast spliceosomes offers also a significant advantage for 
three-dimensional (3D) structure analyses. The EM analyses show for the first time 
images of S. cerevisiae spliceosomal complexes at well defined stages of function. 
These are at an unprecedented quality level, and they are well suited for 3D structure 
investigations, based on criteria such as their structural integrity and homogeneity.  
In this work I have also applied dual-color fluorescence cross-correlation 
spectroscopy (dcFCCS, in collaboration with Prof. Jörg Enderlein, III. Institute of 
Physics, University of Göttingen), to measure the binding affinity of splicing factors – 
which were detected in the first part of this work – to the yeast spliceosome and to 
follow their binding dynamics during the catalytic activation of the spliceosome 
promoted by the RNA helicase/ATPase Prp2 and its co-activator Spp2. dcFCCS is a 
sensitive and versatile optical technique that allows the direct analysis of the dynamic 
association and dissociation events among proteins and/or RNAs in complex systems 
in solution at low nanomolar concentrations and in equilibrium, without requiring 
biochemical or physical perturbation of the sample. For this purpose I have employed 
a recently described purified splicing system developed in our laboratory which 




complexes assembled in extracts where Prp2 is thermo sensitive and can be heat-
inactivated. These B
act
 complexes lacking Prp2 are then purified to near homogeneity 
and complemented with recombinantly expressed Prp2 and Spp2 splicing factors. To 
perform dcFCCS, the B
act
 complexes were assembled on pre-mRNA labeled with a 
red fluorescent dye. In addition, spliceosomal proteins of interest were labeled in vivo 
by fusing them with the green fluorescent protein EGFP, by genetic modification in 
yeast. The purified doubly-labelled spliceosomes were then analyzed before and after 
catalytic activation by Prp2 and the weakening or strengthening of the binding of the 
EGFP-labeled protein to the spliceosome was analyzed by measuring the cross-
correlation between the green label and the red fluorescent dye. The analysis and 
evaluation of the dcFCCS data in this work was done in collaboration with Prof. Jörg 
Enderlein and Mira Prior (III. Institute of Physics, University of Göttingen). 
 The data revealed that the binding affinity of quite a number of proteins is 
significantly changed during the Prp2-mediated catalytic activation of the 
spliceosome. Specifically, the essential zinc finger protein Cwc24, was quantitatively 
displaced from the B* complex. Consistent with this, we show that Cwc24 is required 
for step 1 but not for catalysis per se. Interestingly, the U2-associated SF3a and SF3b 
proteins Prp11 and Cus1 were destabilized during catalytic activation. Indeed, they 
remained bound to the B* spliceosome under near-physiological conditions (i.e. 75 
mM), but their binding was reduced at higher salt. As the U2 SF3a/b proteins bind 
near the branch point sequence, this indicated that the branch site must be remodeled 
in complex B* as a prerequisite for step 1 catalysis. On the other hand, high affinity 
binding sites were created for the step 1 factors Yju2 and Cwc25 during catalytic 
activation, consistent with their requirement for step 1 catalysis. In conclusion, These 
results shed light on the nature of the structural remodeling mediated by Prp2 in the 
spliceosome and suggest that during catalytic activation the spliceosome undergoes 














1.1 From genes to proteins 
The blueprint of cells is encoded in their DNA. The flow of information from genes to 
proteins requires two main steps, termed transcription and translation. Transcription is 
a DNA-controlled process where DNA is “transcribed” into RNA; translation is the 
RNA-controlled synthesis of proteins. In eukaryotic cells, genes are expressed as 
precursor messenger RNAs (pre-mRNAs) due to the fact that in higher eukaryotes the 
coding sequences of genes, the exons are interrupted by non-coding sequences, the 
introns. These mosaic structure or split genes, is only found in eukaryotes. First, the 
precursor is synthesized/transcribed by the polymerase II. After transcription and 
before the transport out of the nucleus into the cytoplasm, the precursor RNA has to 
undergo a maturation process or so-called RNA processing step. Due to the split gene 
character, the non-coding sequences have to be removed from the precursor 
messenger RNA by a mechanism called splicing. During this process, introns are 
removed from the precursor and the flanking sequences, the exons, are joined to build 
the functional mature RNA. RNA processing includes in addition to splicing, the 
modification of both ends of the pre-mRNA: capping of the 5’ end and 
polyadenylation of the 3’ end. Both modifications play an important role in mRNA 
export, stability and translation and occur co-transcriptionally. After RNA processing 
the mature RNA can be transported from the nucleus to the cytoplasm, where it is 
used by ribosomes as a template for the synthesis of the amino-acid sequence, leading 
to the formation of a protein. 
1.2 Conserved sequences and pre-mRNA splicing 
Splicing itself is catalyzed by a macromolecular machinery, the spliceosome and 
requires a set of specific sequences contained within the intron. The boundaries of 
exons and introns must be precisely identified by the spliceosome, because an error of 
only one nucleotide would result in a shift of the gene’s reading frame and would lead 





The process of pre-mRNA splicing is highly conserved from yeast to humans; 
however the degree to which it occurs is clearly different (Ast, 2004). Whereas nearly 
all human genes contain introns, the yeast Saccharomyces (S.) cerevisiae has introns 
in only ~3-4% of its genes (Lopez and Seraphin 1999). Interestingly, about 70% of 
genes encoding for ribosomal proteins contains an intron. Introns vary in their length 
and sequences and exon-intron boundaries are only defined by very short sequence 
stretches, which makes the process of splicing challenging, but both organisms, 
humans and yeast are suitable models for in vitro studies and for understanding the 
highly conserved splicing process. In pre-mRNA transcripts three conserved 
sequences our found which are recognized by different factors during the splicing 
process. The sequences are the 5’ splice site (5’SS), the branch point sequence (BPS) 
and the 3’splice site (3’SS). 
In the yeast (S. cerevisiae) these elements are highly conserved (Fig. 1.1).  
 
The (5’SS) sequence defines the boundary between an exon and a downstream intron 
and is composed of R/GUAUGU (‘R’ is a purine, ‘/’ indicates the exon/intron 
boundary)(Lopez and Seraphin 1999). While in S. cerevisiae the 5’SS is 90% 
conserved, the human consensus sequence AG/GUAGU is rather degenerated.  
The (3’SS) sequence defines the boundary between an intron and a downstream exon 
and is composed of YAG/ (‘Y’ is a pyrimidine, ‘/’ indicates the exon/intron 
boundary) in S. cerevisiae as well as in H. sapiens. In many introns the 3’SS is 
preceded by a stretch of 8-12 pyrimidines called the polypyrimidine tract, which 
 
Figure 1.1: Conserved sequences in intron of S.cerevisiae and Homo sapiens 







usually ends one nucleotide upstream of the 3´SS. The polypyrimidine tract seems to 
be more important for splicing of human than for splicing of yeast introns. 
Another conserved sequence element surrounds the adenosine (branch adenosine, 
branch point, BP), - which forms a branched intermediate in the course of the first 
step of splicing. This sequence is therefore called branch point sequence (BPS). The 
consensus sequence is composed of UACUAAC and in yeast it is usually located 10-
60 nucleotides upstream of the 3’SS (Spingola, Grate et al. 1999). 
 





Figure 1.2: The chemistry of the pre-mRNA splicing reactions (Figure was kindly provided 
by Dr. Nicolas Rasche) Pre-mRNA splicing is carried out via a two transesterification step mechanism. Step 
1 results in formation of a free 5’ exon and a lariat-3’ exon (lariat intermediate). Step 2 produces the ligated 







The process of pre-mRNA splicing consists of a two steps mechanism involving two 
consecutive transesterification reactions (Moore, Query et al. 1993; Moore and Sharp 
1993) . In the first step, the 2’-hydroxyl group (OH) of the conserved branch point 
adenosine as a nucleophile attacks the phosphate at the 5’SS (5’exon/intron junction) 
resulting in a free 5’ exon which contains a 3’ terminal OH group and a branched 
lariat intermediate which contains an unusual 2’-5’ phosphodieseter bond at the 
branchpoint adenosine (Fig. 1.2). In the second step, the 3’ OH of the 5’ exon attacks 
the phosphate at the intron/3’ exon boundary (3’SS) followed by the ligation of the 5’ 
and 3’ exons and the release of the intron lariat. Subsequently, the mRNA is 
transported to the cytoplasm, whereas the intron lariat is degraded (Nilsen 1998); 
(Will and Luhrmann 2011). The splicing process is dependent on ATP. 
                   
1.4 SnRNPs – the building blocks of the spliceosome 
The snRNPs are the main building blocks of the spliceosome. Each of these consists 
of a snRNA molecule (or two in the case of U4/U6), seven Sm proteins (B/B’, D3, 
D2, D1, E, F, and G) that are shared by all of the spliceosomal snRNPs and several 
other, particle specific proteins (Brow 2002); (Will and Luhrmann 2011); (Wahl, Will 
et al. (2009); (Valadkhan and Jaladat (2011). More than 50 proteins are associated 
with the snRNPs and more than 100 non-snRNP proteins are in the spliceosome as 
revealed by mass spectrometry studies (Wahl, Will et al. 2009).  In total five 
spliceosomal snRNAs are found in the yeast S.cerevisiae termed U1, U2, U4, U5 and 
U6. U5 exist in two isoforms: U5 long and U5 short, which originate from the same 
precursor transcript, but are differently cleaved at the 3’-stem loop by RNaseIII 








Figure 1.3: Secondary structures for the yeast U snRNAs 
Schematic representation of proposed secondary structures of yeast snRNAs. The Sm binding site is indicated with 
a grey shadow. The conserved ACAGAGA box motif in U6 snRNA is underlined (adapted from Kretzner, Krol et 
al. (1990)(U1); (Shuster and Guthrie 1988)(U2); Frank, Roiha et al. (1994); (Will and Lührmann 2006)(U5); (Brow 






The U snRNAs, except U6, are transcribed by the RNA polymerase II as snRNA 
precursors that acquire an m
7
G cap. U6 snRNA is transcribed by the polymerase III 
and bears a γ-monomethyl phosphate cap at its 5’-end (Singh and Reddy 1989). These 
pre-U snRNAs are subsequently exported to the cytoplasm where the snRNP 
assembly occurs (Kiss and Jady 2004);(Will and Lührmann 2001). In the cytoplasm, 
the seven Sm proteins bind to the Sm RNA site, a uridine rich consensus sequence, 
found in each of the snRNAs, except U6, and form a doughnut-shaped structure 
around the Sm binding site. In contrast, U6 bears a so-called Sm-like binding site 
(Lsm) at its 3’ end, which also shows a high uridine content. To the Lsm site of U6, 
seven proteins, Lsm 2-8, are recruited during U6 snRNP biogenesis. These proteins 
are homologous to the Sm proteins. This binding process of Sm proteins with the 
snRNAs is an important step for later hypermethylation of the cap structure. In yeast 
this hypermethylation is catalyzed by a RNA-methyltransferase termed Tsg1, which is 
recruited by binding at the Sm site (Mouaikel, Verheggen et al. 2002). After assembly 
in the cytoplasm, the particle is transported back to the nucleus for assembly of the 
spliceosome. 
As already mentioned above and illustrated in Fig. 1.4, each yeast U snRNP contains, 
beside the described seven Sm (Lsm) proteins, its particle-specific set of proteins. 
Both, common and particle specific proteins are evolutionarily conserved between 
organisms, outlining the importance of the protein composition for the mechanism of 
pre-mRNA splicing. If one compares for example the yeast U1 snRNP with the 
human U1 snRNP, one recognizes immediately that the yeast particle is more 
complex than the human one. While the human U1 snRNP is only composed of the 
Sm proteins and three snRNP specific proteins, U1A, 70K and U1C, the yeast U1 
snRNP has ten specific proteins (Gottschalk, Tang et al. (1998); (Neubauer, 
Gottschalk et al. 1997). Three of these proteins are homologues of the human U1 
proteins. Mud1 is the homologue of the human U1A protein, Snp1p of the human 
70K and Yhc1 of the human U1C protein. The function of the specific U1 proteins is 
to stabilize the binding of U1 snRNA to the 5’SS (Gottschalk, Tang et al. 1998); 
(Rosbash and Séraphin 1991). The U2 snRNP in yeast consists of twelve snRNP 
specific proteins; eleven of which are homologues to the human U2 snRNP proteins. 
The U2 associated proteins are Lea1 (homologue of U2A’), Msl1 (homologue of 





(homologues of the human proteins of the SF3a complex: SF3a120, SF3a66, SF3a60), 
Cus1, Hsh49, Hsh155, Rse1 Rds3 and YSF3 (homologues of the human SF3b 
proteins) (Brow 2002); (Caspary and Séraphin 1998); (Wang and Rymond 2003).  
The snRNAs of the U4/U6 di-snRNP are base-paired with each other and in addition 
to the Sm and Lsm proteins, have five particle specific proteins, Snu13 (homologue of 
15.5K), Prp3 (homologue of 90K), Prp4 (homologue of 60K), Prp31 (homologue of 
61K) and Prp6 (homologue of 102K). In the human system, 102K/yeast Prp6 is 
associated with the U5 snRNA (Abovich, Legrain et al. 1990). The U5 particle 
contains six particle-specific proteins, Prp8 (homologue of 220K), Brr2 (homologue 
of 200K), Snu114 (homologue of 116K), Prp28 (homologue of 100K), Snu40 (has no 
homologue in human) and Dib1 (Stevens, Barta et al. 2001). Most of the yeast U5 
proteins have highly conserved human homologues (Bach, Winkelmann et al. 1989; 
Bach and Lührmann 1991). The U5 specific protein Snu114 shows similarity to 
GTPases (Fabrizio, Laggerbauer et al. 1997), while Brr2 and Prp28 belongs to the 
family of the DExD/H-box proteins and are important driving forces during the 
splicing cycle (see chapter 1.6). The pre-assembled U4/U6.U5 tri-snRNP has, beside 
the particle specific proteins of U4, U5 and U6 also factors which only associates with 
the tri-snRNP, Snu66, Prp38, Snu23 and Spp381 (Gottschalk, Neubauer et al. 1999; 







1.5 Assembly of the spliceosome 
The assembly of the spliceosome in the course of the pre-mRNA splicing process 
occurs in a stepwise manner. The spliceosome is a highly dynamic protein-rich 
molecular machinery and is composed of the previously described five snRNPs. In 
vitro studies in humans and yeast showed that the spliceosome consists of several 
different complexes which are formed stepwise one after another termed as E, A, B, 
B
act
, C complex and postspliceosome (in this work yeast complexes are named after 
human spliceosomes). The assembly starts with the recognition of the 5’SS by U1 
snRNP (see Figure 1.3) and the ATP-independent binding of U1 snRNA to the 5’SS 
in the early phase of spliceosome assembly leading to the early E complex (yeast 
Commitment complex; CC). After formation of the early complex, the BPS is 
recognized by the U2 snRNP, forming the spliceosomal A complex or pre-
spliceosome in an ATP dependent manner (Das, Zhou et al. 2000).  
 
 
Figure 1.4: Composition of the yeast U snRNPs. Each  U snRNP consist of a RNA 
molecule and the common Sm- or Sm.like proteins (Lsm) and several particle specific proteins. The 
common Sm proteins are grey boxed, the particle specific proteins are in the same color as the U 








In this step the conserved sequence of U2 snRNA GψAGUA (ψ is pseudouridine) 
allows the branch point adenosine to bulge out of the helix, which is essential for the 
first step of splicing (Query, Moore et al. 1994). The pre-catalytic spliceosomal B-
complex is formed upon recruitment of the pre-assembled tri-snRNP U4/U6.U5 to the 
spliceosomal A-complex. Even if the spliceosome contains now a full set of U 
snRNPs, it is still catalytically inactive. For the activation of the spliceosome a major 
rearrangement of the RNA network is required, including the release of the U1 




Figure 1.5: The assembly cycle of the spliceosome. The stepwise assembly of the 
spliceosome is initiated by the binding of U1 to the 5’SS in an ATP-independent manner, forming the 
early spliceosome or commitment complex. This early step is followed by the stable interaction of the 
U2 snRNP with the branch site generating the A-complex. After recruitment of the pre-formed tri-
snRNP U4/U6.U5 to the A-complex, complex B ist formed. The U1 and U4 snRNPs are released from 
the spliceosome and dramatic rearrangements of the RNA network lead to the activated Bact complex. 
After catalytic activation, step 1 occurs, forming the C complex. After step 2, the spliceosome 






the activated B complex, termed B
act
. At this stage, U1 is replaced by U6 at the 5’SS 
and U6 snRNA contacts also the U2 snRNA forming the catalytic centre, which is not 
catalytically active yet. The B
act
 complex is then catalytically activated to generate the 
B
* 
complex, which catalyzes the first step of splicing and thus generates the 
spliceosomal C complex. Prior to catalysis of the second step of splicing, the network 
undergoes another rearrangement (Konarska, Vilardell et al. 2006). In the second step, 
the lariat-3’exon intermediate is cleaved at the 3’SS and the 5’- and 3’-exon are 
ligated. The mature RNA is released from the spliceosome and the spliceosome 
dissociates, the intron is degraded and the U snRNPs are recycled for another round of 
splicing. 
           
1.6 DExD/H box proteins as the driving force for spliceosome remodeling 
The dynamic interactions of the RNA network during spliceosome assembly 
described above require driving forces at distinct stages. Therefore, members of the 
protein family of DExD/H-box RNA dependent ATPases play an important role in the 
splicing mechanism. This group of enzymes plays a major role at the stage of 
disrupting RNA-RNA, RNA-protein and protein-protein interactions during 
rearrangement (Wahl, Will et al. 2009); (Staley and Guthrie 1998); (Valadkhan and 
Jaladat 2011), 2010); (Cordin, Hahn et al. 2012). At least eight of these proteins are 
conserved between human and yeast and function at various steps during the 







At the early stage of spliceosome assembly, both helicases Sub2 and Prp5 promote 
the displacement of the spliceosomal factor SF1/BBP from the branchpoint region in 
an ATP-dependent manner to prepare the binding of U2 snRNA to the branchpoint 
(Kosowski, Keys et al. 2009); (Valadkhan and Jaladat 2011) 2010; (Wahl, Will et al. 
2009). Prp5 is thought to play also a role in the remodeling of the U2 snRNA that is 
required for stable binding of U2 snRNP to the pre-mRNA branch site (Abu Dayyeh, 
Quan et al. 2002); (Staley and Guthrie 1998); (Wiest, O'Day et al. 1996); (Xu and 
Query 2007). The early binding of the U1 snRNA with the 5’SS has to be disrupted to 
free this position for binding of U6 snRNA with the 5’SS. This step is promoted by 
the protein Prp28 which is involved in the release of U1. Simultaneously, the U4/U6 
snRNA duplex has to be unwound to release U4 from the spliceosome and to ensure 
the proper base-pairing of U6 snRNA with U2 snRNA. Responsible for this step is the 
helicase Brr2. Since Brr2 remains bound to the spliceosome during assembly, and 
seems to be required at a later step in the splicing cycle, has to be controlled very 
strictly (Small, Leggett et al. 2006). One of the major actors during catalysis is the 
helicase Prp2 and its co-activator Spp2. Prp2 acts immediately before the first step of 
splicing. ATP hydrolysis by Prp2 is the main driving force for catalytic activation of 
the spliceosome (transition from B
act 
complex to B* complex), because its action 
leads to dramatic changes in the spliceosomal network (Kim and Lin 1996); (Fabrizio, 
Dannenberg et al. 2009); (Warkocki, Odenwalder et al. 2009) (Ohrt, Prior et al. 2012). 






Tabelle 1.1: Comparison of yeast and human ATPases and their involvement in 
the splicing cycle. The function of each ATPase is described in the main text below (scheme was 






proteins (SF3a and SF3b proteins), most probably in order to expose the branch point 
for catalysis (Lardelli, Thompson et al.); (Warkocki, Odenwalder et al. 2009). At the 
stage of the C complex, another helicase, Prp16 is needed. After the action of Prp16, 
the C complex catalyses the second step of splicing. The DExD/H-box helicase Prp22 
acts subsequent to exon ligation and promotes the release of the mature mRNA from 
the spliceosome (Company, Arenas et al. 1991); (Schwer and Gross 1998). Finally, 
the spliceosome disassembles, the intron-lariat complex has to be degraded and the 
splicing components have to be recycled for another round of splicing. This process is 
triggered by the helicase Prp43 (Arenas and Abelson 1997). Hereby, the splicing 
factor Ntr2 is needed to recruit Prp43 to the spliceosome and Ntr1 is needed to 
activate the helicase activity of Prp43 (Tsai, Fu et al. 2005; Tsai, Tseng et al. 2007); 
(Boon, Auchynnikava et al. 2006); (Tanaka, Aronova et al. 2007);(Valadkhan and 
Jaladat 2011). 
 
1.7 Spliceosome associated non-snRNP factors – proteins of the NTC 
In the work of Tarn et al. in 1993, in vitro studies in yeast revealed the existence of a 
pre-assembled complex associated with the Prp19 protein, the NTC (nineteen 
complex). It was postulated that the NTC most likely plays a major role during the 
transition from the pre-catalytic B complex to the activated  B
act 
 complex (Tarn, Lee 
et al. 1993). It was also shown that the NTC enters the spliceosome subsequently after 
the dissociation of U1 and U4 and stabilizes the U5 and the U6 interaction with pre-
mRNA. The yeast NTC consists of eight proteins, Prp19, Ntc20, Ntc25, Isy1, Syf1, 
Syf2, Clf1 and Cef1. In human there are also eight proteins within the NTC which is 
named Prp19/CDC5 complex, among others the protein CDC25 which is the human 
orthologue to yeast Cef1 is found. The Prp19/CDC25 complex plays also an 
important role in human spliceosomes (Makarova, Makarov et al. 2004). 
 
1.8 Structural rearrangements of the Spliceosomal RNA-RNA network 
 During the assembly of the spliceosome major rearrangements have to occur. The 





and the RNA-protein interactions (Staley and Guthrie 1998); (Brow 2002); (Wahl, 
Will et al. 2009); see Fig. 1.6). 
At the early steps of spliceosome assembly, U1 snRNA contacts the 5’SS and base-
pairs with its complement sequence in the pre-mRNA in an ATP-independent 
manner. In the next step, the U2 snRNA base-pairs with the BPS in an ATP-
dependent manner to form the spliceosomal A complex. At the stage of the pre-
catalytic B complex the pre-formed U4/U6.U5 tri-snRNP is recruited to the 
spliceosome. At this point the spliceosome consists of a full set of snRNPs but it is 
still in its pre-catalytic form, as long as the catalytically important regions of the U6 
snRNA are still base-paired with the U4 snRNA. During activation, base-pairing 
between U4/U6 snRNA is disrupted and the U1 snRNP is replaced at the 5’SS by the 
U6 snRNP. U6 snRNA binds with its conserved ACAGAGA-box motif at the 5’SS of 
the pre-mRNA. This step is important to determine the 5’SS and to initiate the first 
step of catalysis (Fabrizio and Abelson 1990); (Lesser and Guthrie 1993). During this 
step, the U1 and U4 snRNPs are released from the spliceosome. U6 snRNA base-pairs 
with U2 snRNA in form of short helices (U6/U2 helices Ia, Ib and II). Another 
important role of U6 snRNA is the capacity to bind metal ions during catalysis by 
forming an intramolecular stem loops (U6-ISL) (Yean, Wuenschell et al. 2000); 
(Sontheimer 2001). After the recruitment of the tri-snRNP, U5 snRNA binds with its 
loop I to nucleotides of the exon upstream of the 5’SS. After the first step of splicing, 
U5 snRNA contacts also nucleotides of the exon downstream of the 3’SS. This 
mechanism is thought to juxtapose both exons of the pre-mRNA for the catalysis of 







1.9 Approaches for the isolation of native spliceosomal complexes 
As mentioned above, spliceosomes are very dynamic molecular machines, thus, during 
their formation/catalytic activity, they go through many intermediate 
assembly/functional stages (i.e., E, A, B, B
act
, B* and C complex) (Fig.1.5). 
Two general methods have been employed to isolate native spliceosomal complexes. 
The first is to target a protein component of the spliceosome. To isolate a specific 
spliceosomal complex, ideally such a component should transiently interact with the 
spliceosome at a specific stage of its assembly/function. Anti-peptide antibodies raised 
against such a protein would allow immunoprecipitation and subsequent peptide-
induced elution of only those spliceosomal complexes that contain the targeted protein. 
Using anti-peptide antibodies directed against spliceosomal proteins that are transiently, 
but stably associated with the spliceosome, activated spliceosomes from HeLa nuclear 
 
 
Figure 1.6: Structural dynamics during catalytic activation.  On the left hand site the 
pre-catalytic form of the spliceosome, the pre-catalyic B complex is shown. After dramatic 
rearrangements of the RNA-RNA network and the subsequent release of the U1 and the U4 snRNPs, the 
catalytically activated spliceosome, the B* complex is generated. Both exons are grey-boxed, the 
different snRNAs are shown in different colors. The branch point adenosine is highlighted in red (kindly 







extract have been previously isolated (Makarov, Makarova et al. 2002), as well as 
spliceosomal complex B lacking the U1 snRNP (Makarova, Makarov et al. 2002). 
A second approach for the isolation of spliceosomal complexes is targeting the pre-
mRNA by adding an aptamer sequence to its 5' or 3' end (e.g. the hairpin structures 
bound by tobramycin or the MS2 protein). Either prior to or after allowing 
spliceosomal complexes to form under splicing conditions in HeLa nuclear extract or 
in yeast S. cerevisiae whole cell extract (this work), the aptamer is bound by its ligand 
(e.g. tobramycin or MS2 protein fused to the maltose binding protein), which binds or 
is covalently attached to a solid support. After washing, complexes can then be eluted 
under native conditions by the addition of an excess of the aptamer or ligand. This 
approach has been successfully used to isolate a mixture of spliceosomal complexes 
(Zhou, Licklider et al. 2002), as well as spliceosomes at a more defined stage of 
assembly and function such as the A, B, B
act
 , B* or C complexes from human, 
Drosophila and yeast cells (this work, Fig. 1.7) under mild, physiological conditions 
(Jurica, Licklider et al. 2002); (Hartmuth, Urlaub et al. 2002); (Deckert, Hartmuth et 
al. 2006); (Bessonov, Anokhina et al. 2008); (Behzadnia, Golas et al. 2007); (Herold, 
Will et al. 2009); (Warkocki, Odenwalder et al. 2009), (Bessonov, Anokhina et al. 
2010). A general problem of in vitro splicing is that spliceosome assembly is not 
synchronized; at a given incubation time point a heterogeneous population of 
spliceosomal complexes are assembled on the pre-mRNA. Thus, if a specific 
spliceosomal complex is to be isolated, additional measures must be undertaken to 
isolate a more homogeneous population. One approach is to stall spliceosome 
assembly at a given point. For example, an accumulation of human spliceosomal 
complex C can be achieved by removing the 3’ splice site and the 3' exon of the pre-
mRNA (Bessonov, Anokhina et al. 2008). Affinity-purified C complexes formed on 
such a pre-mRNA substrate can even be chased through the catalytic steps of splicing 
and catalyze exon ligation in the absence of added factors. This provides a means to 







Alternatively, splicing can be carried out for only very short periods of time, so that 
predominantly only early spliceosomal complexes such as E, A and B will have time 
to form (Hartmuth, Urlaub et al. 2002; Deckert, Hartmuth et al. 2006). Especially in 
yeast there is one distinctive feature, which provides another tool for stalling the 
spliceosomal assembly cycle at defined stages: the existence of temperature-sensitive 
strains for various spliceosomal factors, in particular for most of the essential 
DExD/H-box helicases. For example, it was shown in previous studies that the 
inactivation of Prp5, an essential DEAD-box helicase, known to function in A 
 
 
Figure 1.7: Schematic of the purification protocol for the isolation of yeast 
spliceosomes. Purification of the Bact spliceosome is depicted. In vitro splicing is carried out using 
yeast whole cell extract. The reactions are first separated via glycerol gradient centrifugation and 
subsequently purified on an amylose matrix. A second glycerol gradient centrifugation is carried out if 
very high purity is required. (This figure was kindly provided by Dr. Patrizia Fabrizio, department of 






complex formation, leads to the accumulation of the early pre-spliceosomal 
Commitment complex in yeast (O'Day, Dalbadie-McFarland et al. 1996); (Dalbadie-
McFarland and Abelson 1990). To isolate and to purify yeast spliceosomes stalled at 
the commitment complex (CC) stage prior to the formation of pre-spliceosomal A 
complex, we used in this work, a temperature-sensitive yeast strain which carries a 
mutant of Prp5 and thus, can be heat-inactivated to accumulate Commitment 
complexes for subsequent biochemical and structural investigations. 
 
1.10 Yeast as a model organism 
Saccharomyces cerevisiae has been considered a model for molecular biology studies 
like pre-mRNA splicing. The benefit is the easy handling of this organism. Over the 
last few decades a set of well-established selection markers and protocols has been 
established which make genetic manipulation of this organism easy and rapid. 
Therefore, a number of different strains, recombinant spliceosomal factors or different 
RNA constructs, especially for studying the mechanism of pre-mRNA splicing, have 
accumulated. Screenings for synthetic lethality and genetic interactions have greatly 
widened our understanding of the complex mechanisms involved in pre-mRNA 
splicing. Moreover, one major aspect is the existence of temperature-sensitive strains 
for various spliceosomal factors in yeast as described above. This has provided a 
perfect device to block the spliceosomal cycle at distinct stages in yeast. Using wild-
type pre-mRNAs that carry all sequences essential for pre-mRNA splicing, the 
purification of spliceosomal complexes that are functional intermediates can be 
perform. This feature and the accumulated knowledge of the last decades allow the 
stepwise reconstitution of the splicing machinery and its assembly in vitro in S. 
cerevisisae and will be described in more details in this work.  
 
1.11 Investigation and characterization of yeast spliceosomal complexes via 
mass spectrometry and electron mircroscopy 
In former biochemical and genetic studies, numerous proteins were found and 





unknown. To understand better their contribution and function in pre-mRNA splicing 
several special methods are required to investigate and characterize them. 
1.11.1 Mass spectrometry 
Mass spectrometry (MS) is one of the major analytical technologies for the 
identification of unknown protein factors and to determine the proteomic composition 
of highly complex samples like spliceosomal complexes. Large and complex 
biomolecules can be analyzed after ionization by either matrix-assisted laser 
desorption ionization (MALDI MS), electrospray ionization (ESI  MS) or tandem MS 
(LC-MS/MS). The electrospray leads to formation of micrometer-sized droplets that 
accelerate in electric field with simultaneous evaporation of the solvent, so that only 
peptide ions enter the mass spectrometer (reviewed by (Fenn, Mann et al. 1989). In the 
mass spectrometer, the ions are separated according to their mass to charge ratio (m/z) 
and detected. For sequence information, one of the ions (peptides) is isolated and 
fragmented, typically by collision-induced dissociation and the fragments are detected. 
Finally, the set of masses obtained from MS analysis is used to search against a protein 
database to identify the peptides, and thus the proteins, contained in the sample. On the 
basis of peptide assignment quality, number of assigned total and unique peptides, and 
sequence coverage, a protein can be identified as a component of the spliceosome. MS 
gives fast and authentic identification of protein factors and it is an essential tool for 
studying protein dynamics (reviewed in (Mann, Hendrickson et al. 2001). 
MS analyses of the spliceosomes purified in our laboratory have been performed in 
collaboration with the MS facility and research group of Prof. Henning Urlaub at the 
MPI-bpc. 
1.11.2 Electron microscopy 
To gain insights into the structure and function of highly dynamic and complex 
structures like the splicing machinery, electron microscopy (EM) is another 
indispensable tool to obtain insights into the three-dimensional structure of the yeast 
splicing machinery. In addition, to learn more about the three-dimensional structure of 
macromolecular complexes in living cells can be considered an approach towards 
understanding better their function and mechanism. One of the major techniques to 





promising results for the analysis of multiprotein complexes with a high resolution (< 
10Å) (Golas, Sander et al. 2003). This technique is ideally suited to investigate the 
structure of spliceosomal complexes in the yeast S.cerevisiae. Previous work from our 
laboratory, Deckert et al. and Bessonov et al. have shown that when single-particle 
cryo electron microscopy was used, higher order structures at a resolution of 30 - 40Å 
were obtained for the human spliceosomal BΔU1 and C complexes (Deckert, 
Hartmuth et al. 2006), (Bessonov, Anokhina et al. 2008). 
The structural analysis of spliceosomal complexes isolated from yeast, done in this 
work, was performed according to the protocol of Kastner et al. with the Grafix-
method. Therefore, spliceosomal complexes were affinity purified under native 
conditions according to the protocol described in this work and in Fabrizio et al. and 
Dannenberg et al., and were then sedimented on a second glycerol gradient containing 
0.1 % Gluteraldehyd. Gluteraldehyd is a light chemical cross-linker which fixes the 
complexes under analysis during gradient centrifugation. The fixation step in this 
preparation allows longer absorption time of the particle on the grid for later analysis 
by the electron microscope (Kastner, Fischer et al. 2008) and Methods). For what 
concerns the 2D EM structure of spliceosomal complexes from the yeast S.cerevisiae 
nothing was known at the start of my work and it is one of the aims of this thesis.  
EM analyses of the spliceosomes purified in our laboratory have been performed in 




1.12 Dual Color Fluorescence Cross-Correlation Spectroscopy – an excellent 
technique to study protein dynamics within the spliceosome 
Standard MS methods are only semi-quantative and can only give good indications 
about the relative abundance of a certain protein associated with various spliceosomal 
complexes. A feature of the spliceosome, however, is the ordered recruitment and 
subsequent release of spliceosomal factors. The spliceosome must therefore create 
binding sites for recruited partners at the correct phase of assembly cycle or existent 
binding sites are modulated to switch from low affinity to high affinity and vice versa. 





of recruitment/release events and the assignment of dissociation constants for 
spliceosomal factors at different stages of the spliceosomal cycle is crucial in 
understanding molecular mechanism of the splicing process in depth. 
 A method that appears to meet the requirements for obtaining this much-needed 
information is dual-color fluorescence cross-correlation spectroscopy (dcFCCS). This 
is a sensitive and versatile optical technique that allows the direct analysis of the 
dynamics of the association and dissociation events among proteins and/or RNAs in 
complex systems in solution, at low nanomolar concentrations and in equilibrium 
without requiring a biochemical/physical perturbation of the sample (see Materials 
and Methods/Results). In brief, dcFCCS is based on the confocal microscope and 
requires particles labelled with two spectrally separated colours (e.g. green and red). 
The fluorescence of the labelled molecules is spectrally separated and detected in two 
channels. The signals are analysed by computing the auto-correlation of each channel 
and their cross-correlation. If molecules bearing different labels are not part of the 
same complex, then they will diffuse independently through the confocal volume. In 
that case, there will be no cross-correlation between both signals. However, if the 
molecules are part of the same complex, they will form doubly labeled entities. Co-
diffusion of the two labels will generate correlated signals in both detection channels 
and therefore a cross-correlation. The amplitude of the cross-correlation is 
proportional to the number of doubly labelled molecules and can therefore be used to 
monitor binding and release reactions (Fig.1.8) (Ricka and Binkert 1989; Schwille, 
Meyer-Almes et al. 1997; Földes-Papp 2005; Mütze, Ohrt et al. 2011). For a detailed 
mathematical description of the auto-correlation function refer to Schwille and 
Haustein, 2002 and to Sauer, Hofkens and Enderlein, 2011, as this is beyond the 
scope of this introduction. The computation and evaluation of the dcFCCS data in this 
work was done in collaboration with Prof. Jörg Enderlein and Mira Prior (III.Institute 
of Physics, University of Göttingen) (Kettling, Koltermann et al. 1998); (Foldes-Papp 








1.13 Aim of this study 
The spliceosome is a protein-rich molecular machine that catalyzes the removal of a 
pre-mRNA intron. Proteomic studies of purified spliceosomes, assembled in vitro at 
defined stages of function, have primarily been carried out with splicing extracts from 
human HeLa cells. Human spliceosomes contain more than 50 proteins associated 
with snRNPs and more than 100 non-snRNP proteins as revealed by mass-
spectrometric studies. Such studies showed that the spliceosome's protein complement 
varies substantially from one stage of the splicing cycle to another (Deckert, Hartmuth 
et al. 2006; Bessonov, Anokhina et al. 2008). One aim of this work was to expand 
these studies to the yeast Saccharomyces cerevisiae, since there is no alternative 
splicing in yeast cells and thus regulatory splicing factors such as SR and hnRNP 
proteins are absent. Nonetheless, the pathway of spliceosome assembly and the main 
 
 
Figure 1.8: The cross-correlation amplitude is proportional to the amount of 
doubly labeled species 
Binding and release of a fluorescently labeled protein (brown or pink rectangles with a “green 
fluorophor”) to a larger assembly of molecules (i.e.the spliceosome with a “red fluorophor”) are 
shown schematically. The effects of the two events on the cross- correlation curves are indicated 






features of its catalytic chemistry appear to be conserved between metazoans and 
yeast. The study of the extent of conservation is not only relevant for tracing 
evolutionary relationships, but it can also lead to conclusions about the mechanisms 
of conformational changes, such as those resulting in spliceosome activation or 
catalysis. Therefore, a comprehensive proteomic analysis of the yeast spliceosomes 
should reveal the minimum set of proteins required for driving the spliceosomal 
dynamics and for catalyzing the removal of a pre-mRNA intron.  
Towards this goal we set up a strategy to purify and isolate spliceosomal complexes 
from yeast under native conditions for the first time, to learn more about the dynamics 
of protein recruitment and release during catalytic activation and step 1 of splicing. 
To isolate biochemically homogenous B, B
act
 and C complexes, we used an actin pre-
mRNA and modifications thereof. For MS2 affinity-purification, three MS2 binding 
sites were fused to the 5’ end of the various pre-mRNA constructs. Previous studies 
showed that truncation/modification of the actin pre-mRNA and adjustment of the 
ATP concentration in the splicing reaction can lead to stalling of the spliceosomal 
cycle (Rymond and Rosbash 1985; Cheng 1994). The intron in the actin pre-mRNA 
contains the yeast consensus branch point (BPS) sequence UACUAAC. The pre-
mRNA ActΔ6 and ActΔ31 were truncated 6 and 31 bases, respectively, after this 
sequence, and thus, lack the 3’ SS and the 3’ exon. These truncated precursors led to 
stalling at the stage of complex B
act
 and C, respectively, when 2 mM ATP was used. 
The inclusion of only 0.05 mM ATP in the splicing reaction led to stalling at the stage 
of complex B. The various spliceosomal complexes were isolated by a three-step 
purification procedure developed in yeast during my PhD work and involves glycerol 
gradient centrifugations and affinity-selection of the MS2 tagged spliceosomal 
complexes with amylose beads. The protein composition of the B, B
act 
and C 
complexes have been determined by mass spectrometry (MS), and the proteins that 
dissociate or are recruited during the transition from one complex to the next have 
been characterized for the first time. MS revealed a dramatic exchange of proteins 
during spliceosome assembly and activation. Specifically, we learned that in yeast, 
activation (B to B
act
 transition) is accompanied by the stable recruitment of ~20 
proteins, whereas ~35 proteins, including all U1 and U4/U6-associated proteins, are 
lost. Nine additional proteins are recruited during the transition from the B
act





complex. At the same time the DEAH-box helicase Prp2 and its co-activator Spp2, as 
well as the U2 SF3a and SF3b complexes, are also destabilised. However, it was not 
yet clear whether the U2 SF3a/SF3b proteins are subsequently lost from the 
spliceosome.  
A fundamental outcome of this work is that it provides an inventory of the 
evolutionarily conserved splicing factors that are stably associated with three 
“snapshots” of spliceosome assembly, activation and catalysis and offer insights into 
the window of function of the proteins exchanged during the transition from one stage 
to the next. Another important outcome of this work is that it revealed that in yeast 
and human, the same homologous proteins dissociate and are recruited during the 
transition from the B to the B
act
, and from the B
act
 to the C complex, indicating that 
these compositional changes are an evolutionarily conserved design principle of the 
spliceosome.  
The isolation of intact yeast spliceosomal complexes has already provided an 
important background not only for further biochemical, biophysical and functional 
studies (see below), but also for initial structural studies. Because of its dynamic and 
complex nature, obtaining structural information about the spliceosome represented a 
major challenge so far. Nevertheless in this work, electron microscopy (EM) of the 
three isolated “snapshots” of the yeast spliceosome revealed a quite homogenous 
general morphology of the B, B
act
 and C complexes and also their significant 
differences in shape and structural details, consistent with their substantial 
compositional differences. Thus, these studies have paved the way to obtain a 
topographic map of the spliceosome, and will also provide novel insights into the 
structural remodeling events occurring during the spliceosome cycle. 
Significantly, the moderate number of phylogenetically conserved proteins recruited 
to the yeast complexes B
act
 and C has made possible targeted investigations of the 
mechanism of activation and catalysis in a fully-defined biochemical reconstitution 
system in our laboratory (Warkocki, Odenwalder et al. 2009). In the latter studies was 
shown that the DEAH-box helicase Prp2 remodels substantially B
act
 into the 
catalytically activated B* complex prior to the formation of the C complex. During 





weakened. Interestingly, these included the proteins of the U2 SF3a/SF3b subunits 
and further suggested that the ATPase Prp2 may facilitate the spliceosome’s catalytic 
activation by inducing destabilisation of U2 SF3a/SF3b proteins. This rearrangement 
is important since it is believed to expose the BPS adenosine as a crucial preliminary 
to step 1. In addition, we observed that there were potentially several other proteins 
whose binding affinity to the spliceosome might have been changed by Prp2 action as 
revealed by the comparative MS analyses of purified spliceosomes described above. 
These included the RES (REtention and Splicing) complex proteins, the NTC-related 
proteins Cwc24 and Cwc27, and the essential catalytic step 1 factors Yju2 and 
Cwc25.  
Thus, a second aim of this work was to study these events in a quantitative manner, 
toward this goal we established a dual color Fluorescens Cross Correlation 
Spectroscopy setup (in collaboration with Dr. Thomas Ohrt, Mira Prior and Prof. Jörg 
Enderlein). In this work, the technique of dcFCCS was applied for the first time to 
investigate the compositional dynamics of yeast spliceosomes in more details. 
Specifically, we have studied the modulation of the binding strength of various 
proteins to the yeast spliceosome during catalytic activation by Prp2 to finally shed 
some light on the nature of the release/loss of splicing factors during this crucial 
remodeling step. For this purpose, spliceosomes were stalled before step 1 by using 
the temperature-sensitive yeast mutant prp2-1 and affinity-purified to near 
homogeneity, yielding a B
actΔPrp2
 spliceosome. Highly purified B
actΔPrp2
 can be 
catalytically activated to form B* when supplemented with recombinant Prp2 and 
Spp2 splicing factors (Warkocki, Odenwalder et al. 2009). We have used purified 
B
actΔPrp2
 complexes assembled on actin pre-mRNA labeled at its 5’ end with the red 
fluorescent dye Atto647N. We labeled proteins by fusing the protein of interest with a 
fluorescent protein EGFP (enhanced green fluorescent protein) by genetic 
modification; the fluorescently labeled protein is uniquely produced in the modified 
yeast strain and is, therefore, quantitatively and selectively labeled in purified 
spliceosomes assembled in splicing extracts derived from such strains. The purified 
doubly-labeled spliceosomes were then analyzed before and after catalytic activation 
by Prp2 and the weakening or strengthening of the binding of the EGFP-labeled 





Using dcFCCS we show that the binding affinity of quite a number of proteins is 
significantly changed during the Prp2-mediated catalytic activation of the 
spliceosome. Finally, we convincingly demonstrate that the U2 SF3a/SF3b proteins 
Prp11 and Cus1 remain bound to the B* spliceosome under near-physiological 
conditions, and that their binding is reduced only when high salt is included. 
Furthermore, high affinity binding sites are created for Yju2 and Cwc25 during 
catalytic activation, consistent with their requirement for step 1 catalysis. This work 
suggests that Prp2-mediated structural remodeling of the spliceosome leads to 
multiple rearrangements and show that dcFCCS is a powerful tool, ideally suited to 
investigate quantitatively the compositional dynamics of the spliceosome during its 
catalytic activation. In addition, this is the first example where purified, catalytically 
active spliceosomes were investigated directly in solution and in equilibrium. In 
conclusion, by combining biochemical, biophysical approaches and ultrastructural 
studies by EM, this work gives new insights and useful information about protein 
dynamics and structural changes occuring during spliceosome activation and 
catalysis.  
  






2. Materials and Methods 
2.1 Materials 
 
2.1.1 Chemicals and media 
 
2-Mercaptoethanol       Roth, Germany 
Acetic acid        Merck, Germany 
Acetone         Merck, Germany 
Agarose, electrophoresis grade  Invitrogen, 
Netherlands 
Ammoniumperoxodisulfate (APS)     Merck, Germany 
Ampicillin      Sigma-Aldrich,  
Germany 
Bacto agar         BD, USA 
Bacto yeast extract       BD, USA 
Bacto peptone        BD, USA 
Bradford-assay solution       Bio-Rad, Germany 
Brilliant Blue G-Colloidal concentrate     Sigma-Aldrich, 
          Germany 
Bromphenol blue        Merck, Germany 
D(+)-glucose monohydrate      Merck, Germany 
Dipotassiumhydrogenphosphate      Merck, Germany 
DNA-molecular weight marker      Gibco, New 
Zealand 
DTT (Dithiothreitol)       Roth, Germany 
EDTA (Disodium salt dihydrate)      Roth, Germany 
Formaldehyde        Merck, Germany 
Formamide        Merck, Germany 




Glycerol         Merck, Germany 
Glycoblue         Ambion, USA 
HEPES (N-2-Hydroxyethylpiperazin-N-2-ethansulfonic acid) Calbiochem, USA 
Imidazole         Merck, Germany 
Lithium acetate        Sigma-Aldrich,  
Germany 
Maltose         Merck, Germany 
Methanol         Merck, Germany 
Polyethylene glycol (PEG)      Sigma-Aldrich, 
 Germany 
Ponceau S         Serva, Germany 
Potassium Chloride       Merck, Germany 
Potassiumdihydrogenphosphate      Merck, Germany 
Pre-stained protein-molecular weight marker   Bio-Rad, Germany 
Roti-Phenol-Chloroform-Isoamyl alcohol (PCI)    Roth, Germany 
Rotiphorese Gel 30 solution      Roth, Germany 
Rotiphorese Gel 40 solution      Roth, Germany 
Rotiphorese Gel A and B solution     Roth, Germany 
Silver nitrate        Merck, Germany 
Sodiumdodecylsulfate (SDS)      Serva, Germany 
Sodiumacetate        Merck, Germany 
TEMED (N, N, N’, N’-Tetramethylethylendiamine)   Sigma-Aldrich,  
Germany 
Tris-(hydroxymethyl)aminomethane (Tris)    Roth, Germany 
Triton X-100        Merck, Germany 
tRNA E. coli        Boehringer,  
Germany 
Nonidet P-40 (Igepal CA-630)     Sigma-Aldrich, 
          Germany 
Urea         Merck, Germany 
Xylene cyanol FF       Fluka, Switzerland 
 
 




2.1.2 Enzymes and enzyme inhibitors 
 
Aprotinin        Serva, Germany 
Benzamidine       Serva, Germany 
Chymostatin       Serva, Germany 
Complete
TM
 protease inhibitor tablets EDTA-free  Roche, Germany 
Leupeptin        Serva, Germany 
Pepstatin A       Serva, Germany 
Phenylmethylsulfonylfluoride (PMSF)    Merck, Germany 
Phusion® High-Fidelity DNA Polymerase   New England Biolabs, 
         Germany 
Proteinase K       Sigma-Aldrich, Germany 
Recombinant RNasin® Ribonuclease Inhibitor   Promega, USA 
Restriction Enzymes      New England Biolabs, 
 Germany 
RNasin (RNase inhibitor; 40 U/μl)    Promega, USA 
RQ DNase I (1 U/μl)      Promega, USA 
SP6 RNA polymerase      New England Biolabs, 
 Germany 
T7 RNA polymerase     dept.  Lührmann 
Taq DNA polymerase      Promega, USA 
 
2.1.3 Nucleotides 
Nucleoside-5´-triphosphate (ATP, CTP, GTP, UTP 100 mM each):  
Pharmacia, Germany 
 
Deoxynucleoside-5´-triphosphate Mix (dATP, dCTP, dGTP, dTTP 10 mM each): 
  















2.1.4 DNA oligonucleotides and plasmids 
2.1.4.1 DNA oligonucleotides 
 
Name  sequence (5’ to 3’)    description 
 
Sp6_for ATTTAGGTGACACTATAG   used for the generation of  
template DNA for in vitro 
transcription 
Act_rev GGAATTCCCCTTCATCACCAA   used for the generation of  
template DNA for in vitro 
transcription 
Act+13+24  GATGGTGCAAGC   used for RNase H directed  
cleavage of M3Act pre-




Name   description 
pUC18_T7_M3Act_wt template for in vitro transcription, generated by Dr. 
Thomas Ohrt 
pUC18_T7_M3Act_Δ6  template for in vitro transcription, generated by Dr. 
Thomas Ohrt 
pMal_MS2-MBP  expression of MS2-MBP fusion protein, provided by 
Robin Reed and Josep Vilardell 
pKT209 used for the amplicfication of the yEGFP cassette by 








2.1.5 Yeast and bacterial strains 
2.1.5.1 Yeast strains 
BJ2168   MATa, leu2, trp1, ura3, prb1-1122, pep4-3, prc1-407,gal2 
This strain carries deletions in protease genes. 
prp2-1 (3.2 AID)  MATalpha, prp2-1, ade2, his3, lys2-801, ura3  
kindly provided by R-JLin. This strain carries a G360D 
mutation in Prp2, rendering it heat labile. 
 
prp5-1   MATa prp5-1,ade2-101, his3-1200 tyr1 ura3-52 
(single base change in the PRP5 gene which lead to the substitution of 
glycine 293 with aspartate (G293D) in the protein. This substitution is 
12 residues upstream of the glycine-lysine-threonine (GKT) triplet in 
the highly conserved, nucleotide-binding motif 1 within the putative 
helicase domain) 
 
YTO13  Snu114-yEGFP MATalpha, prp2-1, ade2, his3, lys2-801, 
ura3; SNU114::yEGFP-CaURA3 C-terminus 
 
YTO15  Cus1-yEGFP MATalpha, prp2-1, ade2, his3, lys2-801, ura3; 
CUS1::yEGFP-CaURA3 C-terminus 
 
YTO17  Prp11-yEGFP MATalpha, prp2-1, ade2, his3, lys2-801, ura3; 
PRP11::yEGFP-CaURA3 C-terminus 
 
YTO18  Cwc24-yEGFP MATalpha, prp2-1, ade2, his3, lys2-801, ura3; 
CWC24::yEGFP-CaURA3 C-terminus 
 
YTO20  Cwc27-yEGFP MATalpha, prp2-1, ade2, his3, lys2-801, ura3; 
CWC27::yEGFP-CaURA3 C-terminus 
 
YTO21  Yju2-yEGFP MATalpha, prp2-1, ade2, his3, lys2-801, ura3; 
YJU2::yEGFP-CaURA3 C-terminus 









2.1.5.2 Bacterial strains 
BL21-CodonPlus(DE3)-RIL cells, F- ompThsdSB (rB- mB-) gal dcm lacY1, 
pRARE22 (CMR) pAR5615 (APR) Novagen, USA 
 
2.1.6 Commercial kits 
ECL western blot detection kit   GE Healthcare, UK 
Prime It II random primer labeling kit   Stratagene, USA 
Qiagen gel extraction kit     Qiagen, Germany 
Qiagen plasmid preparation kit   Qiagen, Germany 
 
 
2.1.7 Chromatography materials and consumables 
Amylose resin     New England Biolabs, Germany 
Cassettes for film exposure    Kodak, USA 
Concentrator     Millipore, USA 
Dialyses membranes MWCO 6000-8000 Da  SpektraPor, USA 
Heparin Sepharose
TM
 6 Fast Flow   GE Healthcare, UK 
HisTrap™ FF crude columns    GE Healthcare, UK 
IgG Sepharose 6 Fast Flow    GE Healthcare, UK 
Nylon membrane Hybond XL    GE Healthcare, UK 
Parafilm       Roth, Germany 
Poly-Prep columns     Bio-Rad, USA 
ProbeQuant
TM
 G-50 micro columns   GE Healthcare, UK 
ProbeQuant
TM
 G-25 micro columns   GE Healthcare, UK 
Protein A-Sepharose CL 4B   GE Healthcare, UK 




Protran Nitrocellulose membrane   Schleicher & Schüll, Germany 
Slide-A-Lyzer dialysis units (MWCO 6 kDa)  Pierce, USA 
Sterile filters 0.2 μm or 0.45 μm    Sarstedt, Germany 
Superdex 75 16/60 column    GE Healthcare, UK 
Whatman 3MM Paper     Whatman Paper, UK 
X-ray films BioMax MR     Kodak, USA 
 
2.1.8 Common buffers 
Media, buffers, and solutions were prepared with deionized water (Millipore) and 
autoclaved if necessary (121 °C, 20 min, 1 bar). Solutions with heat-labile 
components were filter sterilized (0.22 μm).  
 
5x DNA loading dye    30% glycerol 
5 mM EDTA, pH 8.0 
0.25% (w/v) bromophenol blue 
0.25% (w/v) xylene cyanol 
 
4x Separating gel buffer   1.5 M Tris 
0.4% (w/v) SDS 
adjust to pH 8.8 
 
4x Stacking gel buffer    0.5 M Tris 
0.4% (w/v) SDS 
adjust pH to 6.8 
 
10x TBE      0.89 M Tris 
0.89 M boric acid 
25 mM EDTA pH 8.0 
 
Protein loading dye    75 mM Tris-HCl, pH 6.8 
1.25 mM EDTA, pH 8.0 
20% (v/v) glycerol 




2.5% (w/v) SDS 
0.125% (w/v) bromophenol blue 
50 mM DTT 
 
RNA loading dye    80% formamide 
1 mM EDTA pH 8.0 
0.05% (w/v) bromophenol blue 
0.05% (w/v) xylene cyanol 
 
Slab 4 Buffer     50 mM Tris 
105 mM glycine 
0.1% (w/v) SDS 
 
SDS-PAGE Running buffer  25 mM Tris-HCl, pH 6.8 
192 mM glycine 
1% (w/v) SDS 
 
10x TBS      200 mM Tris 
1.37 M NaCl 
adjust to pH 7.6 
 
Western blotting buffer    1.5 L Slab4 Buffer 
0.6 L methanol 
0.9 L ddH2O 
 
 
2.1.9 Machines and working equipment 
ÄKTA Prime      GE Healthcare, UK 
ÄKTA Explorer      GE Healthcare, UK 
Autoclaves      H+P Labortechnik, Germany 
Biofuge fresco      Kendro, USA 
Biofuge pico      Kendro, USA 




DNA Thermal Cycler     Hybaid Omni Gene, UK 
Gel documentation unit     Bio-Rad, USA 
Gelelectrophoresis apparatus    in-house 
Geldryer Model 583     Bio-Rad, USA 
Gradient Master      BioComp Instruments, Canada 
‘head-over-tail’      Rotor Cole-Parmer, USA 
Heating blocks      Eppendorf, Germany 
Hybridization oven     Hybaid Biometra, UK 
Megafuge 1.0R      Kendro, USA 
Milli-Q-water supply apparatus    Millipore, USA 
Nanodrop       Thermofisher, Germany 
pH-Meter       Mettler Toledo, Switzerland 
Phosphorimager Typhoon 8600    Amersham Pharmacia, Germany 
Power supply EPS 2A 2000    Hoefer Pharmacia Biotech, USA 
Power supply EPS 3501/XL    Amersham Pharmacia, Germany 
Liquid Scintillation Analyzer Tri-Carb 2100 T  Packard, USA 
Sorvall SLC-6000 rotor     Kendro, USA 
Sorvall SS-34 Rotor     Kendro, USA 
Sorvall TH660 Rotor     Kendro, USA 
Sorvall T865 Rotor     Kendro, USA 
Sorvall T647.5 Rotor     Kendro, USA 
Speed Vac Concentrator 5301    Eppendorf, Germany 
Spectrophotometer Ultrospec 3000 pro   Amersham Pharmacia, Germany 
Surespin 630 rotor     Thermo Fisher Scientific, USA 
Tabletop centrifuges     Heraeus, Germany 
Trans-Blot Cell      Bio-Rad, USA 
Ultracentrifuge Evolution    Kendro, USA 
UV lamps (254 nm)    Bachofer, Reutlingen 
Vortex       Janke & Kunkel, Germany 
X-ray film developer X-Omat 2000   Kodak, USA 
Liquid scintillation analyzer    Packard, USA 






2.2.1 General molecular biology methods 
Unless otherwise stated all described methods for standard molecular biology are 
essentially performed according to Sambrook et al., 1989. When a commercial 
reaction set was used, the manufacturer’s instructions were followed. 
 
2.2.1.1 Concentration determination of nucleic acids  
The concentration determination of RNA or DNA is based on the absorption 
maximum of the aromatic ring system of nucleic acids at a wavelength of 260 nm. 
The concentration and purity of nucleic acids was estimated using the empirical 
standard values shown below. The ratio between OD260 and OD280 allows to assess 
contaminations with proteins or phenol. 
2.2.1.2 Purification and manipulation of DNA  
Plasmid DNA was obtained from E. coli cells using QIAGEN Plasmid Purification 
Kits according to the manufacturer’s instructions. QIAGEN plasmid purification 
protocols are based on a modified alkaline lysis procedure, followed by binding of 
plasmid DNA to QIAGEN Anion-Exchange Resin under appropriate low-salt and pH 
conditions. Restriction endonucleases were obtained from New England Biolabs 
(NEB) and the reactions were performed according to the manufacturer’s instructions. 
Generally 1-10 units of enzyme were used to cut 1µg of DNA within 1h under the 
recommended conditions. DNA fragments were analyzed and purified by agarose gel 
electrophoresis.  
 
2.2.1.3 Agarose gel electrophoresis 
DNA-fragments generated by PCR were analyzed by agarose gel electrophoresis. 
Gels contained 1-2% agarose (w/v) and 0.4 μg/ml ethidiumbromide in 0,5x TBE 
buffer. DNA samples were supplemented with DNA loading dye and separated 




together with a DNA ladder as size marker at 110 Volts (constant voltage), in 0.5x 
TBE. Nucleic acids were visualized with UV-light at 254 nm. 
2.2.1.4 Polymerase chain reaction  
The polymerase chain reaction (PCR) was used to amplify DNA fragments either for 
analytic (e.g. “colony PCR”) or preparative purposes (e.g. transcription templates). A 
typical reaction mixture contained 0.4 ng/µl of template, 0.2 mM of each dNTP, 0.6 
µM of each primer, the appropriate reaction buffer and the enzyme. Different kinds of 
polymerases (Taq-, Pfu- or Phusion-polymerase) were used depending on the purpose 
of the application.  
 
A typical setup for a PCR included the following steps: 
 
1. 94°C 5 min  initial denaturation 
2. 94°C 1 min  cycle denaturation 
3. 52°C 1 min  primer annealing 
4. 72°C 1 min  elongation  steps 2 to 4 were repeated 35 times 
5. 72°C 10 min  final elongation 
 
For purification of DNA fragments for subsequent in vitro transcriptions, PCR 
reactions were purified with the PCR-clean-up Kit provided by Macherey-Nagel. The 
manufacturer’s instructions were followed and DNA fragments were eluted in TE 
buffer. 5’- and 3’-DNA fragments for subsequent site-overlap extension PCRs were 
separated by agarose gel electrophoresis, visualized by ethidiumbromide and UV 
light. The DNA band was cut out with a razor blade and transferred to a 2 ml-reaction 
tube. DNA was extracted from the agarose and purified with the PCR-clean-up Kit by 
Macherey-Nagel according to the manufacturer’s instructions. 
2.2.1.5 Transformation of yeast and E. coli 
For transformations, chemically competent cells of S.cerevisiae and E. coli were used. 
50 ml cultures of E.coli were grown to an OD600 of 0.3-0.5 and the cell pellet was 
washed twice with an ice cold solution of 50 mM CaCl2. After the addition of 
glycerol to a final concentration of 10% the cells were frozen in liquid nitrogen and 




stored at -80°C. For transformation competent cells were mixed with 50 ng plasmid 
DNA and incubated on ice for 30 min, followed by a heat shock at 42°C for 1 min. 
Subsequently, the cells were incubated for 1h at 37°C in LB medium before being 
transferred to Petri dishes containing a selection medium.  
50 ml cultures of S. cerevisiae were grown to an OD600 of 0.6-0.8. The cells were 
sedimented by brief centrifugation at 2500 x g and washed with buffer containing 10 
mM Tris, pH 7.5. Subsequently, the pellet was resuspended in a buffer containing 10 
mM Tris, pH 7.5 and 100 mM lithium acetate (LiT-buffer) and incubated shaking 
slowly at RT for 40 min. After a brief centrifugation the cells were resuspended in 
800 µl LiT-buffer and the designated DNA construct (250 ng for plasmids, 40 µg for 
PCR constructs) was mixed with 100 µl of cell suspension. As a carrier, salmon 
sperm DNA (1 mg/ml final concentration) was used and a solution of PEG 3350 (0.5 
g PEG/ml LiT final concentration) was added. A heat shock?) treatment was 
performed for 5 min at 42°C (except ts strains) before the cells were transferred to 
YPD medium and incubated at 37°C (or 25°C if the strain was temperature sensitive) 
for 1h. Petri dishes containing a selection medium were used to select for successful 
transformants. Positive clones were checked for the correct integration of the 
construct via colony PCR. 
 
2.2.1.6 Phenol-chloroform-isoamylalcohol (PCI) extraction and ethanol 
precipitation 
The PCI extraction is used to separate nucleic acids from proteins. Phenol and 
chloroform denature proteins and keep them in the organic phase, while nucleic acids 
stay in the aqueous phase. Samples were thoroughly mixed with an equal volume of 
PCI (phenol/ chloroform/ isoamylalcohol, pH 7.5-8.0 in the ratio 25:24:1, 
commercially available from Roth). Phase separation was accelerated by 
centrifugation at 16000 xg for 5 min. The aqueous phase was transferred into a new 
tube and nucleic acids were precipitated by adding 3 volumes of absolute ethanol, 0.1 
volume of 3M sodium acetate pH 5.3 and, in case of nucleic acid concentrations 
below 200 ng/µl, 10 µg/ml Glycoblue (Ambion) was added as a carrier. Proteins were 
precipitated from the organic phase by adding 5 volumes of absolute ethanol or 
acetone. Both, RNA and protein samples were kept at -20°C for at least 30 min. The 




precipitates were sedimented by centrifugation at 16000 x g for 20 min. The pellet 
was washed with 70% ethanol (v/v), subsequently dried and resuspended in the 
desired solution. 
 
2.2.1.7 Proteinase K digestion 
Proteinase K digestion of (reconstitution) reactions were performed to obtain protein-
free RNA samples. All proteinase K digestions were done at a final concentration of 
0.2 % (w/v) SDS, 10 mM EDTA and 0.3 mg/ml proteinase K. Reactions were mixed 
thoroughly and incubated for 30 min at 37 °C. Subsequently, reactions were filled up 
to 200 μl with  “stop- splicing” buffer and RNAs were extracted by PCI and 
precipitated with ethanol. 
 
“stop-splicing” buffer 
50 mM NaOAc (pH 5,3) 
0,27 mM EDTA 
0,1 % (w/v) SDS 
 
2.2.1.8  In vitro transcription 
In vitro transcriptions of RNA were carried out using different DNA templates 
derived from PCR reactions or linearized plasmid DNA (plasmid was restricted with 
Acc651 and then purified via PCI and ethanol precipitation). Depending on the type of 
the promoter of DNA templates, either Sp6 or T7 were used as DNA-dependant RNA 
polymerases. The synthesis of radioactively labeled pre-mRNA was performed using 
[α-32P] UTP in a small  reaction whereas the transcription of “cold” pre-mRNA was 
carried out in a preparative scale. For subsequent labeling of pre-mRNAs with a 
fluorescent dye, α-GMPS was used in a 10:1 ratio over α-GTP to be used as a starter 
nucleotide (for details see “pre-mRNA labeling”). The transcription reactions were 
incubated for 2,5 h at 37 °C or 40 °C (for T7 and Sp6 polymerases, respectively). The 
reaction mixture was then loaded on a 5 % denaturing polyacrylamide RNA gel 
containing 8 M urea. In the case of radioactively labeled RNA, the transcript was 
detected by autoradiography whereas cold transcript was visualized by UV-




shadowing at 312 nm. The RNA bands were cut out from the gel and transferred to a 
2ml reaction tube, 1,8 ml of RNA elution buffer was added to the tube and the elution 
of the pre-mRNA from the gel piece was carried out by shaking at 4°C over night. 
The next day, the supernatant without gel pieces was transferred to a chromatography 
column and filtered followed by ethanol precipitation as described above. The 
resulting pellet was resuspended in ddH2O and stored at -20 °C. The concentration of 
the cold RNA was determined as described above. From the radioactively labeled pre-
mRNA, 1 μl was counted in a scintillation counter and the specific activity of the 
transcript was calculated with the formula: 
 
 
  where age of 32P is in weeks; SA 32P = specific activity of 32P, usually 3μCi/pmol; 
  # of Us = number of U residues per transcript. 
 
Radioactivly Labeled Transcription 
Template   0.1 µg /µl 
RNA polymerase buffer (NEB) 1x    
rNTPs     A,C+G [0.5 mM];  U [0.1 mM] 
RNasin (Promega)  2 U/µl   
α -32P] UTP (3000 Ci/mmol) 1 µl/4 µl reaction  
 
 
Unlabeled Transcription  5x selfmade transcription buffer 
Template   0.05-0.1 µg/µl   200 mM  Tris pH 8.0 
Selfmade transcription buffer 1x    150 mM  MgCl2 
rNTPs     2.5 mM each   10 mM   Spermidine 
RNasin (Promega)  2 U/µl    50 mM   DTT 
Pyrophosphatase (NEB)  0.02 U/µl    
RNA polymerase (Sp6/T7) 2 U/µl     
    
 
 




2.2.1.9 Denaturing polyacrylamide gel electrophoresis of RNA (splicing 
products) 
Denaturing polyacrylamide gel electrophoresis was mainly used to separate RNA 
species up to 1500 bp in size. The gels contained 8M urea as denaturing agent and 
were used with acrylamide concentrations between 5% and 10%. The acrylamide 
polymerization was initiated by adding ammonium persulfate and TEMED. RNA 
samples were resuspended in RNA loading dye and denatured at 70°C for 3 min prior 
to gel loading. The electrophoresis was performed in 1x TBE buffer at a constant 
voltage. To allow a better separation of the splicing products and intermediates, an 
optimized ratio of acrylamide to bisacrylamide (29:1) was used. RNAs were 
visualized either by silver staining or autoradiography. In case of preparative 
separations e.g. electrophoresis of in vitro transcriptions, UV highlighting was 
sufficient to visualize the RNA fragments. 
 
RNA Gel solutions (per 20 ml): 
8 M (w/v) Urea 
5 % to 10 % acrylamide (either Rotiphorese Gel 40 solution or a 29:1 mixture of 
Rotiphorese Gel A and B) 
2 ml 10 x TBE 









[%] [bases] [bases] 
   
5 130 35 
6 106 29 
8 76 26 
10 55 12 
20 28 8 
 




2.2.1.10 Silver staining of RNA gels  
Silver staining of RNA gels was essentially performed as described by (Merril, 
Goldman et al. 1981). First, the gel was fixed in a solution of 40% methanol and 10% 
acetic acid for at least 30 min or overnight. The gel was then washed twice with a 
solution of 10% ethanol and 5% acetic acid for 15 min. Afterwards, it was briefly 
rinsed with ddH2O and subsequently stained with a solution of 12 mM AgNO3 for 30 
min. The stained gel was briefly rinsed with ddH2O again and then incubated with the 
developing solution (0.28 M Na2CO3, 0.0185% formaldehyde) until RNA bands 
became visible. The developing reaction was stopped by the addition of 5% acetic 
acid.    
 
2.2.1.11 Northern blot analysis  
Northern blotting was used to detect specific RNAs, using radioactively labeled DNA 
probes complementary to the respective RNA.  
RNA samples were separated using denaturing polyacrylamide gel electrophoresis 
(see 2.2.1.9) and subsequently transferred to a nylon membrane via a semidry blotting 
procedure. The transfer was carried out in 0.5x TBE at 3mA/cm² of gel surface for 2h. 
After blotting, the RNAs were crosslinked to the membrane via UV irradiation with 
1200 µJoule x100. Before adding the probes, the membrane was incubated with pre-
hybridization buffer (see Table 2.1) at 42°C for 2h. The pre-hybridization buffer was 
exchanged with fresh hybridization buffer containing the radioactive probes, and the 
hybridization was carried out for 24-48h at 42°C.  
 
 
Pre-/ Hybridization Buffer     20 x SSC 
25 mM Na3PO4 pH 6.5      300 mM Na-Citrate 
6 x SSC       3 M NaCl 
5 x Deinhardt’s solution 
0.5 % (w/v) SDS      100 x Deinhardt’s solution 
50 % (v/v) Deionized formamide     2 % (w/v) Polyvenylpyrolodase 
0.1 mg/ml Salmon sperm DNA (5 min denat.)   2 % (w/v) BSA 
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Wash Buffer 1      Wash Buffer 2  
2 x SSC       2 x SSC 
0.5 % (w/v) SDS      0.1 % (w/v) SDS 
 
Table 2.1: Solutions for Northern blotting 
After hybridization, the membrane was washed twice at RT for 5 min with wash 
buffer 1 and twice with wash buffer 2. A third wash step with wash buffer 2 was 
performed for 30 min at 50°C.  The radioactive probes were visualized via 
autoradiography. 
The radioactive probes were generated using the Prime It II random primer labeling 
kit according to the manufacturer’s instructions. 
 
 
2.2.2 Protein-biochemistry standard methods  
2.2.2.1 Concentration determination of proteins  
To determine the concentration of proteins mainly the Bradford protein assay was 
used. This method involves the binding of Coomassie Brilliant Blue G-250 dye to 
proteins (Valadkhan and Jaladat 2010). The dye exists in three forms: cationic (red), 
neutral (green), and anionic (blue). Under acidic conditions, the dye is predominantly 
in the cationic form with an absorption maximum at 470 nm. When the dye binds to 
protein, it is converted to the blue form and the absorption maximum shifts to 595 nm. 
Using a protein standard, it is possible to determine the concentration of a protein 
solution. During this work the Bradford protein assay kit from Biorad was used, 
according to the manufacturer’s instructions.  
 
2.2.2.2  Ethanol precipitation of proteins for Mass Spectrometric analysis 
For mass spectrometry analyses of proteins associated with spliceosomal complexes, 
the peak fractions of the respective second glycerol gradient were combined in low-
protein binding 1.5 ml reaction tubes (Eppendorf). 350 μl of combined fractions (in 
case it was more, dried down to ~300µl) were supplemented with 40 μg glycoblue, 35 




μl of 3 M NaOAc (pH 5.2) and 1100 μl of ethanol. After thorough mixing the solution 
was stored at least over night at -20 °C and then centrifuged for 30 min at 13.000 rpm 
and 4°C in a table top centrifuge. Subsequently, the pellet was washed with 70 % 
ethanol, dried in a vacuum dryer and resuspended in 1x SDS PAGE loading buffer 
from invitrogen. 
      
2.2.2.3 Denaturing Polyacrylamide Gel Electrophoresis (PAGE)  
To analyze proteins via denaturing PAGE either pre-casted NuPAGE® Bis-Tris gels 
(4-12%) or self-casted polyacrylamide gels which were use for mass spec only were 
prepared according to the procedure established by Laemmli (1970). Commercial gels 
were used according to the manufacturer’s instructions. For self-casted gels typical 
gel compositions are listed below: 
 
stacking gel      8% separating gel 
4x stacking gel buffer   375.0 µl  4x separating gel buffer  1250.0 µl 
Rotiphorese Gel 30  250.5 µl  Rotiphorese Gel 30  1332.5 µl 
H2O    874.5 µl  H2O   2417.5 µl 
APS      10.0 µl  APS      16.75 µl 
TEMED        1.0 µl  TEMED       16.75µl  
  
Protein samples were dissolved in protein loading dye and heated up to 95°C for 5 
min prior to loading. Electrophoresis was typically performed at 150-200V for 45 min 
using Biorad mini gel systems. The gels were stained either with Coomassie Brilliant 
Blue or with silver.  
2.2.2.4 Coomassie staining of protein gels  
Coomassie Brilliant Blue G-250 is a triphenylmethane dye forming strong non 
covalent complexes with proteins. Coomassie staining of protein gels was essentially 
performed as described in (Sambrook, Russell et al. 1989).   For preparing a staining 
solution, 80 mg Coomassie Brillant Blue G-250 were dissolved in 1l ddH2O and 
stirred for at least 2 h. Subsequently, 3.5 ml of 37.5 % HCl was added to the solution 
and the solution was stored in an amber glass bottle at room temperature. For 




Coomassie staining of proteins, gels were first fixed for 30 min with 40% 
methanol/10% acetic acid at room temperature on a shaker. After rehydration of the 
gel in ddH2O pre-heated, staining solution was added to the gel. After incubation for 
at least 1 h at room temperature under gentle shaking the gel was destained over night 
with water. Finally, the gel was scanned and lanes were cut into 23 slices and 
analyzed by mass spectrometry in Prof. Urlaub’s department. 
 
Coomassie staining solution:    Destaining solution:  
50% (v/v) Methanol      50% (v/v) Methanol  
10% (v/v) Acetic acid      10% (v/v) Acetic acid  
0.25% (w/v) Coomasie Brillant Blue G-250  
 
2.2.2.5 Silver Staining of Protein Gels 
Silver staining of protein gels was performed according to Blum (1987). First, the gel 
was fixed in a solution of 50% (v/v) Methanol/ 12% (v/v) acetic acid for at least 30 
min or overnight. Subsequently, the gel was washed twice with 50% (v/v) ethanol and 
once with 30% (v/v) ethanol for 20 min each. The gel was then treated with a solution 
of 0.8 mM Na2S2O3 for 60 s and briefly rinsed with water. Afterwards, the gel was 
stained with a solution of 12 mM AgNO3/ 0.026 % formaldehyde for 20 min. The 
staining solution was removed and the gel was rinsed with water, before adding the 
developing solution (56 mM Na2CO3, 0.0185% formaldehyde, 16 μM Na2S2O3). To 
stop developing, the gel was transferred in a solution of 50% (v/v) Methanol/ 12% 
(v/v) acetic acid.  
 
2.2.2.6 Western blot analysis  
For western blot analysis, proteins were transferred to a nitrocellulose membrane 
(Protan BA83 nitrocellulose, 0.2 µm by Schleicher & Schuell) by a wet blot 
procedure. A Biorad Mini Trans-Blot cell was used according to the manufacturer’s 
instructions. The transfer usually was performed at 250 mA for 2h and a Slab4, 
methanol, H2O mixture (in a ratio of 5:2:3) was used as transfer buffer. After the blot, 
the membrane was stained with Ponceau S to check for a proper transfer. The stain 




was removed by washing with a TBS-Tween solution (1x TBS, 0.1% Tween) 2-3 
times for 5 min each. Next, the membrane was incubated for 1h at RT in a TBS-
Tween solution containing 5% fat free milk powder, to block unspecific interactions 
between the antibody and the membrane. The antibody was then added to the 
blocking solution in the designated dilution and incubated at RT for 1h. Afterwards, 
the membrane was briefly rinsed with TBS-Tween twice, and then 2 times with TBS-
Tween for 20 min each. If a second antibody was needed, it was added after this step 
and the previous steps were repeated.  
 
2.2.3 Purification of recombinant proteins  
Cloning of the genes and purification of the recombinant proteins described in this 
work was performed by Dr. Jana Schmitzová, Group of Dr. Pena, MPI-BPC 
Göttingen. 
  
2.2.3.1 Cloning strategy and overexpression 
Genes, coding for the proteins used in this study, were cloned as described in 
Warkocki et al., 2009: full length PRP5, PRP2 and CWC25 genes (genes are always 
in italics) and the N-terminally truncated form of SPP2 (aa 36-185) were amplified by 
standard PCR and ligated into the following vectors: PRP2, SPP2 into pET21a 
(Novagen). This resulted in fusion proteins with a C-terminal hexahistidine tag. 
CWC2 was  ligated into pETM11, resulting in N-terminal hexahistidine tagged fusion 
proteins. Here the tag was cleavable with a tobacco etch virus (TEV) protease. For 
subsequent labeling of Cwc25, an N-terminal or C-terminal Cysteine tag was 
introduced by standard PCR and the resulting DNA was cloned as done for 
the wildtype CWC25. After verification of the constructs by sequencing, the plasmids 
were transformed into the E.coli strain Rosetta II (Novagen) and cultures were grown 
in 2xYT medium or in autoinducing medium containing antibiotics for selection of 
the plasmids (Studier, 2005). In the case of 2xYT medium, cultures were induced by 
adding 0.6 mM IPTG for His-tagged proteins and by 0.1 mM IPTG for GST-tagged 




proteins. After 20 h (or 48 h in the case of auto-inducing medium) at 17°C, the cells 
were harvested, the pellets were washed and stored at -80°C. 
 
2.2.3.2 Purification of proteins 
All purification steps were performed at 4°C. First, the cell pellets were resuspended 
in 5 ml lysis buffer per 1g of cells and lysed with a microfluidiser at 80 psi for six 
times (Microfluidics). After pelleting insoluble material by centrifugation for 40 min 
at 10,000 rpm in a Sorval SS34 rotor, the supernatant was applied to HisTrap HP FF 
crude or GSTrap HP columns (GE Healthcare) which were equilibrated with the 
respective lysis buffer using the Äkta Prime system (GE Healthcare). For His-tagged 
proteins the column was first washed with 10 column volumes (CV) of Hislysis 
buffer, then with 2 CV of washing buffer, again with 2 CV of lysis buffer and finally 
with 3 CV of 5% elution buffer in lysis buffer. After additional washing with 2 CV 
each of 10, 15 and 20 % elution buffer, proteins were eluted in a 20 CV gradient of 
20-100 % elutionbuffer.For GST-tagged proteins the columns were washed with 10 
CV of GST-lysis buffer, then with2 CV of washing buffer followed by 2 CV of GST-
lysis buffer. The proteins were eluted with 2 CV of 30 mM reduced glutathione 
containing lysis buffer. Eluted proteins were dialyzed against His-lysis buffer 
containing 20 mM imidazol for Histagged proteins and against GST-lysis buffer for 
GST-tagged protein versions. The tags were cleaved by the addition of TEV (Cwc25) 
proteases. The proteases were removed by affinity chromatography, retaining the 
proteases on the matrix, while purified proteins were eluted in the flow-through. 
Proteins were finally concentrated using Centricon concentrators (Millipore) and 
underwent further purification by gel filtration chromatography in buffers containing 
20 mM HEPES-NaOH pH7.5, with salt concentrations between 100 and 300 mM 
NaCl (depending on the protein), 2 mM DTT and 5 % glycerol. Fractions of the gel 
filtration step were analyzed by SDS-PAGE and Coomassie staining. Fractions with 
97 % or higher purity were aliquoted, deep-frozen in liquid nitrogen and stored at -
80°C. Concentration was determined as described above using BCA protein assay 
standard kit. 
His-tag Lysis buffer      His-tag Elution buffer 
50 mM HEPES pH 7.5     50 mM HEPES pH 7.5  
600 mM NaCl      600 mM NaCl  




-Mercaptoethanol    -Mercaptoethanol 
10 % glycerol      10 % glycerol  
20 mM Imidazole     250 mM Imidazole   
 
His-tag Wash buffer   
20 mM HEPES-NaOH pH 7.5       
2M LiCl          
5% glycerol  
 
Buffer for gelfiltration of His-tagged proteins 
20 mM HEPES pH 7.5  
200 mM NaCl   




2.2.4 Purification of MS2MBP Protein 
The MS2-MBP fusion protein used for the purification of spliceosomal complexes 
was expressed and subsequently purified from electrocompetent BL21 DE pLysS 
cells. Cells containing the plasmid encoding the MS2-MBP protein were grown to an 
OD600 = 0.3-0.6 at 37°C in LB medium supplemented with the respective antibiotics. 
To induce the expression, IPTG was added to a final concentration of 0.1 mM and the 
cells were incubated further until they reached an OD600 = 2-2.5. The cultures were 
harvested by centrifugation and the cell pellets were subsequently washed with 
ddH2O. For cell lysis, the pellet was resuspended in 5 ml lysis buffer (20 mM Tris-
HCl, pH 7.6, 200 mM NaCl, complete EDTA-free protease inhibitors from Roche 
according to the manufactures instructions) per gram of cells and processed with a 
microfluidiser (Microfluidics) at 80 psi for 2-3 times. The lysate was separated from 
cell debris by centrifugation (12000 x g, 4°C, 40 min) and incubated head-over-tail 
with 500 µl of amylose resin per 10 ml of lysate for 2h. Afterwards, the suspension 
was transferred into a Bio-Spin chromatography column (Biorad) and the resin was 
washed with 10 column volumes (CV) of wash buffer (20 mM HEPES, pH 7.9, 150 
mM NaCl, 0.05% NP-40). To decrease the salt concentration in view of the next 




purification step the amylose resin was washed with 5 CV of 5 mM Na2HPO4, pH7.0 
before the protein was eluted with 5 mM Na2HPO4 containing 20 mM maltose. The 
eluate was loaded onto a heparin agarose column equilibrated with 5 mM Na2HPO4, 
pH7.0. After washing with 10 CV of 5 mM Na2HPO4, pH7.0, the MS2-MBP protein 
was eluted using a higher salt concentration within the elution buffer (20 mM 
HEPES/KOH, pH 7.9, 100 mM KCl, 15% Glycerol, 0.5 mM DTT). The protein was 
shock frozen in liquid nitrogen and stored at -80°C. 
 
 
2.2.5 Cell culture and extract preparation  
2.2.5.1 Cultivation of bacteria 
E. coli cells were grown in lysogeny broth (LB) medium (Sambrook, Russell et al. 
1989), 2xYT medium or in autoinducing medium (Studier 2005). The medium was 
autoclaved for 15 min at 121°C. For the selection of antibiotic resistances the medium 
contained Ampicillin (100 µg/ml), Chloramphenicol (30 µg/ml) or Kanamycin (30 
µg/ml). Cells were stored for long term at -80°C by adding 15% glycerol as a 
cryopreservative.  
 
2.2.5.2 Cultivation of yeast cells  
S. cerevisiae yeast cells were cultivated according to standard methods in YPD 
medium or on YPD-plates. To prepare YPD plates, first YP-medium including agar 
was autoclaved for 15 min at 121°C and cooled down to 60 °C. Subsequently, 40 ml 
of sterile 50 % glucose was added per liter of YP medium (final concentration of 2 
%). Subsequently, about 20-25 ml of this medium was poured into Petri dishes. Plates 
were cooled down for ca. 1 h at roomtemperature and kept at room temperature for 
long-term storage. To start cultivation of a yeast strain, yeast cells were picked from a 
glycerol stock and streaked on a YPD-plate. The plate was then incubated for 2-3 
days at 25°C or 30°C depending on the phenotype of the cells (BJ2168 at 30°C, prp2-
1 and prp5-1 at 25°C). In the case of a replica-assay (named also frog-assay), a serial 
dilution of the yeast strain of interest was spotted on four different YPD-plates which 




were then incubated at 16°C, 25°C, 30°C and 37°C. Cell growth was checked after 1-
3 days and documented. For a long-term storage of the cells, the plates were sealed 
with parafilm and kept at 4°C up to 2 months. For subsequent extract preparation, a 
single colony of yeast cells from the YPD-plate was transferred to 50 ml YPD-
medium in a 250 ml Erlenmeyer flask and incubated under shaking at the optimal 
temperature (25°C -30 °C) depending on the yeast strain. OD600 of the cells in the 
pre-culture was determined and usually 20 OD of cells was inoculated into 2 liters of 
YPD medium in a 5 L Erlenmeyer flask. Alternatively, 100 L of YPD medium in a 
fermenter were inoculated with 1000 - 2500 OD600 of yeast cells (depending on the 
strain) and supplemented with 4 L 50% glucose and tetracycline and ampicillin (10 
μg/ml final concentration each) and incubated at the optimal temperature. Usually 
after 18-22 hours, cells reached an OD600 of 3-5 / ml and were harvested. For a 
longer storage in YPD medium, 800 μl of yeast cells were mixed with 400 μl of sterile 
50% glycerol and kept at -80°C. 
 
YPD-medium 
2 % (w/v) Bacto pepton 
1 % (w/v) Yeast extract 2 % (w/v) Glucose (sterile filtered) 
1 % (w/v) Bacto agar in the case of YPD-plates 
2.2.5.3 Preparation of yeast whole cell extracts and immunodepletion  
The preparation of yeast whole cell extracts for subsequent use during in vitro 
splicing reactions was performed essentially as described by Gottschalk, Neubauer et 
al. (1999). Yeast cells from the strains BJ2168, prp5-1 or prp2-1 (and its tagged 
derivatives), were grown overnight at 30°C (or 25°C for temperature sensitive strains) 
up to an OD600 of 3.5-4.5/ml in 5 L flasks or 10 L up to 100 L fermenter. Cells were 
pelleted for 10 min at 5000 rpm in an SLC-6000 rotor. The pellet was washed twice 
with cold H2O and subsequently resuspended in cold AGK buffer (20 mM 
HEPES/KOH pH 7.9, 200 mM KCl, 1.5 mM MgCl2, 8% (v/v) glycerol) supplemented 
with 0.5 mM DTT, 0.5 mM PMSF, 2 mM benzamidine, 1 μM leupeptin, 2 μM 
pepstatin A, 4 μM chymostatin, and 2.6 μM aprotinin. Alternatively, AGK buffer was 
supplemented with 0.5 mM DTT, 0.5 mM PMSF, 2 mM benzamidine and one EDTA-
free complete protease inhibitor tablet from Roche per 50 ml of AGK buffer. The 




volume of the suspension was measured and the concentration of KCL was adjusted 
to 200 mM again. To obtain yeast beads 2-5 mm in diameter, the cell suspension was 
dripped into liquid nitrogen, using a separating funnel. For cell lysis, these beads were 
ground in liquid nitrogen at 18000 rpm using a centrifugal mill (Retsch). The powder 
formed during the grinding process was slowly thawed at RT, and the cell debris were 
separated from the extract by centrifugation (25000 x g, 4°C, 30 min). A second 
centrifugation step at high speed was used in order to clarify the extract (100000 x g, 
4°C, 1h). During the centrifugation the extract was separated into three phases. The 
upper phase contained lipids and liposomes, the middle phase was clear and the pellet 
contained ribosomes, DNA and fine cell debris. The middle phase was recovered and 
dialyzed twice against 50-100 volumes of buffer D (20 mM HEPES/KOH pH 7.9, 50 
mM KCl, 0.2 mM EDTA, 0.4 mM MgCl2, 20% (v/v) glycerol, 0.5 mM DTT, 0.5 mM 
PMSF, 2 mM benzamidine) for 1.5h each. After dialysis, the extract was centrifuged 
at 17000 x g for 5 min and subsequently frozen in liquid nitrogen. The extract was 
stored for long term at -80°C. 
2.2.6 Special methods 
2.2.6.1 In vitro splicing reactions  
In vitro splicing reactions were performed essentially as described by Fabrizio, 
McPheeters et al. (1989). A splicing reaction usually contained 40% total yeast 
extract, 1x splice cocktail (see below) and 40.000 cpm (0.4 nM) of radioactively 
labeled Actin WT pre-mRNA. The reactions were incubated at 23°C for 0-60 min and 
aliquots were taken at several time points. The reactions were stopped by storing them 
on ice. Afterwards, Proteinase K digestion was used to strip off completely the 
proteins of the RNA. A typical Proteinase K reaction included the sample to be 
digested, 0.2% SDS (w/v), 10 mM EDTA and 0.3mg/ml proteinase K. The reactions 
were incubated at 37°C for 30 min. Subsequently, 200 µl of  “Stop-splicing” buffer 
were added, PCI extraction was performed followed by ethanol precipitation (2.2.1.6). 
The RNAs were separated by denaturing PAGE and the gels were analyzed by 
autoradiography.  
 
5x splicing cocktail: „stop splicing“ buffer 
50 mM NaOAc (pH 5.3) 
0.27 mM EDTA 
0.1 % (w/v) SDS 




300 mM phosphate buffer, pH 7.3* 
15 % (w/v) PEG 8000 
10 mM ATP 
12.5 mM MgCl2 
10 mM spermidine 
 
*phosphate buffer at pH 7.3 was prepared by mixing solutions of K2HPO4 and KH2PO4 according to 
Sambrook, Russell et al. (1989). 
 
2.2.6.2 Purification of spliceosomal complexes 
To isolate spliceosomal complexes under native conditions according to the protocol 
of Fabrizio, Dannenberg et al. (2009); (Dannenberg, Fabrizio et al. 2012) the M3-Act 
pre-mRNA wild type or truncated substrate was bound to the MS2-MBP fusion 
protein by incubating a 30-35 times molar excess of MS2-MBP with the designated 
pre-mRNA and 20 mM HEPES-KOH, pH 7.9 on ice for 30 min.  
Depending on the required amount of spliceosomal complexes, a 6–72 ml splicing 
reaction containing 1.8 – 2.5 nM of 32P-labeled M3-Act pre-mRNA (specific activity 
20–300 cpm/fmol) was performed in 60 mM K-PO4 (pH 7.4), 3% PEG 8000, 2.5 mM 
MgCl2, 2.0 mM ATP, 2.0 mM spermidine, and 40% yeast extract in buffer D (20 mM 
HEPES-KOH, pH 7.9, 50 mM KCl, 0.2 mM EDTA pH 8.0, 20% (v/v) glycerol, 0.5 
mM DTT, and 0.5 mM PMSF). The complexes were assembled by incubating at 23°C 
for 50 min.  Complex C was treated additionally with a 125-fold molar excess of a 
DNA oligonucleotide complementary to nt +13 to +24 of the actin intron and the 
reaction was incubated for 10 min at 30 °C to allow cleavage by RNaseH present in 
the extract (Fabrizio, Dannenberg et al. 2009); (Bessonov, Anokhina et al. 2008) 
During this procedure, the endogenous RNase H present in the extract digests the 
RNA intron of early spliceosomal complexes whose presence would complicate the 
purification.  
After this procedure, six ml aliquots of the splicing reaction were loaded onto 36-ml 
linear 10-30% (w/w) glycerol gradients containing GK150 buffer (20 mM HEPES-
KOH pH 7.9, 1.5 mM MgCl2, 150 mM KCl). Gradients were centrifuged for 14 h at 
23.000 rpm in a SureSpin 630 rotor (Thermo Scientific) and harvested manually in 
1500-μl fractions from the top. Fractions were analyzed by Cherenkov counting in a 




scintillation counter and peak fractions containing complexes were pooled and loaded 
onto columns containing 250–300 μl of amylose matrix euilibrated with GK150 
buffer. The matrix was washed two times with 10 ml GK150 buffer and two times 
with GK75 buffer supplemented with 5% glycerol and 0.01% NP40, and spliceosomal 
complexes were eluted dropwise with 750 μl elution buffer (GK75 buffer containing 
12 mM maltose, 5% glycerol and 0.01% NP40). The elution fractions were either 
used directly for reconstitution assays or for FCCS. 
 
2.2.6.3 Non-denaturing Complex gels 
First, a standard splicing assay is performed. After the incubation time of the splicing 
reaction (10 µl sample volume) 2 µl Stop Heparin Mix* has to be added to each 
sample. Keep on ice, treat the sample gently. Do NOT vortex. Then, 3.0 µl of teach 
sample has to be loaded on a complex gel* 4% (80:1). The gel should be poured one 
day before and wrapped with foil. Keep at 4°C. Run the gel at 300V for 30 min and 
then at 230V for 5 h at 4°C. Change the T.E. running buffer every hour. For analysis 
of the splicing intermediates on denaturing PAGE, PK-digestion has to be performed. 
Therefore, 40 µl of PK-mix has to be added to the rest of each sample (see PK-
digestion of proteins) 
“Stop Heparin” Mix: 
Complex gel solution 4 %/(80:1; Acrylamide/Bis-Acrylamide): 
In T.E 1x (20 mM Tris-HCl, pH 8.0, 1 mM EDTA, pH 8.0) 
 
2.2.7 Reconstitution of functional spliceosomes for FCCS 
2.2.7.1 Treatment of complexes for RNA PAGE 
10 fmol of B
act_ΔPrp2 complexes from the elution of the amylose  matrix  were 
supplemented with 100 fmol (10x molar excess) of recombinant proteins in a 40 μl 
reaction. After incubating the reconstitution reaction for 10 min on ice, a 10x “rescue” 
solution was added to the reaction. After thorough mixing the reactions were 
incubated at 23 °C for 40 to 50 min. After Proteinase K digestion the RNAs were 




extracted by PCI and ethanol precipitation and analyzed by an 8% denaturing PAGE 
followed by autoradiography. 
 
2.2.7.2 Reconstitution on Amylose Matrix 
For reconstitution assays on the amylose matrix, complexes were kept on the matrix 
and transferred to a 1.5 ml reaction tube. Complex concentration was determined by 
Cherenkov counting and recombinant proteins were added in 10x molar excess. A 
typical reconstitution reaction was performed with 250 µl-300 μl amylose beads in a 
final volume of 600 μl (in GK 75 buffer) containing 60 μl “rescue” solution. 
Reactions were incubated  at 23°C for 45 min and transferred back to a plastic column 
(one per each reaction). If ATP had to be depleted, the reaction was supplemented 
with 2 mM glucose and 2 Units recombinant hexokinase and incubated for 10 min at 
23 °C before the matrix was transferred back to the column. The reaction was then 
washed thoroughly with 10 ml of GK75 buffer and the complexes were eluted with 20 
mM maltose as described above. If several reactions were to be reconstituted on the 
amylose matrix, the peak of the SureSpin gradient was divided equally to the 
appropriate number of chromatography columns containing 250 μl amylose beads. 
Reactions were then carried out like described above, but in a final volume of 500 μl. 
 
2.2.7.3 In-solution 
For real-time FCCS measurements, i.e. from reactions carried out in solution, 
reactions were carried out in a final volume of 60 μl with a final complex 
concentration of 0.8 nM-1.1 nM. Recombinant proteins were added in 10 fold excess. 
Instead of the 10x rescue mix, however, the reaction conditions were only adjusted to 
final concentrations of 2.5 mM MgCl2 and 2 mM ATP (or other analogues), as 
PEG8000 increased the background of the FCCS measurements. 
10x “rescue” solution 
200 mM phosphate buffer, pH 7.3 
10 mM MgCl2 
20 mM ATP 




14 % PEG 8000 
 
2.2.8 Mass spectrometry 
For Mass spectrometry, proteins recovered from purified spliceosomal complexes 
(usually between 100-400 fmol), were separated by SDS-PAGE using a 4-12% Bis-
Tris-HCL (pH 7.0) NUPAGE polyacrylamide gel (Invitrogen) and stained with 
Coomassie. Entire lanes were cut into 23 slices and proteins were digested in-gel with 
trypsin and extracted as described by described Shevchenko, Wilm et al. (1996). 
Resulting peptides were analyzed in an LC-coupled ESI Q-ToF (QToF Ultima, 
Waters) and/or OrbitrapXL (ThermoFisher Scientific) mass spectrometer under 
standard conditions. Proteins were identified by searching fragment spectra against 
the NCBI nonredundant (nr) database using Mascot as search engine. 
 
2.2.9 Electron Microscopy 
Eluted complexes were fixed by loading onto a 3.8 ml linear 10%–30% glycerol 
gradient containing 0.1% gluteraldehyde in the 30% gradient solution and centrifuged 
for 107 min at 490,000 g (Kastner, Fischer et al. 2008). Gradients were fractionated 
from the bottom using a fraction collector. Particles were negatively stained by the 
double-carbon film method (Golas, Sander et al. 2003). Images were taken at 160 kV 
and a magnification of 88,000 or 115,000 in eucentric height at a defocus of 1.5 mm 
in a CM200FEG microscope (FEI, Eindhoven, The Netherlands) at RT on a 4 k 3 4 k 
CCD camera (TVIPS GmbH, Gauting, Germany) using 2-fold pixel binning. About 
10,000 particle images were collected for each data set and were subjected to single-
particle image processing at the level of 2D projection images using the IMAGIC-V 
software package (Image Science GmbH, Berlin, Germany). Good-quality class 
averages were obtained after several iterations of alignment, multivariate statistical 
analysis (MSA), and classification. 
 




2.2.10 Labeling Methods 
2.2.10.1 Preparation of yeast strains expressing EGFP-tagged proteins 
To construct yeast strains with the yEGFP tag at the C terminus of selected proteins, 
the yEGFP cassette was amplified by PCR from the plasmid pKT209 (purchased from 
Euroscarf, Frankfurt am Main). We used this PCR product to transform haploid yeast 
cells from strain 3.2.AID/CRL2101 (Yean and Lin 1991), and transformants were 
selected on synthetic dextrose dropout medium lacking uracil. The correct integration 
of the tag in the genome was confirmed by PCR, and on the protein level by western 
blotting. The resulting strains carry a single chromosomal copy of the gene of interest, 
containing the yEGFP tag, the Candida albicans URA3 marker at their C terminus and 
in addition a temperature-sensitive Prp2 ATPase (prp2-1). 
 
2.2.10.2 Pre-mRNA labeling with a fluorescent dye 
Guanosine-5’-O-monophosphorothioate (59-GMPS) can be incorporated as the first 
nucleotide by T7 or Sp6 RNA polymerase (dependent of the used promoter) in vitro. 
5’-GMPS-containing mature actin pre-mRNA was prepared by in vitro transcription 
of Acc65I digested pUC18-Actin-wt plasmid DNA with T7(Sp6) RNA polymerase 
(40 mM Tris-HCl, pH 8.0, 30 mM MgCI2, 10 mM DTT, 2 mM spermidine, 0.1 U 
yeast inorganic pyrophosphatase (NEB), 0.5 U RNasin (Promega), 4 mM ATP, 4 mM 
CTP, 4 mM UTP, 1 mM GTP, 10 mM 5’-GMPS (Biolog); 37°C, 3 h). Transcripts 
were purified by electrophoresis through 5% polyacrylamide, 8 M urea gels and 
passively eluted into 0.5 M NaOAc, pH 5.3, 1 mM EDTA, pH 8.0, 2.5% phenol–
chloroform–isoamyl alcohol. To link the 5’-GMPS-modified pre-mRNA covalently to 
the fluorescent dye Atto647N, Atto647N-maleimide was incubated with the pre-
mRNA in the presence of 100 mM NaPO4 (pH 7.2) at RT for 4 h. The Atto647N-
labeled pre-mRNA was prepurified by 4x ethanol precipitation and several washing 
steps to remove unreacted dye, resulting in nearly 100% labeled pre-mRNA. The 
dye:RNA stoichiometry was calculated according to the manufacturer’s protocol 
(Molecular Probes). 
The thiol group of the pre-mRNA and the maleimide group of the dye form a 
thioether linkage and are therefore covalently attached to each other. The labelling 




efficiency was determined by measuring the absorption of the RNA molecules at 260 
nm and the absorption of the attached dye at 647 nm. Efficiency in % is then 




where ε is the molar extinction coefficient,  # is the number of nucleotides of the 
respective pre-mRNA and A is the absorption. Usually a labeling efficiency of more 
than 98 % was obtained. 
 
 
2.2.11  Fluorescence Cross Correlation Spectroscopy (FCCS) 
2.2.11.1 Setup 
The two-color-dual-focus setup is based on an inverse epi-fluorescence microscope 
(MicroTime 200, PicoQuant GmbH, Berlin, Germany).The system is equipped with 
two identical pulsed 470 nm diode lasers (LDH-P-C-470 B, PicoQuant GmbH, Berlin, 
Germany) and two identical pulsed 635 nm diode lasers (LDH-P-635, PicoQuant 
GmbH, Berlin, Germany) with linear polarization and a pulse duration of 50 ps 
(FWHM). The lasers are pulsed alternately with an overall repetition rate of 10 MHz 
(PIE mode) corresponding to a delay between pulses of 25 ns (PDL 828 “Sepia II”, 
PicoQuant GmbH, Berlin, Germany). The light of each of the two pairs of identical 
wavelength lasers is combined by two polarizing beam splitters (Ealing Catalogue, St. 
Asaph, UK) into single beams. These beams are combined by a dichroic mirror (490 
dcxr, Chroma Technology, Rockingham, VT, USA) resulting in a single beam 
containing both wavelengths. The beam is coupled into a polarization-preserving 
single mode fiber. At the fiber output, the light is collimated and reflected up by a 
dichroic mirror (Q660LP, Chroma Technology, Rockingham, VT, USA). Before 
entering the objective, the light is passed through a Nomarski prism (U-DICTHC, 




Olympus Europa, Hamburg, Germany) which splits the beam deflects into two 
slightly different directions depending on their polarization. Then the light is focused 
into the microscope’s objective (UPLAPO 60x W, 1.2 N.A., Olympus Europa, 
Hamburg, Germany) and one thus obtains two overlapping foci with a fixed lateral 
distance determined by the properties of the Nomarski prism. Fluorescence is 
collected by the same objective (epi-fluorescence setup), passed through the 
Nomarski prism and the dichroic mirror, and focused by a tube lens through a single 
circular aperture (diameter 150 mm). After the pinhole, the light is re-collimated, split 
by a polarizing beam splitter cube and a dichroic mirror (640 dcxr, Chroma 
Technology, Rockingham, VT, USA), and focused onto two single photon avalanche 
diodes (SPAD, AQR13, Perkin Elmer, Wellesley, MA, USA), respectively for the red 
and the blue excitation. Emission bandpass filters HC692/40 and HC520/35 
(Semrock, USA) for red and blue excitation, respectively, positioned directly in front 
of each detector, discriminate fluorescence against scattered light. A single-photon 
counting electronics (HydraHarp 400, PicoQuant GmbH, Berlin, Germany) 
independently records the detected photons of all detectors with an absolute temporal 
resolution of 4 ps on a common time frame. 
2.2.11.2 Measurement protocol 
Spliceosomal complexes were assembled on fluorescently labeled pre-mRNAs 
(bearing Atto647 as a fluorescent label at the 5’-end) and purified as described above. 
On the amylose matrix complexes were supplemented with recombinant proteins as 
described. Complexes were kept on ice until measured by FCCS. Complexes were 
measured in a volume of 25 μl at a concentration of 1.1 nM in a reaction chamber 
consisting of two glass slides connected through a 1 mm spacer. Measurement was 






Spliceosome dynamics comprise a complex, but regulated interplay of several 
snRNPs and factors that interact sequentially with the pre-mRNA. The purification of 
spliceosomal complexes at distinct stages is very helpful to learn more about the 
composition, structur and function of the yeast spliceosome. In the last years, a 
number of purification strategies have been employed to purify human spliceosomes 
at different time points in vitro. To isolate and characterize biochemically 
homogeneous B, B
act
 and C complexes from the yeast S. cerevisiae, we first had to 
establish a system which is suitable for stalling the spliceosome assembly at distinct 
stages of the splicing cycle and allows purifying these complexes under native 
conditions. To purify the stalled complexes, we made use of an affinity selection 
method by using pre-mRNAs, modified at their 3’ or 5' end, which were fused to 
three MS2-binding sites (M3) to their 5’ end. Each stalled complex was isolated by a 
three step affinity selection method including centrifugation and affinity-selection  
(Deckert, Hartmuth et al. 2006); (Jurica and Moore 2002).Their proteomes was 
determined by mass spectrometry (MS), and their structures were examined by 
electron microscopy (EM). 
 
3.1  Pre-mRNA constructs and conditions used for the isolation of yeast 
spliceosomal complexes  
To isolate biochemically homogeneous B, B
act
 and C complexes actin pre-mRNA and 
its modifications were employed. For the later affinity purification, three MS2 binding 
sites were fused to the 5’ end of the various pre-mRNA constructs; the resulting 
constructs were termed “M3-Act”. Previous studies have shown that 
truncation/modification or mutation of the actin pre-mRNA and adjustment of the 
ATP concentration in the splicing reaction lead to stalling of the spliceosomal cycle 
(Cheng 1994);(Vijayraghavan, Parker et al. 1986); (Rymond and Rosbash 1985). The 
intron in the actin pre-mRNA contains the yeast consensus branch point sequence 





this sequence. Both of these, thus, lacked the 3'SS and the 3' exon. The variant M3-
ActACAC contained a mutation in the introns' 3'SS (AGAG to ACAC), which was 
followed by an unmutated but shortened 3' exon. The inclusion of only 0.05 mM ATP 
in the splicing reaction led to stalling of the spliceosomal cycle at the stage of the pre-
catalytic B complex for the wild-type and for the M3-ActΔ6 construct, as already 
observed in previews studies (Tarn, Lee et al. 1993).  
 
 
3.2 Preliminary work for stalling and isolating active spliceosomal complexes 
from yeast at defined stages 
Our first goal was to test if our “set up” worked for the isolation of spliceosomal 
complexes from the yeast S.cerevisiae thus, we verified that the presence of the three 
MS2 hairpins did not interfere with the splicing cycle and that the constructs were 
able to undergo spliceosome assembly. 
 
 
Figure 3.1: Pre-mRNA constructs used for the purification of spliceosomes    
(adapted from (Fabrizio, Dannenberg et al. 2009) 
M3-Act wt is used to assemble either complex B under low ATP concentrations while M3-ActΔ6 is used 
to stall Bact complexes. M3-ActΔ6 is truncated six nucleotides downstream of the BPS, M3-ActΔ31 is 
truncated 31 nucleotides after the BPS and stalls spliceosome assembly at the stage of complex C.  M3-






For the in vitro assembly of yeast spliceosomal complexes we made use of whole cell 
extract made from the S.cerevisiae strain BJ-2168 (a protease deficient strain) and the 
various M3-Act pre-mRNA constructs mentioned above. The extracts were made 
according to the protocol (see methods; (Fabrizio, Dannenberg et al. 2009); 
(Dannenberg, Fabrizio et al. (2012). A prerequisite for this was to in vitro transcribe 
the pre-mRNA constructs via SP6 or T7 polymerase For detection of the RNA by 
autoradiography, the pre-mRNA was radioactively labeled with [
32
P] -UTP during 
transcription. The inclusion of only 0.05 mM ATP in the splicing reaction led to 
stalling of the splicing cycle at the stage of complex B, both for M3-Act and M3-
ActΔ6 (Fig. 3.2 A lanes 6-8, 14-16). Raising the ATP concentration to 2.0 mM ATP 
led the splicing reaction to proceed to completion for the M3-act wt construct while 
the pre-catalytic B complex was converted into the activated B
act
 complex, showing 
neither splicing intermediates nor mature RNA, which identifies these complexes as 
pre-catalytic splicing intermediates (Figs. 3.2 A and B lanes 2-4, 10-12). When we 
applied the same conditions to the M3-ActΔ31 construct, we observed a different 
behavior compared to the M3-ActΔ6 version of pre-mRNA truncation. In this case, 
the spliceosome assembly could proceed up to the stage of the C complex (Fig. 3.2 A 
lanes 18-20). The presence of the cleaved 5’ exon and intron-3’SS intermediates 
without products formation (i.e. mRNA and intron-lariat), identified this complex as a 
C complex which performed the first but not the second step of splicing (Fig. 3.2 B 
lanes 18-20). The characteristics of splicing using the M3-ActACAC construct was 
similar to the M3-ActΔ31 construct, but if one compares the intensities of the band 







3.3 Purification of yeast spliceosomes 
To obtain preparative amounts for the isolation of spliceosomal complexes and for 
later analysis by mass spectrometry and electron microscopy we performed upscale 
experiments. Therefore we incubated first each of the different [
32
P]-labeled M3-Act 
substrates with the MS2-MBP fusion protein to allow the binding of the MS2-MBP to 
the three MS2 hairpins at the 5’End of the pre-mRNA for later affinity-purification on 
 
 
Figure 3.2: Kinetics of splicing and splicing complex formation. Panel A shows the 
kinetics of in vitro splicing complex formation and in panel B splicing is depicted. In lanes 1-8 of both 
panels M3-Act wt was used; in lanes 9-16, M3-ActΔ6 and in lanes 17-20, M3 ActΔ31 was used. The 
constructs are shown as a scheme above panel A. The panels C and D shows the kinetics of 
spliceosomal complex formation using the 3’SS mutant construct M3-ActACAC. Splicing was 
performed under the same conditions using 2.0 mM ATP in yeast whole-cell extract for 0-180 min. In 
the panels A and C the splicing complexes were analyzed on non-denaturing RNA-PAGE. In the panels 
B and D, the RNA substrates were analyzed by denaturing RNA-PAGE. The position of the complexes, 
the pre-mRNA and the splicing intermediates are indicated as a scheme on the left and right. The 






amylose beads. Yeast whole-cell extracts prepared from the protease-deficient strain 
BJ2168 were used in these experiments and the reactions were incubated at 23°C for 
50-60 min to allow formation of spliceosomal complexes. Mainly, the time point of 
50 min was chosen, since after 50 min of incubation, the majority of spliceosomal 
complexes have formed. In case of low ATP, only pre-catalytic B complexes could be 
formed, with high ATP but with the M3-ActΔ6 substrate, spliceosomal assembly 
stopped at the stage of the activated B
act
 complex. After incubation under splicing 
conditions, the reaction was placed on ice and subsequently loaded on six linear 10%-
30% glycerol gradients in the presence of 150 mM KCl and was centrifuged in a 
Sorvall SureSpin rotor 630 at 22.100 rpm for 18 h at 4 °C. This step serves as a first 
isolation step to enrich the B, B
act
 or C complexes and separate them from the 
majority of other spliceosomal complexes and also to remove unbound MS2-MBP 
fusion protein. After centrifugation, 23 fractions of 1.5 ml were collected by hand 
from the top of the gradient and the peak fractions were determined by Cherenkov-
counting of all fractions. The peak fractions were located in the 40S-45S region of the 
gradient, containing the major amount of complex B, B
act
, or C. These fractions were 
pooled and bound on an amylose column, pre-equilibrated with wash buffer G-150 
(containing 150 mM KCl) at 4°C. The complexes were bound to the matrix by gravity 
flow and afterward washed two times with ~ 10 ml of G-150 buffer, two times with ~ 
10 ml of buffer G-75 (containing 75 mM KCl) and then eluted with a buffer 
containing 12 mM Maltose, 0.01 % NP40 and 5% glycerol in G-75. The purification 
was carried out under stringent conditions so that only stably bound proteins would be 
present. For mass spectrometry or electron microscopy, the eluted complexes 
underwent a second centrifugation step, this time on a 10%-30% glycerol gradient 
containing 75 mM KCl for 1h and 47 min at 60,000 rpm in a Sorvall TH660 rotor at 
4°C (see methods). Their distribution in the gradient was determined again by 
Cherenkov-counting and their RNA and protein content were analyzed by denaturing 
PAGE. 
 
3.3.1 Purification of the pre-catalytic B complex 
 Spliceosomal B complexes were assembled on M3-ActΔ6 pre-mRNA substrate under 





carried as described above. The verified sedimentation coefficient known as Svedberg 





Figure 3.3: Characterization of the pre-catalytic B complex. Upper panel: Profile of 
purified B complex (specific activity of 100 cpm/fmol) separated on a glycerol gradient. The radioactivity 
contained in each gradient fraction was determined by Cherenkov counting. Sedimentation was 
determined by analyzing the UV absorbance of a reference gradient containing prokaryotic ribosomal 
subunits. Lower panel: RNA from gradient fractions (# 13–14) was recovered, analyzed by denaturing 
PAGE, and visualized by silver staining, autoradiography, and Northern analysis. RNA identities are 








 The distribution of the main population of the spliceosomal B complexes is shown 
schematically in Fig. 3.3 A as a graph which corresponds to the gradient profile. After 
pooling the fractions of the main peak of the gradient, they were analyzed by RNA 
PAGE and Northern Blot. The autoradiography of the RNA PAGE revealed the pre-
mRNA. Silverstaining of the RNA gels afterwards revealed a full set of snRNPs, U2, 
U4, U5 and U6, in equimolar amounts, whereas U1 was slightly underrepresented. 
The snRNAs were additionally analyzed by Northern Blot (Fig. 3.3 B). No splicing 
intermediates were detected by denaturing PAGE, but only unspliced pre-mRNA. 
 
3.3.2 Affinity-purified complex B is functionally committed for 
subsequent activation and splicing catalysis 
To examine whether the affinity-purified B complexes stalled by using 0.05 mM ATP 
are functionally committed to splicing, we performed “chasing experiments”. 
Therefore, we assembled them on M3-Act wt pre-mRNA but with 0.05 mM ATP. 
The complexes isolated as described above were then incubated with a mixture of 2.0 
mM ATP and MN-digested extract, where all endogenous snRNAs have been 
digested by treating with microccocal nuclease (MN). 
 In the presence of 2.0 mM ATP and MN-digested extract, the purified B complexes 
were able to catalyze both steps of splicing (Fig. 3.4, lanes 1 and 2), whereas no 
splicing was observed when an equimolar amount of only naked [32P]-labeled M3-
Actin pre-mRNA was used under the same conditions (Fig. 3.4, lanes 9 and 10). As 
expected, neither affinity purified B complex nor the naked M3-Actin pre-mRNA 
underwent splicing in the MN-treated extract when treated with only 0.05 mM ATP 
(Fig. 3.4, lanes 5-6 and 11-12). Taken together, these experiments demonstrate that 
our isolated B complexes do not require complementation with any of the 
spliceosomal U snRNAs for their activity. Thus, we could demonstrate that the B 
complexes, isolated from the yeast S.cereviesiae, were no “dead-end” complexes and 
were able to perform the subsequent steps of splicing, on the other hand, the 
incubation of purified B complexes under splicing conditions, but in the absence of 
MN-extract, did not result in splicing (Fig. 3.4, lanes 3-4 and 7-8). This suggested that 
likely, these purified complexes lacked one or more factors required for subsequent 






3.3.3 Purification of the activated Bact complex 
For the activated, but not catalytically active spliceosomal complex B
act
 the 
purification procedure was the same except the concentration of ATP during the 
splicing reaction. Complex B
act
 was prepared by using M3-ActΔ6 as splicing substrate 
and 2.0 mM ATP. The B
act
 complex has a slightly higher S value than the B complex. 
The S value changes from 40S to 45S due to the activation of the spliceosome which 
is accompanied by conformational changes of the RNA network (Fig. 3.5 A).  
 
 
Figure 3.4: Affinity-purified complex B is functionally committed for subsequent 
activation and splicing catalysis. Affinity-purified B complexes were incubated (0 and 40 
minutes) with 2.0 mM ATP and micrococcal nuclease (MN) digested extract under splicing conditions 
(lanes 1-2), 2.0 mM ATP and Buffers D (lanes 2-3), (MN) digested extract and 0.05 mM ATP (lanes 5-6) 
and 0.05 mM ATP and Buffer D. An equimolar amount of naked, [32P]-labeled wt M3-Actin pre-mRNA 
was analyzed under the same conditions (lanes 9-12), or with whole cell extract and 2.0 mM or 0.05 mM 







Nearly stochiometric quantity of unspliced pre-mRNA and U2, U5 and U6 snRNAs 
were detected by silverstaining, whereas U1 and U4 snRNAs were absent from this 
complex which is an indication that the isolated complex was the activated B
act
 





Figure 3.5: Characterization of the purified B
act
 complex. Upper (A): Profile of 
affinity-purified complex Bact (specific activity of 185 cpm/fmole) separated on a glycerol gradient 
centrifuged for 15 hours at 20.700 r.p.m. (58,257 g) in a Sorvall TH660 rotor. The radioactivity 
contained in each gradient fraction was determined by Cherenkov counting. Sedimentation coefficients 
were determined by analyzing the UV absorbance of fractions of a reference gradient containing 
prokaryotic ribosomal subunits. Lower (B): RNA from gradient fractions (#18-20), were separated by 
denaturing PAGE and visualized by silver staining, autoradiography and Northern analysis (fraction # 
19). RNA identities are indicated on the right. Protein composition of purified complex Bact. Proteins 









3.3.4 Purification of the first step spliceosome complex C 
Complex C was assembled on either M3-ActΔ31 or M3-ActACAC pre-mRNA. The 
use of the two different constructs was done to determine whether additional factors 
were recruited to M3-ActACAC as compared to the shorter M3-Act Δ31 pre-mRNA. 
To remove earlier pre-catalytic spliceosomal complexes like A, B and B
act
 complexes, 
we performed oligo-directed RNaseH cleavage immediately after the splicing 
reaction. RNasH was not added since the yeast whole cell extract already contains this 
enzyme. The cleaving procedure was proofed in preliminary experiments with 
numerous oligos which covered the whole length of our actin pre-mRNA construct to 
optimize the cleavage; simultaneously, we obtained additional information about the 
accessibility of the pre-mRNA at the stage of the first step spliceosome (Fig.3.6 A). 
To control that our pre-catalytic complexes underwent digestion of their pre-mRNAs, 
we treated also our B and B
act
 complexes with the oligo for RNAse H cleavage that 
we used for our C complex. We demonstrated by non-denaturing PAGE that the C 
complex was not affected by RNase H cleavage and that only the free pre-mRNA or 





Fig. 3.6 A: Sequence of the actin wt pre-mRNA. The promoter sequence is indicated as a 
yellow box; both exons are shown in turquoise and the 5’ and 3’ SS are indicated as red boxes. The 
numbers stand for the region on the pre-mRNA complementary to the individual oligo. The black circle 










Figure  3.6 B: Test of various oligos for the oligo-directed RNAseH digestion of 
Actin wt pre-mRNA.RNA-PAGE of actin pre-mRNA after treatment with different oligos for 
directed RNase H cleavage. Sequence of the individual oligo is indicated above each lane, splicing 









The cleaving procedure was carried out for 20 min at 30 °C with an oligo 
complementary to the downstream region of the 5’ss +13+24 (Fig.3.6; Methods).  
The purification strategy for complex C was as described for the other complexes. 
Irrespective of which pre-mRNA was used (M3-ActΔ31 or M3-ActACAC), complex 
C exhibited an S value of ~ 40 S and contained similar amounts of U2, U5 and U6 
snRNA (see Fig.3.8). Denaturing PAGE revealed an excised 5’ exon and intron-
3’exon, which confirmed the isolation of the step 1 spliceosome. Quantitative analysis 
of the radioactive bands as revealed by RNA PAGE, silver staining and Northern 
blotting showed that only 5%-10% of unspliced pre-mRNA remained in the purified 






Figure  3.7: Oligo-directed RNaseH digestion of yeast B, B
act 
and C complexes. 
Kinetics of in vitro splicing with M3-Actin wt, M3-ActΔ6 and mutated at the 3’ss (see text for 
details). Splicing was performed at 2.0 or 0.05 mM ATP, in yeast whole cell extract for 0-30 min 
followed by oligo-directed RNaseH digestion for an additional 20 min at 30 C° (+oligo). RNA was 






3.4 Protein composition of purified yeast spliceosomes 
To determine the protein composition of the complexes isolated from the yeast 
S.cerevisiae via the three steps method described above, the peak fractions of the 





Figure 3.8: Characterization of affinity-purified C complex. Profiles of affinity-purified 
complex C (specific activity 200, 160 and 180 cpm/fmole, respectively) assembled on M3-Actin 
pre-mRNAs  mutated at the 3’ SS,  respectively and separated on glycerol gradients. The radioactivity 
contained in each gradient fraction was determined by Cherenkov counting. Sedimentation coefficients 
were determined by analyzing the UV absorbance of fractions of a reference gradient containing 
prokaryotic ribosomal subunits. Splicing was performed in yeast whole cell extract for 60 min at 23 C°, 
followed by oligo-directed RNaseH digestion for an additional 20 min at 30 C° to allow RNaseH 
digestion of early spliceosomal complexes. RNA from gradient fractions 12-15 was separated by 
denaturing PAGE and visualised by silver staining and autoradiography. Splicing substrates 






prepared for denaturing SDS-PAGE and the proteins were visualized by Coomassie or 
silver staining. The Coomassie stained protein gels were subsequently identified by 
liquid chromatography-coupled tandem mass spectrometry (LC-MS/MS) and scored 
by the absolute number of peptides found in each preparation. MS analyses were 
repeated several times, with a minimum of two times for each complex. Proteins 
which we found only in one out of two or more preparations were considered as 
contaminants, while the majority of the proteins found in our preparations were 
reproducibly detected. 
 
3.4.1 The proteome of the pre-catalytic B complex 
The pre-catalytic B complex was isolated as described above. After the second 
centrifugation step in a Sorvall TH660 rotor, the peak fractions of the gradient were 
pooled and the sample volume was concentrated down to a volume of 500 µl-350 µl 
by drying under vacuum. Samples were precipitated with 2–4 volumes of ethanol 
100%, washed with ethanol 70% and the pellet was resuspended in MS sample buffer. 
The protein sample was separated in 4–12% Bis-Tris-HCl (pH 7.0) NuPage 
polyacrylamide gels (Invitrogen) and stained with G-colloidal Coomassie Brilliant 
Blue. An entire lane of the Coomassie-stained gel was cut into 23 slices and proteins 
were digested in-gel with trypsin and extracted according to (Shevchenko, Wilm et al. 
1996). The peptides extracted from the samples were analyzed in an LC-coupled ESI 
Q-ToF (Q-ToF Ultima, Waters) mass spectrometer under standard conditions. 
Proteins were identified by searching fragment spectra of sequenced peptides against 
the NCBI non-redundant database by using the search engine Mascot. 
The proteins we found associated with the yeast pre-catalytic B complex revealed a 
set of ~ 60 proteins and is shown in Table 1. This set was comprised of all known U1- 
and U2 snRNP specific proteins (U1 snRNP: Prp39, Snu71, Prp40, Prp42, Nam8, 
Snu56, Snp1/U1-70k, Mud1/U1-A, Luc7Luc7B1 and Yhc/U1-C; U2 snRNP: 
Rse1/SF3b130, Hsh155/SF3b155, Prp9/SF3a60, Cus1/SF3b145, Prp21/SF3a120, 
Prp11/SF3a66, Lea1/U2-A’, Hsh49/SF3b49, Msl1/U2-B’’, Rds3/SF3b14b and 
Ysf3/SF3b10). For the U5 snRNP we could detect the U5 specific proteins Prp8, 
Brr2, Snu114, Prp6 and Dib1. Lin 1 was not detected, because Lin1 is thought to 





integrated into the B complex. Also all U4/U6 particle specific proteins were found in 
the B complex as well as the tri-snRNP specific proteins Snu66, Spp381 and Snu23. 
The RNA helicase Prp28 which is known to displace the U1 snRNA from the 5’SS to 
allow the formation of a duplex between the 5’SS and U6 snRNA was found in any of 
our preparations. By RNA-PAGE and Northern blotting we could also observe a 
slightly underrepresentation of the U1 snRNA (see Fig. 3.3 above). These 
observations led to the assumption that we isolated a B complex at the stage shortly 
after Prp28 has acted and from which U1 snRNA is already destabilized from the 
5’SS. 
In all of our B complex preparations we detected each of the three candidates of the 
retention and splicing complex (RES complex): Bud13, Pml1 and Ist/Snu17 which is 
consistent with previous studies showing that these proteins associate with the yeast 
spliceosome before the first step. Another group consisting of eight proteins already 
known to contribute to splicing is the NTC (Nineteen-complex, proteins associated 
with Prp19). All eight proteins were found in our purified B complexes. Former 
experiments indicated that the NTC is required for the catalytic activation of the 
spliceosome and is recruited after U4 release. Our data show that the NTC is already 
bound to the spliceosome at the stage of the pre-catalytic B complex, but is 
underrepresented compared to our Bact and C complexes (see below). Most of the 
NTC proteins found in yeast have human counterparts, which were also found 
associated with the human B complex (Deckert et al., 2006). The full set of the 60 
proteins together with all the miscellaneous proteins found in the yeast B complex 
was already described in my Diploma thesis and will not be one of the main focuses 
of this work. The description of the yeast B complex should only give a brief insight 
into spliceosome assembly to understand better the transition from the pre-catalytic 
spliceosome to the activated B
act
 complex and the first step spliceosome, the C 
complex. 
 
3.4.2 The proteome of the activated Bact complex 
The method for analyzing the protein content of the purified yeast B
act
 complex was 
the same as for the B complex and the first step spliceosome. In comparison to the B 
complex, the proteome of the activated B
act





composition (Table 1). The changes in the organization of the proteome included 
mainly the loss of all U1- and U4/U6 snRNP specific proteins and also the U6 
associated Lsm2-8 proteins. This observation is consistent with the published data 
which showed the destabilization of the Lsm2-8 proteins during activation of the 
spliceosome (Chan, Kao et al. 2003). The U5 proteins Prp6 and Dib1, all proteins 
specific for the tri-snRNP, plus Prp5 and Urn1 are slightly underrepresented but 
likewise present in B complex but not in B
act
. In conclusion, ~ 35 proteins, more than 
half of the ~ 60 proteins found in complex B, are released or destabilized and then lost 
during purification. Proteins recruited to B
act
 which were not present in B complex 
included ~12 proteins, several of which are well-established splicing factors or were 
previously detected in the endogenous Cef1-associated complex (Ohi and Gould 
2002). Among these are the NTC-related proteins, which are homologous to human 
proteins that either physically interact with Prp19 or CDCL5 in humans or are present 
in the human 35 S U5 snRNP. Two of these proteins are also part of the human 
Prp19/CDCL5 complex – Cwc15/AD002 and Prp46/PRL1 – and are already 
integrated into human B complex (Deckert, Hartmuth et al. 2006). Two additional 
proteins of the NTC, termed Bud31 and Ecm2, are homologous to the human Prp19-
related proteins G10 and RBM22 (Makarova, Makarov et al. 2004). Another 
important result of the MS analysis of the protein content of the activated B
act
 
complex was the remarkable number of peptides which was sequenced for the RNA 
helicase Prp2 and its binding partner Spp2. It is already known that both proteins are 
required prior to step 1. Both of them are recruited during B
act 
formation and their 
quantity is consistent with B
act
 being pre-catalytic. Indeed, Prp2 action is needed for 
catalytic activation of the spliceosome, which leads to its release. Other studies 
showed that another protein factor found in complex B
act
, Yju2, is also needed for 
step 1 and is known to promote step 1 after Prp2 function (Liu, Chen et al. 2007). All 
of the step 2 factors were absent in complex B
act
, except Prp17, a step 2 factor known 
to play an important role in step 1 of the splicing reaction (Sapra, Khandelia et al. 
2008). In contrast, several well-established spliceosomal proteins known to act during 
step 2 of splicing were not found in B
act
, as for example Prp22, Prp16, Slu7 and 
Prp18, suggesting that B
act
 is very pure. Indeed, this group of proteins is recruited at a 
later stage. In summary, the transition from the pre-catalytic B to the activated B
act
 





dissociate from the spliceosome, 12 new ones associate and eight, the NTC-complex, 
are stably bound. Thus, B
act
 is composed of ~ 40 proteins. 
 
3.4.3 The proteome of the step1 spliceosome C complex 
For the assembly of complex C, we used the M3-ActΔ31 or the M3-ActACAC 
substrate. Both complexes have exactly the same protein composition (compare Table 
1) and for both complexes we applied the three steps affinity-purification method. The 
evaluation of complex B
act
 and C reveals nearly the same protein content, only the 
number of peptides changes if one compares individual proteins. One prominent 
example is the RNA helicase Prp2 and its counterpart Spp2. Both show reproducibly 
a reduced number of peptides in complex C as compared to B
act
. This observation is 
consistent with the findings of previous studies, Prp2 binds at the stage of the B
act
 
complex and dissociates from the spliceosome concomitant with the first step of 
splicing (Kim and Lin 1996). Surprisingly, this dissociation was also observed for 
some of the members of the U2-associated, heteromeric SF3a complex and also for 
parts of the SF3b, like for example Rse1, Hsh155, Prp11 or Cus1, for which the 
peptide number decreased more than half. In comparison to Prp2 and the U2 
associated proteins, the proteins of the U5 snRNP are present in equal amounts in B
act 
and in C complexes. The proteins associated with Prp19 exhibit a higher number of 
peptides in complex C which indicates a more stable integration in the spliceosome. 
Proteins which are really characteristic for C complex and never found in complex 
B
act
 or B, are a set of nine proteins, Slu7, Prp18, Prp22, Prp16, Cwc23 and Cwc25, 
Ntr1 and Ntr2 and Prp43. The most prominent factors are the step 2 factors Prp22, 
Slu7 and Prp18. Prp17 was already mentioned to be present in the B
act
 complex, while 
Prp16 could only be detected by one peptide but only in complex C. For Prp16 we 
have hypothesized that it is only transiently associated with the spliceosome, so it 
might be that we stalled complex C after Prp16 action. Another possibility is that we 
purified an intermediate spliceosome stalled after step 1 and before step 2. We found 
two additional proteins in our C complex preparation, Cwc23 and Cwc25. At least 
Cwc25 is known to be essential for growth, but the precise function of both proteins 
was still unknown when I started my PhD work (Ohi and Gould 2002). The helicase 





C (Table 1). This is consistent with earlier observations that Spp382 and Ntr2 
associate with Prp43 (forming the NTR complex) and thereby modulate its helicase 
activity (Tsai, Tseng et al. 2007). The NTR complex is associated with the 
spliceosome before step 2, but it acts later during the disassembly of the post-
spliceosomal complex (Tanaka, Aronova et al. 2007). In summary, the biochemical 
composition of the spliceosome changes not only during early assembly steps, but 
also during the transition from B
act
 to C; although this compositional change is not as 
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B YER029C 22.4 31 3 49 8 9 33 14 5 B 
D1 YGR074W 16.3 22 4 3 5 5 10 8 1 D1 
D2 YLR275W 12.8 26 9 27 7 10 6 5 3 D2 
D3 YLR147C 11.2 14 4 3 10 6 8 5 2 D3 
E YOR159C 10.4 2 1 6 5 7 1 1  E 
F YPR182W 9.6 20 2 9 4 4 1 2 2 F 
G YFL017W-A 8.5 3 2 4 1 1 1 2 2 G 
U1 snRNP proteins 
Prp39 YML046W 74.7 27 8  1   3   
Snu71 YGR013W 71.4 26 8 1 1   3  S164 
Prp40 YKL012W 69.0 19 12 1 4   7  FBP11 
Prp42 YDR235W 65.0 17 7     2   
Nam8 YHR086W 56.9 5 3 1 3   2  TIA1/TIAR 
Snu56 YDR240C 56.5 6 2     4   
Snp1 YIL061C 34.4 18 1     5  U1-70K 
Mud1 YBR119W 34.4 14 5 1   1 3  U1-A 
Luc7 YDL087C 30.0 1  2    2  LUC7B1 
Yhc1 YLR298C 27.0 5      2  U1-C 
U2 snRNP proteins 
Rse1 YML049C 153.8 91 63 111 61 32 52 6 1 SF3b130 
Hsh155 YMR288W 110.0 93 24 83 23 22 16 9 1 SF3b155 
Prp9 YDL030W 63.0 70 25 66 45 14 12 7 2 SF3a60 





Prp21 YJL203W 33.0 50 4 35 16 5 14 13 2 SF3a120 
Prp11 YDL043C 29.9 30 5 25 22 2 9 11 1 SF3a66 
Lea1 YPL213W 27.2 28 3 47 11 22 17 10 6 U2-A' 
Hsh49 YOR319W 24.5 4 2 41 2 6 2 9  SF3b49 
Msl1 YIR009W 12.8 8  10 4 2 7 7 2 U2-B'' 
Rds3  YPR094W 12.3 3  4 1     SF3b14b 
Ysf3  YNL138W-A 10.0 3 1 9 2 1 1   SF3b10 
U5 snRNP proteins 
Prp8 YHR165C 279.5 233 81 166 125 176 306 22 38 220K 
Brr2 YER172C 246.2 197 90 237 197 110 126 30 17 200K 
Snu114 YKL173W 114.0 66 54 159 51 113 130 18 24 116K 
Prp6 YBR055C 104.2 73 37  1 4 11 29  102K 
Prp28 YDR243C 66.6         100K 
Lin1 YHR156C 40.4         52K 
Dib1 YPR082C 16.7 10 1     5  15K 
U4/U6 snRNP proteins 
Prp31 YGR091W 56.3 27 11     12  61K 
Prp3 YDR473C 56.0 27 11     29  90K 
Prp4 YPR178W 52.4 27 14  1  2 12  60K 
Snu13 YEL026W 13.6 2      3  15.5K 
U4/U6.U5 snRNP proteins 
Snu66 YOR308C 66.4 39 14     15  110K 
Sad1 YFR005C 52.2       5  65K 
Spp381 YBR152W 34.0 26 6     3   
Prp38 YGR075C 28.0 21 8 1 1 2 3 7  hPRP38 
Snu23 YDL098C 23.0 33 8     13  hSNU23/ZMAT
2 
Lsm proteins 
LSm4 YER112W 21.3 16 3  1   5  LSm4 
LSm7 YNL147W 13.0 3 1     2  LSm7 
LSm8 YJR022W 12.4 3 1     4  LSm8 
LSm2 YBL026W 11.2 8 4   2  2  LSm2 
LSm5 YER146W 10.4 2 1       LSm5 
LSm3 YLR438C 10.0 1      2  LSm3 
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#1 #2 #1  #2 
RES complex 
Bud13 YGL174W 30.5 23 4 81 26 11 30  1 MGC13125  









Syf1 YDR416W 100.0 28 19 124 67 52 69 8 18 hSYF1/XAB2  
Clf1 YLR117C 82.4 16 6 40 18 44 33 12 16 CRNKL1 
Cef1 YMR213W 68.0 21 18 87 24 72 69 7 11 CDC5L 
Prp19 YLL036C 56.6 49 31 235 50 195 150 13 17 hPRP19 
Isy1 YJR050W 28.0 8 1 37 11 14 17 8 2 KIAA1160  
Syf2 YGR129W 25.0 11 2 43 16 14 37 2 2 GCIP p29 
Snt309 YPR101W  21.0 2 1 21 11 17 10 6 9 SPF27 
Ntc20 YBR188C 16.0 11 2 8 1 2 11 3 4  
NTC related proteins 
Prp46 YPL151C 51.0 20 9 97 35 20 28 7 20 PRL1 
Prp45 YAL032C 42.5 19 5 70 15 13 37 18 16 SKIP1 
Ecm2
 
 YBR065C 41.0   35 5 26 32 1 8 RBM22 ? 
Cwc2 YDL209C 38.4   43 19 9 45 11 5 RBM22 ? 
Cwc15 YDR163W 20.0   38 10 16 22  3  AD-
002/HSPC148 
Bud31 YCR063W 18.4   12 1 4 11 10 2 G10  
Early splicing factors 
Prp5 
b
  YBR237W 96.4 10 5       hPRP5 
Urn1 
b
 YPR152C 54.0 8 5       TCERG1 
d
 
Known splicing factors 
Prp2 YNR011C 100.0   116 64 24 19   DDX16 
Spp2 YOR148C 20.6   15 6 1 1     5 * GPKOW/T54 
Yju2 YKL095W 32.0   27 8 10 16  5 CCDC130 
 
Cwc21 YDR482C 15.7   14 8 5 6  2 Srm300 
Cwc22 YGR278W 67.3   48 17 33 67  2 KIAA1604  
Cwc24 YLR323C 28.0   40 20 2 9     4 * RNF113A 
Cwc27 YPL064C 35.0   29 11 2 6  1 NY-CO-10 
 
Cwc23 YGL128C 33.2     2 3  2 DNAJ A1 ? 
c
 
Cwc25 YNL245C 20.4     2 3  1 CCDC49 
Step 2 proteins 
Prp17 YDR364C 52.0     24  10 14 36  5 hPRP17 
Prp22 YER013W 130.0         24 68  2 hPRP22 
Prp16 YKR086W 121.6          1   hPRP16 
Slu7 YDR088C 44.6         2 17  1 hSLU7 








Prp43 YGL120C 87.6     9 2   hPRP43 
Spp382 YLR424W 83.0     2 4   TFIP11 
Ntr2 YKR022C 36.6     2     
CBP proteins  
Sto1 YMR125W 100.0 7        CBP80 
d
 




Table 3.1: The table shows the protein content of spliceosomal complexes 
isolated from the yeast S.cerevisiae. Proteins were identified by LC-MS/MS after three steps 
purification and separation by PAGE. Proteins identified in two out of two preparations are shown. 
Numbers represent the absolute number of peptides sequenced for a protein found in a particular 
preparation (i.e., #1 or #2). The table contains information about the S.cerevisiae protein, the 
systematic gene name, the calculated molecular weight in kDa, and the concentration in pmols of each 
complex are also included (Ohi and Gould 2002);(Stevens, Ryan et al. 2002). The last column contains 
the name of the human protein to aid comparison with previous studies of human spliceosomal 
complexes. Proteins are grouped in organizational and/or functional subgroups. Prp28, Lin1 and Sad1 
were not detected by MS and are included for completeness. 
aHomologs could not be assigned unambiguously on the basis of BLAST data. 
bNever detected in yeast spliceosomal complexes. 
cExtensiv homology between protein family members prevents assignement of S.cerevisiae homologs 
on the basis of BLAST data. 
dHuman homolog previously detected in one or more human spliceosomal complex. 
(Table adapted from Molecular cell Paper,(Fabrizio, Dannenberg et al. 2009) 
 
3.5 Electron microscopy of Yeast spliceosomes 
To obtain the insights into the structure and the rearrangements of yeast spliceosomes 
during the transition from B to B
act 
to C complexes, we purified complexes as 
described above. After two steps purification we loaded the isolated complexes onto a 
second glycerol gradient containing glutaraldehyde to fix the particles (Kastner, 
Fischer et al. 2008). The gradient was collected from the bottom with a gradient 
collector (see Methods). Particles from the peak fractions were then negatively 
stained and analyzed by EM. To obtain a better resolution, the single-particle images 
were classified, and members of each class were averaged. Results are summarized in 





averages (middle) and interpretative sketches (right). All three complexes showed 
monodisperse distributions with a particle size of approximately 40 nm. 
 
3.5.1 Electron microscopy of yeast spliceosomal complexes Complex B, 
B
act
 and C 
The B complex shows in most projection classes a triangular or rhombic shape 
(uppermost block). The most noticeable structural feature of the predominant classes 
(Fig. 3.9, columns 1 and 2) is an almost straight element, ~30 Å long and 7–10 Å 
wide; in the orientation shown, this element runs from the bottom of the image (foot) 
to the upper left (stump). Classes looking approximately like mirror images of the 
main form are also found but rarely (Fig. 3.9, column 3). Other more frequently seen 
forms include those shown in columns 4–6. These forms could be attributed to side-




. The images analyzed from the B 
act
 complex were very different from 
those of B. Most classes show a protruding domain resembling that of the foot of 
complex B (shown pointing downwards in the representations of B
act
) (Figure 3.9). 
However, the main body appears more compact. The most frequent images of B
act
 
(Fig. 3.9, middle block, columns 1 and 2) display a slightly asymmetrical main body 
with outlines running left and right at different angles, such that the left appears 
steeper than the right. A more elongated accumulation of stain is found parallel to the 
left flank, while on the right there is a point-like accumulation of stain. B
act
 also 
shows relatively frequent symmetric (Fig. 3.9 column 3) and asymmetric (Fig. 3.9, 
column 4) variants of the main form. Further typical images of B
act
 are shown in 
columns 5 and 6 (Fig. 3.9). On the left-hand side, these show a pronounced axis while 





Complex C. The C complex was assembled on M3-ActACAC and exhibits also in 
most image classes an approximately straight element (Fig. 3.9, lowest block). Here, 
the axis is always on the right-hand side of the particle in the “foot-down” orientation 
(Fig. 3.9, columns 1–4). Less frequent forms include those shown in columns 5 and 6 
 
 
Figure 3.9: Negative stain Electron Microscopy of yeast spliceosomes. Overview of negatively 
stained samples is shown in the left panels. Representative class averages are shown in the galleries in the middle 
(numbered 1 to 6), starting with the most frequently observed class, for which a schematic drawing is shown on 
the right. All three particles display a short protuberance that in the class averages is shown pointing downward 
(foot). Some structural features are labeled. Names introduced by Boehringer (Boehringer, Makarov et al. 2004) 
for the human B complex are used also for the yeast B complex. A small fraction of images typical of the most 
frequent classes of complex Bact was also detected in the C complex preparation. Scale bars, 50 nm (Fabrizio, 






(Fig.3.9). In summary, the image classes of complex C appear less compact than those 
of B
act
. Thus, the analysis of the EM images of the three purified complexes reveals 
structures of about the same size but with quite different morphology. The most 




 and C 
also exhibit differences, but some views possess similar main features. 
3.6 Isolation and characterization of early spliceosomal complexes isolated 
from the Yeast S. cerevisiae 
As described above, we have purified in vitro assembled spliceosomal complexes B, 
B
act
 and C from yeast and revealed that yeast spliceosomes contain fewer proteins 
than metazoans and that each functional stage is very homogeneous and well suited 
for three dimensional structure analyses. Next, we wanted to obtain more insights into 
the very early steps of spliceosomal assembly. Little is known about the 
compositional organization of early spliceosomal complexes harboring the U1 and U2 
snRNPs, which together with several non-snRNP proteins are involved in juxtaposing 
the functional sites of the pre-mRNA. Here, we have stalled yeast spliceosomes at the 
commitment complex (CC) stage prior to pre-spliceosome (A complex) formation. 
Therefore we used the temperature-sensitive (ts) yeast strain carrying the mutant of 
the Prp5 helicase, termed prp5-1, where the helicase Prp5 can be heat-inactivated 
(Ruby, Chang et al. 1993) (see Introduction/Helicases). Previous studies have shown 
that Prp5 is thought to play an important role for the stable association of the U2 
snRNP to form the pre-spliceosome. The stable integration of U2 is the first ATP-
dependent step in the splicing cycle and requires the helicase Prp5 (O'Day, Dalbadie-
McFarland et al. 1996) 
Recognition and pairing of the correct 5', 3' splice sites (SS) and branch point 
sequence (BPS) of a pre-mRNA are critical events that occur early during 
spliceosome assembly in metazoans as well as in yeast. Our aim was to investigate in 
more detail the early events and to obtain more knowledge about the transition from 
commitment complex to complex A. In addition, it would be interesting to determine 
how the Prp5-mediated hydrolysis of ATP, promotes the stable association of the U2 
snRNP in the pre-spliceosome. Therefore we used our well-established in vitro 





3.6.1 Inactivation or removal of Prp5 stalls the spliceosome assembly at 
the stage of the CC complex  
To stall the spliceosomal assembly at a very early stage of the assembly pathway and 
prior to the pre-spliceosomal A complex we used extracts made from the yeast 
temperature-sensitive (ts) mutant strains of Prp5 (prp5-1). 
After testing the prp5-1 ts-mutant strains (kindly provided by the lab of John 
Abelson) for temperature sensitivity, yeast whole cell extract was made according to 
the protocol (Dannenberg, Fabrizio et al. 2012); see Methods). For the assembly of 
early complexes we used our wt M3-Act pre-mRNA substrate, 
32
P-labeled, and whole 
cell extract made from the ts-strain prp5-1 and a concentration of ATP of 2.0 mM. 
After heat-inactivation of the extract at 35°C, we incubated the reaction with the pre-
mRNA substrate at 23°C for 50’ and incubated the sample under standard splicing 
conditions. Subsequently, we up scaled the experiments and purified the complexes 
obtained. The purification strategy was the same as for the B, B
act 




Figure 3.10: Northern Blot and autoradiography of the RNA-PAGE of the 
commitment complex. Profile of affinity-purified Commitment complex separated on a glycerol 
gradient centrifuged for 3 hours at 60.000 r.p.m. in a Sorvall TH660 rotor. The radioactivity contained in 
each gradient fraction was determined by Cherenkov counting. Sedimentation coefficients were determined 
by analyzing the UV absorbance of fractions of a reference gradient containing prokaryotic ribosomal 
subunits. Lower (B): RNA from gradient fractions (#14-18), were separated by denaturing PAGE and 







The gradient profile of the distribution of the radioactive labeled pre-mRNA in the 
complex, compared to co-sedimentation of 30 S and 50 S ribosomal subunits, 
revealed a sedimentation coefficient of ~26S for our stalled complex. RNA PAGE 
and Northern blot analysis of the purified complex showed that it contained 
exclusively pre-mRNA and U1 snRNPs, thus this complex had the characteristics of a 
CC (Fig. 3.10). 
Following these preliminary studies, the protein composition of the isolated 
complexes has been determined by mass spectrometry. The mass spectrometry data 
revealed a full set of U1 snRNP proteins, all Sm proteins and the early protein factors 
Msl5 and Mud2, which indicated that our complex was a commitment complex 2 
(CC2) (Fig. 3.11). Thus, our complexes stalled at the stage of the early commitment 
complex, were stable for mass spectrometry analysis. These complexes might be well 
suited for further studies, i.e. reconstitution of the pre-spliceosomal A complex or for 
further investigations concerning the role of the ATP-driven stable association of the 
U2 snRNP with the spliceosome. 
 
If one compares the protein content analyzed by silver or coomassie stained gels of 
the early CC complex with the one of B and B
act
 complexes (see Figures 3.3 and 3.5 
 
 
Figure 3.11: Proteins of the Commitment complex. On the left: Proteins of affinity-
purified commitment complexes were analyzed by PAGE and silver staining. On the right: Table of 









above), one can observe a dramatic difference in the number of proteins which are 
associated with each individual complex.  
Peptides sequenced in the CC preparations obtained from yeast extracts heat-inactivated for Prp5-1 
(inact) and additionally ATP depleted. Proteins were identified by LC-MS/MS after three steps 
purification and separation by PAGE. Numbers represent the absolute numbers of peptides sequenced 
for a protein found in each preparation. The table contains information about the S.cerevisiae protein, 
the systematic gene name, and the calculated molecular weight in kDa. The last column contains the 
name of the human protein to aid comparison with previous studies of human spliceosomal complexes. 
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Description Human protein 
name 
U1snRNP proteins 
Snu71 YGR013W 71.4 8   S164 
Prp40 YKL012W 69.0 6   PRP40B 
Prp39 YML046W 74.7 5   PRPF39 
Prp42 YDR235W 155.
0 
5   PRPF39 
Nam8 YHR086W 57.0 1   TIA1/TIAR 
Snp1 YIL061C 34.4 2   U1-70K 
Mud1  YBR119W 34.8 3   U1-A 
Luc7 YDL087C 30.2 3   LUC7B 
Snu56 YDR240C 56.4 2    
Yhc1 YLR298C  -   U1-C 
 
Sm proteins 
SmB YER029C 22.4    B 
SmD2 YLR275W 12.8 1   D2 
SmD3 YLR147C 11.2    D3 
SmF YPR182W   9.7    F 
Commitment complex associated proteins 
Msl5  53.0  21   BBP1 
Mud2 YKL074C 60.0 17   U2AF65 




YNL004W 49.1 2 2 export of mRNAs PABPC4L 
Npl3 YDR432W 45.4 2  export of mRNAs SFRS4 
Cft1  15.3 3 4 involved in poly(A) site 
recognition and required for 
both pre-mRNA cleavage and 
polyadenylation 
 
Pab1  64.5 3 30 Poly(A) polymerase, one of 
three factors required for 
mRNA 3~-end polyadenylation 
 
Pta1  27.6 1    
Fip1  35.8 3  Polyadenylation factor  







Additionally, to investigate the role of ATP at the early steps of spliceosomal 
assembly and to see whether there is a difference in the recruitment of spliceosomal 
factors to the early complex, we repeated the experiments with ATP-depleted whole 
cell extracts made from functional, not heat-inactivated prp5-1 strains.  As revealed 
by MS, no changes in peptide numbers sequenced for proteins recruited to early 
spliceosomes were detected when the extract was ATP-depleted (Table 2). 
 
3.7 Investigation of the protein rearrangements at the catalytic core of the 
spliceosome as revealed by dual color FCCS 
In the first part of our work we isolated spliceosomal complexes from the yeast 
S.cerevisiae and obtained important information of the proteome and the three 
dimensional structure of spliceosomal B, B
act
 and C complexes. Such a 
characterization of the protein content of spliceosomal complexes was done for the 
first time and gave important insights of the protein dynamics at the core of the 
spliceosome during assembly and step 1 catalysis. To identify the factors recruited at 
distinct stages of spliceosome assembly, has helped us to understand better the 
mechanistic aspects of the catalytic activation and the process of pre-mRNA splicing 
in general. Our MS analysis showed a dramatic change of the protein factors which 
were recruited and released during catalytic activation and spliceosome assembly.  
While the studies summarized above provide initial indications of the dynamics of the 
spliceosome’s protein composition during its catalytic activation, they provide only 
little information about the degree of weakening or stabilization of the binding 
affinity of individual proteins or about the order in which proteins are bound to the 
spliceosome or dissociate from it. For example, there is disagreement in the literature 
as to the binding behavior of the U2 SF3a/b proteins during the catalytic phase of the 
yeast spliceosome. Depending on the conditions under which the catalytically active 
spliceosomes are isolated, these proteins are reported to be ‘‘completely absent’’ to 
‘‘stoichiometrically present’’. In view of our observation of the reduced peptide 
numbers sequenced for the U2 proteins in our affinity-purified first step spliceosomes, 
as compared to the B
act
 and B complexes, we wanted to learn more about their 
binding behavior during catalytic activation and first step of splicing. Indeed, our 





destabilized or even released from the spliceosome during the catalysis of the first 
step of the splicing reaction. To address this and additional questions, we applied the 
technique of dual color Fluorescence-cross correlation spectroscopy (dcFCCS) to 
study the dynamics of protein factors during the catalytic activation of the 
spliceosome mediated by Prp2 helicase. DcFCCS had to fulfill some important 
properties, for example it should allow us to measure the dynamics of the spliceosome 
in solution, i.e. in thermodynamic equilibrium and it should deliver quantitative data 
about the protein factors of interest.  
The dcFCCS technique is an optimal method to study the dynamics of spliceosomal 
protein recruitment and dissociation, because i) it is a versatile and very sensitive 
method and requires sample concentrations in the low nM range, ii) it allows real time 
measurements in solution and in thermodynamic equilibrium and iii) provides 
quantitative data and is suitable for the elucidation of dissociation constants. The 
biochemical set up for using dcFCCS (reviewed in (Haustein and Schwille 2007) was 
already well established in our laboratory by Dr. Peter Odenwälder and Dr. Thomas 
Ohrt and the technical setup for dcFCCS was done in collaboration with Prof. Jörg 
Enderlein and Mira Prior, from the III. Institute of Physics, University of Göttingen. 
First we applied a strategy to stall the spliceosome assembly at the B
act 
complex using 
the prp2-1 strain. As demonstrated by the work of Kim and Lin (Kim and Lin 1996) 
the Prp2 helicase functions before the first step of splicing and can be heat inactivated 
in the temperature sensitive strain prp2-1. As a result, the spliceosome assembly can 
be stalled at the stage of an activated, but not yet catalytically active complex. In the 
work of Warkocki et al., 2009 an in vitro reconstitution system was established in our 
laboratory using this temperature-sensitive mutant of the RNA helicase Prp2 and the 
M3-Act wt substrate, to investigate the role of Prp2 in catalytic activation (Warkocki, 
Odenwalder et al. 2009). It could be demonstrated that B
act 
spliceosomes stalled prior 
to the first step by inactivating Prp2 could be purified. The protein composition of 
these complexes, termed B
actΔPrp2
, was characteristic for spliceosomes which have not 
yet undergone first step and are thus pre-catalytic. Importantly, it was shown that the 
complexes were able to catalyze efficient step 1 when supplemented with 
recombinant Prp2, Spp2 and first step factor Cwc25 and step 2 when supplemented 






Second, we chose proteins of interest, which were suitable for the investigation of the 
compositional dynamics of the spliceosome during conversion from the B
act
 to the B* 
complex (adapted from Warkocki et al, 2009), i.e. the proteins Cwc24, Cwc27, Yju2, 
Bud 13, a factor of the RES complex and the U2 snRNP-associated SF3a factor Prp11 
and SF3b factor Cus1. The majority of these factors are recruited to the spliceosome 
during its activation (see Table 1). 
 
3.8 Generation of doubly labeled spliceosomes for dcFCCS measurements 
Our experimental strategy is outlined in Figure 3.12. The (stable) core spliceosome 
was tagged with the red fluorescent dye Atto647N at the 5’ end of actin pre-mRNA. 
For this purpose, a wild-type actin pre-mRNA that included three binding sites for 
MS2 phage coat protein upstream of the first exon (M3Act) was prepared by 
transcription in vitro with T7 RNA polymerase in the presence of a 10-fold molar 
excess of guanosine-5’-O-monophosphorothioate (5’-GMPS) over unmodified GTP. 
The gel-purified pre-mRNA was then allowed to react with a 100-fold excess of Atto-
647N malemide, whereby the 5’-terminal phosphorothioate group of the M3Act 
reacted with the C=C-double bond of the maleimide group of the dye, forming, 
almost quantitatively, the stable thioether product Atto647N -M3Act (see Methods; 
(Ohrt, Prior et al. 2012). We confirmed that Atto647N-M3Act was as active in a 
splicing assay in vitro as unmodified M3Act pre-mRNA (data not shown, experiment 
done by Dr. Peter Odenwälder from our laboratory). 
The individual proteins were genetically fluorescently labeled by constructing yeast 
strains (in collaboration with Dr. Thomas Ohrt and Dr. Patrizia Fabrizio; see 
Methods; (Ohrt, Prior et al. 2012) that expressed the protein of interest with a C-
terminal EGFP (enhanced green fluorescent protein) fusion domain on the basis of the 
temperature-sensitive Prp2-1 strain, containing the mutated ATPase Prp2 which is 




) (Fig. 3.12). 
The following spliceosomal proteins were expressed stably as EGFP fusion proteins: 
Cus1, Prp11, and Bud13 (members of the SF3b, SF3a, and RES protein complexes, 
respectively), and Cwc24, Cwc27 and Yju2. All constructed strains grew like the 
unmodified strain prp2-1. Next we checked whether the tagged proteins and the 






reconstitution system. Therefore we used the labeled RNA substrate Atto647N-M3-
Act wt together with the different yeast whole cell extracts made from the constructed 
EGFP strains in comparison with unlabeled substrate or prp2-1 extracts. After 
assembly and separation of the B
actΔPrp2
 complexes by glycerol gradient 
centrifugation, the pooled peak fractions from the gradient were loaded on an affinity-
selection column containing amylose beads. The bound complexes were washed one 
time with G-150 buffer (containing 150 mM KCl) and two times with G-75 
(containing 75 mM KCl) and were subsequently eluted with 20 mM Maltose. For 
real-time dcFCCS measurements, reactions were carried out in a final volume of 60 μl 
 
 
Figure 3.12: Experimental design and example of data. The Prp2-deficient spliceosomal 
complex BactΔPrp2 (stalled through the inactivation of Prp2) is catalytically activated by the addition of 
Prp2 together with Spp2 and ATP. This leads to complex B*, which on binding the step1 factor 
Cwc25, catalyses the the first step of splicing and forms the C complex. U2/5/6 snRNPs are shown as 
circles. The composition of the activated spliceosome is shown underneath; green stars indicate the 
spliceosomal proteins that were tagged with EGFP. (Inset) Release or recruitment of an EGFP-labeled 
protein (green star) from/to the spliceosome (carrying Atto647N, red star). The cross-correlation 
amplitude at short correlation time t is proportional to the amount of doubly labeled spliceosomes 






with a final complex concentration of 1.1 nM. The eluted fractions were 
supplemented with ten times excess of recombinant proteins and instead of the 10x 
rescue mix (used for reconstitution on beads), the reaction conditions were only 
adjusted to final concentrations of 2.5 mM MgCl2 and 2 mM ATP (or other 
analogues) in buffer G-75 in a final volume of 60 µl. The reactions were incubated at 
23°C for 45 min and subjected subsequently to dcFCCS measurement.  Indeed, all 
EGFP-tagged extracts and substrates were able to form B
actΔPrp2 
spliceosomes and all 
tested preparations led to equal amounts of spliceosomal particles stalled prior to first 
step of splicing. Even all purified complexes were able to perform first step when 
supplemented with recombinant proteins required for the activation and for the first 
step of splicing. 
 
3.8.1 Stability of the binding of EGFP fusion proteins to the BactΔPrp2 
complex under dcFCCS conditions 
First we performed some preliminary experiments to set up our dcFCCS conditions. 
For dcFCCS measurement our complexes had to fulfill two important requirements (i) 
they had to be stable at least for ~ 3 h and (ii) we had to avoid the aggregation of our 
complexes during dcFCCS measurement. Toward this goal, we used the well-known 
protein Snu114. Snu114 is a GTPase that remains stably bound to the spliceosome 
during the whole splicing cycle (Bartels, Urlaub et al. 2003). We found that the 
B
actΔPrp2
 complexes which contained the  Snu114-EGFP fusion protein showed 
constant high cross-correlation  between the green label (protein) and the red label 
(RNA), Fig. 3.13, column 1, indicating that the B
actΔPrp2
 complexes do not dissociate 
under the conditions used for dcFCCS. When we induced the catalytic activation of 
our Snu114-EGFP-B
actΔPrp2
 complexes by incubating them with recombinant 
Prp2/Spp2 proteins plus 2.0 mM ATP for 45 min at 23°C, we observed an almost 
quantitative conversion (>90%) of the 45 S B
actΔPrp2
 complex to the slower migrating 
40 S B* complex (see Cwc24-EGFP experiments; Fig.3.17, shown for Cwc24-EGFP 
complexes and also demonstrated for unlabeled spliceosomes in (Warkocki, 





As also shown in Fig. 3.13, column 2 the activation of the spliceosome and the 
conversion from the B
actΔPrp2
 complex to the B* complex had no effect on the binding 
behavior of Snu114-EGFP to the spliceosome. Even addition of Cwc25, which results 
in the first step spliceosome showed no alteration of the association of Snu114-EGFP 
with pre-mRNA (Fig. 3.13, column 3) and we observed still a high level of cross 
correlation between the green label and the red Atto 647N labeled pre-mRNA. The 
results indicate that Snu114-EGFP remains stably bound in the B* and C complex 
under non-stringent conditions, i.e. low salt (75 mM KCl). 
To determine the boundary of the stability Snu114-EGFP with the spliceosomal 
complexes we performed additional salt treatment experiments by increasing the KCl 
concentration in our experiments for both, B
actΔPrp2
 and for B* complexes. Fig. 3.14 
shows that up to a concentration of 300 mM KCl we observed high cross correlation 
and Snu114-EGFP still remained bound to the complexes. By increasing the salt 
concentration up to 500 mM KCl, dcFCCS measurement was no longer possible 
 
Figure 3.13: Binding behavior of Snu114-EGFP fusion protein to the spliceosome 
analyzed by dcFCCS. Affinity-purified BactΔPrp2 complexes assembled on Atto647N-M3Act, 
carrying Snu114-EGFP (column 1), were complemented with Prp2, Spp2, and ATP (column 2) and 
Cwc25 (column 3). After incubation (45 min at 23°C; see Methods), dcFCCS measurements were then 
performed at complex concentrations of 1.0 nM. Cross-correlation amplitudes derived from two 
independent preparations are shown for each complex. Error bars indicate the standard deviation from 






because of precipitation and aggregation of the complexes on the cover slide used for 
dcFCCS measurement (data not shown, demonstrated by the work of Dr. Peter 
Odenwälder from our laboratory). 
Our experiments demonstrated that Snu114-EGFP remained stably associated to the 
spliceosome even after catalytic activation and high salt conditions as also postulated 
for native Snu114 (Bartels, Urlaub et al. 2003). In summary, we demonstrated that our 
complexes were stable enough for dcFCCS measurements after Prp2-mediated 
activation of purified complexes. 
 
3.8.2 Cwc24 and Cwc27 leave the spliceosome during Prp2-mediated 
catalytic activation under near-physiological conditions 
After the pilot experiments done with our Snu114-EGFP-B
actΔPrp2
 complexes, we 
investigated the changes in the binding behavior of Cwc24 upon Prp2-mediated 
activation. Therefore we first isolated the Cwc24-EGFP-B
actΔPrp2
 complexes by two 
steps purification via glycerol gradient centrifugation (10%-30%, 75 mM KCl, in 
Sorvall SureSpin630 rotor) and affinity chromatography on amylose beads. After 
elution from the amylose beads (in 75 mM/20 mM Maltose), we induced the catalytic 
 
Figure 3.14: Salt-resistance of Snu114-EGFP binding to the spliceosome during 
catalytic activation. Affinity-purified BactΔPrp2 complexes assembled on Atto647N-M3Act, carrying 
Snu114-EGFP (columns 1–3), were complemented with Prp2, Spp2, and ATP (columns 4–6). After the 
standard incubation, increasing concentrations of KCl were added to the samples, which were then 






activation by incubating our complexes with recombinant Prp2 and Spp2 proteins and 
2.0 mM ATP under non-stringent condition (75 mM KCl). After the incubation for 45 
min at 23°C, the activated spliceosomes were directly transferred on the cover slide 
for dcFCCS analysis. In the Cwc24-EGFP-B
actΔPrp2
 complex we observed a cross 
correlation between the green Cwc24 and the red pre-mRNA of ~ 60%. After the 
Prp2-mediated activation of the spliceosome, the cross correlation between the green 
and the red label was reduced to less than 5 % in the B* complex as shown in Fig. 
3.15 column 2.  
 
This observation indicates almost quantitative dissociation of Cwc24-EGFP from the 
complex during activation. The addition of Cwc25 to form C complex revealed a 
complete loss of the binding affinity of Cwc24 with the complex as demonstrated in 
Fig. 3.15, column 3. The cross correlation amplitude went down near to background 
noise (< 3%) which implies that Cwc24, although essential for pre-mRNA splicing, is 




Figure 3.15: Displacement of Cwc24 from the spliceosome during Prp2-mediated 
catalytic activation, implying its non-involvement in the catalytic step 1 of splicing. 
(A) Affinity-purified BactΔPrp2 complexes assembled on Atto647N-M3Act carrying Cwc24-EGFP (column 
1) were complemented as indicated above each bar or (B) Affinity-purified BactΔPrp2 complexes assembled 
on 32P-labelled M3Act, carrying Cwc24-EGFP (lane 1) were complemented with Prp2, Spp2 and ATP 
(lane 2), plus the addition of Cwc25 (lane 3). The positions of the pre-mRNAs, the splicing intermediates 






the presence of non-hydrolysable AMP-PCP or without ATP (columns 4–5), or 
without Prp2 or Spp2 (columns 7–8), the cross-correlation of ~60% remained 
unchanged. These results show that the dissociation of Cwc24-EGFP from the 
spliceosome accompanies the Prp2-mediated transformation of the B
actΔPrp2
 complex 
into B*. The almost complete loss of Cwc24-EGFP from the activated spliceosome is 
all the more notable, as this protein is very stably bound to the Cwc24-EGFP–B
actΔPrp2
 
complex, as indicated by its presence at 300 mM salt (Figure 3.16, column 3). The 
dissociation of Cwc24-EGFP during the B
actΔPrp2
 to B* complex transition also 
occurred efficiently in the presence of UTP (Fig. 3.15, column 6), consistent with the 
fact that Prp2 has a broad rNTP specificity (Kim, Smith et al. 1992). As yeast Brr2 is 
strictly ATP-specific, it is very unlikely that Brr2 ATPase activity is involved in the 
displacement of Cwc24 from the spliceosome, suggesting that this dissociation is 
solely due to the action of Prp2. 
 
Cwc27, although not essential for the growth of yeast under normal physiological 
conditions (Winzeler, Shoemaker et al. 1999; Giaever, Chu et al. 2002), behaved in a 




Figure 3.16: Salt resistance of Cwc24-EGFP binding to the spliceosome during 
Prp2-mediated activation. Affinity-purified BactΔPrp2 complexes assembled on Atto674N-M3Act 
wt pre-mRNA carrying the Cwc24-EGFP protein were eluted from the amylose matrix and were treated 







correlation was seen after incubation with Prp2, Spp2 and ATP, but not when any of 
these components was absent from the reaction mixture; in addition, ATP could be 
replaced by UTP but not by AMP-PCP. We conclude that both Cwc24 and Cwc27 
lose their affinity for – or are displaced from – the spliceosome upon catalytic 




3.8.3 Cwc24 is essential for the first step of splicing in vitro but it is not 
required for catalysis of the splicing reaction per se 
The above results indicate that Cwc24 dissociates almost quantitatively from the 
spliceosome during or after its catalytic activation, thus suggesting that it is not 
required for the actual first step of splicing. To determine whether the essential 
protein Cwc24 is required for the actual catalytic step, affinity-purified B
actΔPrp2 
complexes assembled on 
32
P-labelled M3Act pre-mRNA (Fig. 3.15 B, lane 1) were 
complemented with Prp2, Spp2 and ATP to allow the dissociation of Cwc24 (lane 2). 
Cwc25 was then added (lane 3). The spliceosomes from which Cwc24 had dissociated 
(Fig. 3.15 A, column 3), were capable of carrying out catalytic step 1 of splicing (Fig. 
3.15 B, lane 3), supporting the idea that Cwc24 is required before the action of Prp2 
and not for catalytic step 1 per se. 
 
Figure 3.17: Catalytic activation of the Cwc24-EGFP–B
actΔPrp2 
complex by Prp2. 
Profile of affinity-purified Cwc24-EGFP–BactΔPrp2 spliceosomes separated on a glycerol gradient 
containing 75 mM KCl after incubation with Prp2/Spp2 without the addition of ATP (45S; black line) 
or with the addition of 2 mM ATP (40S, B* complex; red line). The radioactivity contained in each 
gradient fraction was measured by Cerenkov counting. Sedimentation coefficients were determined by 
analyzing the UV absorbance of fractions of a reference gradient containing prokaryotic ribosomal 
subunits. The y axis shows the percentage of radioactively labeled RNA found in each fraction relative 





3.8.4 The U2-associated SF3a and SF3b proteins Prp11 and Cus1 remain 
bound to the B* complex under physiological conditions, but their 
affinity is weakened at high salt 
We observed a reduction of the U2 snRNP associated proteins as revealed by Mass 
spectrometry analysis (First part of this work; (Fabrizio, Dannenberg et al. 2009). For 
this reason we chose the U2 snRNP-associated SF3a protein Prp11 and the SF3b 
associated protein Cus1 to examine the binding behavior of these individual proteins 
by dcFCCS as representatives for the U2 snRNP proteins. We therefore constructed 
Prp11-EGFP and Cus1-EGFP strains and used the whole cell extract made from these 
strains for our experiments. The experimental procedure was the same as for Cwc24-
EGFP and Snu114-EGFP. We purified our B
actΔPrp2
 complexes assembled on 
Atto674N-M3Act wt pre-mRNA carrying the Prp11-EGFP or Cus1-EGFP protein. 
After reconstitution with recombinant proteins Spp2, Prp2 and 2.0 mM ATP they 
were analyzed by dcFCCS. For investigation of the salt stability of these complexes, 
the samples were treated with different salt concentrations by adding KCl to a final 
concentration of 150 mM or 300 mM to the samples and incubated for 30 min on ice 
before measurement. The results, shown in Fig. 3.18., revealed that both proteins, 
Prp11-EGFP and Cus1-EGFP remained stably bound to the B
actΔPrp2
 complex even at 
high salt concentrations with a cross correlation of ~45% (Fig. 3.18 A and B, column 
1-3). As well after the addition of Prp2, Spp2 and 2.0 mM ATP at a salt concentration 
of 75 mM KCl, the Prp11-EGFP and Cus1-EGFP stayed associated with the B* 
complex (Fig. 3.18 A and B, columns 4). Only after increasing the salt concentration 
from 75 mM KCl up to 300 mM KCl we could observe a dramatic decrease of cross 
correlation and a weakening of the binding of Prp11-EGFP and Cus1-EGFP from the 
B* complex (Fig.3.18 A and B, columns 5-6). At 150 mM KCl (column 5) a 
reduction of 20%  of cross correlation could be observed, whereas at 300 mM KCl 
(column 6) the majority of the proteins, more than 70%, had dissociated from the B* 
complex. In contrast to the observations of the binding behavior of Snu114-EGFP, 
which remained stably bound even under high salt conditions, we demonstrated that 
the U2-SF3a/b proteins were tightly bound to the pre-catalytic spliceosome, but their 
binding is weakened after Prp2 action and the catalytically activation of the 





higher than that of Cwc24-EGFP or Cwc27-EGFP. Even after addition of 
recombinant Cwc25, i.e. upon C complex formation, Cus1 and Prp11 remained bound 
to the spliceosome at a salt concentration of 75 mM KCl (data not shown). 
 
 
3.8.5 The binding of the RES complex protein Bud13 is weakened during 
catalytic activation 
The pre-mRNA Retention and Splicing (RES) complex plays an important role in 
nuclear retention of un-spliced pre-mRNAs. The yeast RES complex consists at least 
of three proteins: Ist/Snu17, Pml1 and Bud13. Our previous results confirmed the data 
from the literature that the RES complex associates with the spliceosome before step 
1 of splicing, as we showed for the yeast spliceosomal B complex (Dziembowski, 
Ventura et al. 2004);(Fabrizio, Dannenberg et al. 2009). For investigating the binding 
behavior of the RES complex to the spliceosome, we chose the protein Bud13 as a 
representative for the RES complex and we applied the same experimental strategy 
using dcFCCS described above. The cross correlation intensity of the Bud13-EGFP-
B
actΔPrp2
 under non-stringent conditions (75 mM KCl) was at ~ 28% between the green 
 
 
Figure 3.18: Binding of U2 SF3a/b proteins Prp11-EGFP and Cus1-EGFP to the 
spliceosome is made salt-sensitive by the Prp2-mediated catalytic activation. 
Affinity-purified BactΔPrp2 complexes were assembled on Atto674N-M3Act wt, carrying Prp11-EGFP 
(A) or Cus1-EGFP (B). The complexes were incubated with increasing salt concentrations before 






labeled protein Bud13-EGFP and the red labeled pre-mRNA (Fig. 3.19, column 1), 
but was reduced by almost 50% (down to ~15%) when treated with high salt 
concentrations (300 mM KCl; Fig. 3.19, column 3) in the Bud13-EGFP-B
actΔPrp2 
complex. 
 In comparison to the binding strength of Cwc24-EGFP and Snu114-EGFP, we 
observed a weaker association of Bud13-EGFP with the spliceosomal B
actΔPrp2
 
complex. Even more significant was the dramatically reduced affinity of Bud13-
EGFP for the B
* 
complex after Prp2-mediated activation of the Bud13-EGFP-B
actΔPrp2
 
complex under high salt conditions (300 mM KCl, Fig. 3.19, column 6). At these 
stringent conditions Bud13-EGFP was almost displaced from the spliceosome after 
catalytic activation (Fig. 3.19, column 5 and 6). This observation is congruent with 
the idea that the members of the RES complex remain bound to the spliceosome until 
the Prp2-mediated catalytic activation of the spliceosome takes place, to avoid the 
premature release of unspliced pre-mRNA from the nucleus. It was demonstrated by 
Dziembowski et al. that inactivation of these proteins causes leakage of unspliced pre-
mRNA from the nucleus (Dziembowski, Ventura et al. 2004). 
 
 
Figure 3.19: Displacement of Bud13-EGFP from the spliceosome during Prp2-
mediated catalytic activation. Affinity-purified BactΔPrp2 complexes assembled on Atto647N-
M3Act, carrying Bud13-EGFP (columns 1–3), were complemented with Prp2, Spp2, and ATP (columns 







3.8.6 Binding of Yju2 to the spliceosome is strengthened upon catalytic 
activation 
Yju2 is a novel splicing factor known to be associated with components of the NTC 
and to play a role in pre-mRNA splicing, both in vivo and in vitro. Yju2 is recruited to 
the spliceosome prior the action of Prp2 and the first step of splicing at the stage of 
the B
act 
complex. Its role is in promoting step 1 of splicing after Prp2-mediated 
structural rearrangement of the spliceosome (Liu, Chen et al. 2007). 
 
 
The investigation of the binding affinity of Yju2-EGFP to purified spliceosomal 
complexes revealed that Yju2-EGFP has a lower affinity for the B
actΔPrp2
 complex 
than for B* complex as demonstrated by dcFCCS data.  Under non-stringent 
condition, Yju2-EGFP seemed to be associated with the B
actΔPrp2
 complex, but already 
at a concentration of 150 mM KCl more than 50% of the Yju2-EGFP was dissociated 
 
 
Figure 3.20: Strengthening of binding of Yju2-EGFP to the spliceosome upon 
catalytic activation. Affinity-purified BactΔPrp2 complexes assembled on Atto647N-M3Act, 
carrying Yju2-EGFP (columns 1–3), were complemented with Prp2, Spp2, and ATP (columns 4–6), or 
with Prp2, Spp2, ATP, and Cwc25 (columns 7–9). After standard incubation, increasing concentrations 






from the complex and at 300 mM KCl the dissociation was complete (Fig. 3.20, 
column 1-3). Interestingly, after the Prp2-mediated activation of the spliceosome, the 
binding affinity of Yju2-EGFP protein was higher for the B* complex than for the 
corresponding B
actΔPrp2
 (Fig. 3.20, column 4). The higher binding affinity was more 
prominent at 150 mM and 300 mM KCl (Fig. 3.20, column 5 and 6). We concluded 
that the Prp2-dependent rearrangement of the spliceosome changes the binding 
affinity of Yju2 for the spliceosome from low to high. The addition of Cwc25, leading 
to the first step spliceosome had no additional effect on the binding strength of Yju2-
EGFP to the C complex. Moreover, the affinity of Yju2 was minimally affected by 
the first step of splicing (Fig. 3.20, column 7-9). 
 
3.8.7 Prp2-mediated catalytic activation of the spliceosome creates also a 
high affinity binding site for Cwc25 in the spliceosome 
We showed in our experiments described above, that the Prp2-mediated 
rearrangement of the spliceosome is accompanied by changes of the binding affinity 
of many proteins. Some were only destabilized during activation like the U2 snRNP 
associated SF3a/b proteins, other were displaced completely, i.e. Cwc24, Cwc27 or 
Bud13 or their binding was even enhanced like the factor Yju2. The essential factor 
for promoting the first step of splicing is Cwc25 as shown in Warkocki et al., 2009. 
To investigate the role and the binding affinity of Cwc25 during pre-mRNA splicing 
we conjugated the green fluorescent dye Alexa488N-maleimide to Cwc25 via 
cyteines which were linked to the protein at the C or N terminus of the protein. After 
labeling the overexpressed and purified protein (in collaboration with Dr. Jana 
Schmitzova and Dr. Thomas Ohrt) a second step of purification was performed to 
remove unbound Alexa488N-maleimide. Fluorescently labeled protein was obtained 
with a label efficiency of ~ 70% (see Methods). 
Next steps were to test whether fluorescently labeled Cwc25 was functional or 
whether Alexa488N-maleimide interferes with spliceosome assembly. Therefore, we 
purified B
actΔPrp2
 complexes assembled on Atto647N-M3Act pre-mRNA as already 
described, and complemented them with Prp2, Spp2, ATP, and either unlabeled 





all Cwc25 preparations we have tested led to the identical step 1 efficiencies (done by 




Next, we studied the recruitment of Cwc25 to the spliceosome in more detail. 
Therefore, using extracts from the prp2-1 strain, B
actΔPrp2 
complexes were assembled 
on Atto647N-M3Act. After gradient separation and affinity-purification, the bound 
complexes were transferred into a new 1,5 ml Eppendorf tube and complemented with 
Prp2, Spp2, Cwc25-Alexa488 (C-terminally labeled) and ATP or only with Cwc25-
Alexa488. Reaction mixtures were incubated for 45 min at 23°C and transferred back 
into the chromatography columns for washing. After washing the reconstituted 
 
 
Figures 3.21: Functional assay using Cwc25-Alexa488N-maleimide. Complexes 
assembled on Atto647N-M3Act undergo the first step of splicing when complemented with Prp2, 
Spp2, ATP and Cwc25 labelled with the fluorescent dye Alexa488. BactΔPrp2 complexes assembled on 
Atto647N-M3Act (lane 1) were purified, eluted from the amylose matrix and complemented with Prp2, 
Spp2, ATP and Cwc25 (lane 2), or fluorescently labelled Cwc25 (lanes 3 and 4). Two preparations of 
Cwc25, C-terminally (lane 3) and N-terminally labelled (lane 4) were used. RNA was analysed on an 
8% polyacrylamide–urea gel and visualised by autoradiography. The positions of the pre-mRNAs and 
the splicing intermediates are indicated on the left. Asterisks: uncharacterised pre-mRNA bands (Assay 






complexes twice with G-75 buffer to remove unbound Cwc25-Alexa488, the 





complexes complemented with Cwc25-Alexa488 displayed only a 
background cross-correlation of <5% (column 2). On the other hand, when the 
B
actΔPrp2
 complex was supplemented with Prp2, Spp2, ATP, and Cwc25-Alexa488, it 
showed a cross correlation amplitude of ~ 50% (Fig. 3.22, column 3). Accordingly, 
Cwc25 binds efficiently to the spliceosome only after ATP-hydrolysis by Prp2 and 
rearrangement of the structure of the spliceosome, i.e. only after the release or 
destabilization of several proteins. This suggests that the remodeling of the 
spliceosome by Prp2 helicase generates a binding site for Cwc25 in the spliceosome. 
To study how the affinity of Cwc25 changes during catalytic activation of the 
spliceosome, we determined quantitatively the binding constants for Cwc25 at the 
B
actΔPrp2 
and B* stages, i.e., immediately before and after catalytic activation by Prp2 
 
 
Figure 3.22: Catalytic activation by Prp2 creates a high-affinity binding site for 
Cwc25 in the spliceosome.  BactΔPrp2 complexes assembled on Atto647N-M3Act (column 1) were 
complemented on the amylose matrix with C-terminally labeled Cwc25-Alexa488 (column 2) or 
Cwc25-Alexa488 together with Prp2, Spp2 plus ATP (column 3). After incubation, the complexes were 
washed and eluted with maltose, and dcFCCS measurements were performed (this experiment was 






done in parallel experiments by Dr. Peter Odenwälder (Computational analysis of the 
data was done by Mira Prior, III. Institute of Physics, University of Göttingen; data 
not shown) (Ohrt, Prior et al. 2012). The results of these additional experiments were 
in line with our results, thus, we conclude that the Prp2-dependent rearrangement of 
the spliceosome generates a high-affinity binding site for Cwc25. In conclusion 
dcFCCS is a high resolution and quantitative technique for the investigation of highly 
dynamic complexes like the spliceosome and we have obtained important insights 
about protein dynamics at the catalytic core of the spliceosome during pre-mRNA 







In this work we established a method to isolate and to purify spliceosomal complexes 
from the yeast S. cerevisiae stalled at defined stages of spliceosome assembly for the 
first time (Dannenberg, Fabrizio et al. 2012); (Fabrizio, Dannenberg et al. 2009) We 
characterized the proteome of the B, B
act
 and C complexes and could give first 
insights into the protein dynamics and the two-dimensional (2D) structural changes 
during transition from B to B
act
 and from B
act
 to C complexes during pre-mRNA 
splicing as revealed by Mass spectrometry (MS) and Electron microscopy (EM) 
analyses. During the conversion from B to B
act
 to C, the compositional changes are 
accompanied by structural remodeling of the spliceosome which results in changes of 
the S values of the individual complexes, 40S for B complex, 45S for B
act
 and 40S for 
C complexes. EM studies revealed that these compositional changes correlate with 




 to C. Our results give 
insights into the highly dynamic RNP machine that undergoes many changes in 
composition and conformation. 
 
4.1 The structural dynamics of the spliceosome are modulated by multiple 
DExD/H-box RNA helicases, the driving forces of the spliceosome 
Among these helicases are Prp5 and Prp2, which are essential ATPase required prior 
to the first step of pre-mRNA splicing. The DEAD-box ATPase Prp5 enables stable 
U2 snRNP association with the branch point sequence (BPS). We showed here that 
the use of temperature-sensitive mutants of Prp5 (prp5-1) led to accumulation of 
early, pre-spliceosomal complexes, identified by MS as commitment complex 2 
(CC2). Another important helicase, the DEAH-box ATPase Prp2, is known to 
promote a structural rearrangement that transforms the B
act 
into the catalytically 
activated B* complex. Our MS results already revealed that a number of proteins are 
affected by the Prp2-mediated catalytic activation. Consequently, a second approach 
of this work was to deepen our previous results by studying the modulation of the 





activation by Prp2 in a quantitative manner. Therefore, we applied the technique of 
dual color Fluorescens Cross Correlation Spectroscopy (dcFCCS) which was 
established during this work in collaboration with Dr. Thomas Ohrt, Dr. Peter 
Odenwälder, Mira Prior and Prof. Jörg Enderlein. The combination of our established 
three-step purification strategy (Fabrizio, Dannenberg et al. 2009); (Dannenberg, 
Fabrizio et al. 2012) together with in vitro reconstitution of functional spliceosomes 
(Warkocki, Odenwalder et al. 2009) and with the dcFCCS technique made it possible 
to shed some light on the nature of the release/loss of splicing factors during the 
crucial remodeling step of catalytic activation. This is the first example where 
purified, catalytically active spliceosomes were investigated directly in solution and in 
equilibrium. By dcFCCS we showed that the U2 SF3a/SF3b proteins Prp11 and Cus1 
are destabilized and Cwc24, Bud13 and Cwc27 are released from the spliceosome 
after Prp2-mediated catalytic activation. Furthermore, we demonstrated that high 
affinity binding sites are created for the step 1 factors Yju2 and Cwc25 during 
catalytic activation, consistent with their requirement for step 1 catalysis. This work 
demonstrates that Prp2 has a major role in the structural remodeling and in the 
multiple rearrangements at the core of the spliceosome.  
 
4.2 The protein composition of yeast spliceosomes is less complex than that of 
metazoan spliceosomes 
If one compares the proteome of the yeast B, B
act
 and C complexes with spliceosomal 
complexes isolated from other species, i.e. Drosophila or human spliceosomes, it is 
obvious that the yeast spliceosome has significantly less proteins than metazoan 
spliceosomes. The human and the Drosophila B complex isolated under similar non-
stringent conditions contain ~ 110 proteins (Deckert, Hartmuth et al. (2006); (Herold, 
Will et al. 2009), whereas the yeast B complex comprises ~ 60 proteins. The most 
drastic difference was shown for the purified Bact complexes from human with more 
than ~ 140 proteins compared to the yeast Bact complex with only ~ 40 proteins 
(Bessonov, Anokhina et al. (2010). A similar minimal protein composition like for the 
yeast B
act
 complex was revealed for the yeast C complex, which is composed of only 





(2008). As a result we can conclude that the number of proteins of each yeast 
complex is less than half compared to human spliceosomal complexes (Fig 4.1.). We 
identified in total, ~ 90 proteins in the three isolated yeast complexes. 
The proteins identified here include the majority of proteins which were found to be 
associated with previously isolated yeast complexes such as the purified penta-snRNP 
and the Cef1-associated complex (Ohi and Gould (2002); Stevens, Ryan et al. 
(2002)). Established splicing factors that were known to contribute to pre-mRNA 
splicing as revealed by genetics or other techniques, which were not found in our 
three complexes, include those that were only loosely associated and lost during 
purification, such as Prp28 and Sad1 or those that act even earlier in pre-mRNA 
splicing, e.g. Npl3 or Mud2 and Msl5 which were however found associated with the 
early pre-spliceosomal Commitment Complex that we have also isolated, purified and 
characterized in this work (Table 3.2 and Figure 4.1). 
 
4.3 Isolation and characterzation of early spliceosomal complexes from yeast 
Here, we have also purified yeast spliceosomes stalled at the commitment complex 
(CC) stage prior to prespliceosome (A complex) formation using a temperature 
sensitive yeast strain, which carries the mutant Prp5 protein (named prp5-1). The 
DEAD-box Prp5 is an essential, RNA dependent ATPase present in the CC that 
functions in subsequent A complex formation containing both the U1 and U2 
snRNPs. Our stalled 26S complex contained exclusively pre-mRNA and U1 snRNPs. 
The protein composition of this complex has been determined by MS and contained in 
addition to all known U1 proteins, three additional splicing factors: Mud2, Msl5 and 
Npl3, thus has all the characteristics of a CC2. In yeast two kinds of commitment 
complexes have been identified, termed CC1 and CC2. The CC1 is characterized by a 
faster mobility and is dependent on the presence of the 5’SS and the U1 snRNP, 
which binds to the 5’SS in an ATP-independent manner. CC2 has a lower mobility 
and needs the 5’SS and a functional BPS for proper formation. 
The presence of Mud2, Msl5 and Npl3 in our MS analyses suggests that our isolated 
early complex is CC2. Npl3 is a SR-like protein in S. cerevisiae that was recently 





machinery. It is involved in the recruitment of splicing factors to chromatin-
associated transcripts. Npl3 was shown to promote efficient splicing of a large subset 
of genes via co-transcriptional recruitment of U1 and U2 snRNPs (Kress, Krogan et 
al. 2008); (Moehle, Ryan et al. 2012). SR and hnRNP proteins in metazoans are best 
understood for their role in alternative and constitutive splicing, although they have 
also been implicated in additional steps in gene expression, including mRNA export, 
translation, and even transcription itself (Singh and Valcarcel 2005); (Long and 
Caceres 2009); (Dreyfuss, Kim et al. 2002). The yeast S. cerevisiae, contains at least 
three genes with a canonical SR protein domain structure: one or more RNA 
recognition motifs and a domain enriched in arginine-serine-di-peptides (Long and 
Caceres 2009); (Manley and Krainer 2010). It was shown that deletion of Npl3 causes 
splicing defects. The affected genes were exclusively those encoding ribosomal 
proteins which represent the major class of intron containing genes in budding yeast, 
in other respects alternative splicing is extremely rare in yeast (Kress, Krogan et al. 
2008; Long and Caceres 2009); (Moehle, Ryan et al. 2012). Recent experiments 
demonstrated that Npl3 remains associated with mRNA after splicing is completed 
(Moehle, Ryan et al. 2012). The fact that we found Npl3 only associated with our 
CC2 might be due to our purification strategy. Likely, Npl3 might be tightly 
associated with early spliceosomal complexes consistent with its suggested role of co-
transcriptional recruitment of the splicing machinery.  
Mud2 is a splicing factor known to be involved in early pre-mRNA splicing events 
and it has been shown to interact with the highly conserved BPS in yeast and with the 
U1 snRNP (Krämer et al., 1996). Msl5/BBP (homologue to SF1) is a branch point 
binding protein and recognizes the intron BPS UACUAAC in the pre-mRNA 
transcripts during spliceosome assembly. Msl5 is recruited to the spliceosome at a 
very early stage of assembly. Mud2 has been identified as the yeast homolog of 
U2AF65, the large subunit of U2AF that interacts with the polypyrimidine tract 3’ to 
the mammalian BPS (Kistler and Guthrie 2001). In previous studies it was shown that 
Mud2 interacts with Msl5/BBP splicing factor and Sub2. 
Sub2 was completely absent from our purified complexes (i.e. CC, B, Bact and C). 
Sub2 is a DEAD-box helicase, which acts very early in pre-mRNA splicing. Sub2 
belongs to the DExD/H-box ATPase family, like Prp5 and Prp2, and is one of the 





helicase Sub2, Prp5, was absent from our purified complexes. Prp5 and hydrolysis of 
ATP are required for stable binding of the U2 snRNP with the pre-mRNA in the 
presence of Cus2 which is thought to be the first ATP-dependent step in the splicing 
cycle (Liao, Colot et al. 1992); (Ruby, Chang et al. 1993);(Perriman, Barta et al. 
2003). The reason for the absence of Prp5 in our CC preparations is that we used a 
thermo sensitive mutant of Prp5 (prp5-1), which is heat-inactivated and lost, thus 
blocking spliceosome assembly at the stage of CC2. However, Prp5 was never 
detected with high peptide numbers in our spliceosomes due to the fact that Prp5 acts 
at the stage of the pre-spliceosomal A complex prior to the formation of the B 
complex. We also could not detect the U2 snRNP associated protein Cus2 in our CC2. 
Cus2 belongs to the members of the RNA recognition motif (RRM) family of RNA 
binding proteins and it was suggested to mediate a functional interaction between the 
U2 snRNA and/or the U2 associated SF3a complex protein Prp11 and Prp5 (Yan, 
Perriman et al. 1998). The work by Perriman and Ares suggested a model for the 
interplay between Cus2, Prp5 and the U2 snRNP in which Prp5 might be needed for 
the ATP-dependent removal of Cus2 from the U2 snRNP leading to subsequent stable 
integration of the U2 snRNP into the spliceosome (Perriman, Barta et al. 2003). The 
absence of Cus2 in our complexes could be explained by the absence of U2 snRNPs 
in our CC2 preparations. It might be that Cus2 is recruited together with U2 to the 
spliceosome to stabilize the binding of the U2 snRNA/snRNP until its stable 
integration into the spliceosome. To promote this, the Prp5-mediated removal of Cus2 
is needed (Perriman, Barta et al. 2003). Our isolated CC2 could be used in the future 
for in vitro reconstitution of A complexes upon addition of purified U2 snRNPs and 
recombinant Prp5. In addition it would be interesting to investigate how the Prp5-
mediated hydrolysis of ATP promotes the stable association of the U2 snRNP in the 
pre-spliceosome 
 
4.4 Evolutionary conservation of yeast spliceosomes 
The large number of proteins found associated with human spliceosomal complexes 
are due to the higher amount of regulated splicing in the metazoan system whereas, as 
mentioned above, alternative splicing is nearly completely absent in yeast. However, 





homolog and thus, are evolutionarily conserved in humans. Remarkably, more than 
85% of the yeast splicing factors listed in Table 3.1 have a clear evolutionarily 
conserved counterpart (Fig. 4.1). The comparison of the proteome of metazoan and 
yeast spliceosomes revealed an evolutionarily conserved core design of the splicing 
machinery. In Fig 4.1 are shown the protein factors which associates with human 
spliceosomes without an obvious conserved counterpart in yeast. There are ~ 80 
proteins without a yeast homolog, known to play a role in regulating alternative 
splicing, i.e. among others SR and hnRNP proteins (Wahl, Will et al. (2009). A set of 
about ten SR and hnRNP proteins and several U2-related proteins are present in early 
human spliceosomes but essentially absent from yeast (Fig. 4.1). We expected that 
one or more yeast SR-like or hnRNP proteins would be found in early yeast 
spliceosomal complexes (e.g. A complex). Indeed we found the yeast SR-like protein 
Npl3 associated with our early pre-spliceosomal CC2 (Table 3.1). Indeed, Npl3 was 
also recently shown to promote the recruitment of the U1 snRNP to the pre-mRNA 
(Kress, Krogan et al. 2008). The human splicing machinery contains many regulatory 
proteins needed for alternative splicing. The majority of these regulatory protein 
factors are only required in certain situations and are loosely associated with the 
human spliceosome. Obvious counterparts for many of these proteins are not present 
in yeast. For example, the members of the PPIase family (peptidyl-prolyl cis/trans 
isomerase) are represented with seven proteins in the human spliceosomes, but only 
one PPIase, NY-CO-10, shows 28% identity (45% similarity) with the yeast Cwc27, 
which harbors a PPIase domain. This lead us to conclude that the yeast splicing 










Figure 4.1: The yeast splicing machinery is less complex than that of humans 
Upper rectangle: Yeast proteins (yeast nomenclature) evolutionarily conserved between yeast and man, 
associated with purified yeast B, Bact, and C complexes, are placed inside of the rectangle. Proteins above 
the rectangle do not have a human counterpart. Lower rectangle: Human proteins (human nomenclature) 
evolutionarily conserved between yeast and man, associated with purified human A, B, and C complexes, are 
placed inside of the rectangle. Proteins below the rectangle were found associated with purified human 
spliceosomal complexes, but the majority of them do not have a yeast counterpart (Behzadnia, Golas et al. 
2007); (Bessonov, Anokhina et al. 2008). Numbers indicate the total number of individual proteins in a 
particular group. (Asterisks) Proteins that do have homologs in yeast or human but were not found or found 
loosely associated with purified spliceosomal complexes; yeast Msl5, Npl3, Mud2, and Hub1 were found 
with low peptide numbers in the 20S–25S peak shown in the results section for the B complex and Msl5, 
Npl3 and Mud2 were found in the commitment complex. Cus2, Prp28, and Sad1 were not detected by MS 
and are included for completeness, as well as human TIA-1, which is the homolog of yeast Nam8. Proteins 
are grouped according to snRNP association, function, presence in a stable heteromeric complex, or 








4.5 Spliceosomal dynamics during catalytic activation 
Comparative proteomics of human and Drosophila spliceosomal complexes showed a 
dramatic exchange of proteins during the transition from B to C complexes. More 
than 60 proteins are exchanged during catalytic activation of the metazoan splicing 
machinery (Bessonov, Anokhina et al. (2008); (Herold, Will et al. 2009). Our studies 
show that the yeast spliceosome is also in a highly dynamic state during its assembly 
and step 1 catalysis. The most dramatic compositional change in the yeast 
spliceosome occurred during the transition from the pre-catalytic B complex to the 
activated Bact complex. During the step of activation, the entire U1 snRNP is 
released, whereas the tri-snRNP undergoes massive remodeling, This entails dramatic 
structural rearrangements that at the RNA level involve unwinding of the U4/U6 
duplex and the formation of U2/U6 base-pairing, a reorganization that is exceptional 
among RNP machines (Wahl, Will et al. (2009). Concomitant with the unwinding of 
the U4/U6 duplex, all U4 and U6 snRNP associated proteins are released from the 
spliceosome as well, together with factors that link the U5 snRNP to the U4/U6 di-
snRNP (Fig. 4.2)(Hacker, Sander et al. 2008). As a consequence, our B
act
 complexes 
lack all U4/U6 snRNP specific proteins and several U5 snRNP proteins, except Brr2, 
Prp8 and Snu114 which are present throughout the whole splicing cycle (Fig.4.2). In 
total ~ 35 proteins are lost during the transition from the B to the B
act
 complex. 
Subsequently after the disruption of the U4/U6 duplex and the loss of pre-catalytic 
binding partners, new partners have to be provided to stabilize the U6 snRNA 
interaction with pre-mRNA and the U2 snRNA. The factors which are recruited 
during the formation of the U2/U6/pre-mRNA base-pairing interaction were unclear 
at the start of this work, as well as the precise time at which such proteins are 
recruited. Here, we could demonstrate that 12 known splicing factors were recruited 
at the time of spliceosomal activation and that the eight proteins of the NTC-complex 
become more stably bound (Fig. 4.2, B
act
, and compare with B complex). As a result 
of this reproducible observation we regard these factors as characteristic for the yeast 









Figure 4.2: Compositional dynamics during catalytic activation 
The protein composition of the yeast B, Bact, and C complexes was determined by MS. Proteins (yeast 
nomenclature) are grouped as described in the legend of Figure 4.1. The relative abundance of proteins is 
indicated by light (substoichiometric amounts) or dark (stoichiometric amounts) lettering and is based on 






The proteins recruited to the Bact complex can be divided into two classes: (i) those 
most probably required to establish and/or stabilize the U2/U6 base-pairing 
interaction (e.g Cwc24, Ecm2 and Cwc2 a protein that contains a RNA recognition 
motif [RRM] (Hogg, McGrail et al.) and (ii) those more directly required to promote 
step 1, such as Prp2, Spp2, and Yju2. U6 snRNA not only engages in novel base 
pairing interactions with U2 and the pre-mRNA but also new protein-RNA 
interactions are established (Wahl, Will et al. 2009). It was postulated that members 
of the NTC complex and NTC-related proteins play an important role in restructuring 
the U6 and U2 snRNAs, and it was previously shown by Chan et al. (2003) that 
proteins of the NTC play a critical role in tethering and stabilizing the U6 and U5 
snRNAs at the time of activation (Chan, Kao et al. 2003) NTC-dependent 
stabilization of U6 is mediated through remodeling of U6 snRNP, which includes the 
stabilization of U6/5′SS base pairing interaction, and destabilization of Lsm proteins 
from U6 (Chan, Kao et al. 2003). Additional rearrangements are required to shape and 
juxtapose evolutionarily conserved sequences of U6 snRNA (e.g. the internal stem-
loop structure (ISL) with the pre-mRNA 5'SS for catalysis of the first step. One of the 
proteins that influence the catalytic conformation of the RNA network in the 
spliceosome is Cwc2 which interacts physically with Prp19 (Hogg, McGrail et al.). 
Recent data from our laboratory indicate that Cwc2 interacts with the catalytically 
important ISL of U6 snRNA and the pre-mRNA substrate in B
act
, B* and C 
complexes (Rasche, Dybkov et al. 2012). Thus, it might play a crucial role in 
positioning the catalytic site into an active structure. The U2 snRNP is also 
substantially remodelled during splicing, with an apparent destabilization of SF3a and 
SF3b proteins prior to formation of the C complex, which suggested that they are not 
required after step 1 (Bessonov, Anokhina et al. 2008); (Fabrizio, Dannenberg et al. 
2009). Thus, a large number of structural and compositional rearrangements 
accompany the assembly and catalytic process of the spliceosome. As mentioned 
above, the activation of the spliceosome and splicing catalysis requires formation of 
an active catalytic centre. In this context, the Prp2 DEAH-box ATPase is known to 
act subsequently of the U4/U6 unwinding by the helicase Brr2 but just prior to step 1 
of splicing catalysis. It was suggested that Prp2 is released from the spliceosome upon 
ATP hydrolysis. We could show that Prp2 is recruited very stably to the spliceosome 





complex, as determined by the high peptide numbers analyzed by MS. This suggested 
that Prp2 cannot hydrolyze ATP in this specific spliceosomal "snapshot", otherwise it 
would dissociate from it. This observation led us to conclude that the Bact complex is 
not yet catalytically activated. This is further confirmed by the high S value of our 
B
act
 complex (45S) and is consistent with previous studies that showed that, prior to 
ATP hydrolysis, the spliceosome has a higher S value than it has after ATP hydrolysis 
by Prp2 (Kim and Lin (1996). Despite the fact that we used a concentration of 2.0 
mM ATP during the assembly of our B
act
 complexes, Prp2 is “trapped” in Bact. This 
is because our B
act
 complexes were assembled on the truncated M3-ActΔ6 pre-mRNA 
substrate and were able to undergo pre-catalytic activation in the presence of high 
ATP but not to proceed to catalytic activation and step 1 catalysis. As step 1 catalysis 
occurs in our complex C when we used the M3-ActΔ31 pre-mRNA, which is only 25 
nucleotides longer downstream of the BPS, this led us to speculate that a longer RNA 
stretch downstream of the BPS may be required - either directly or as a protein-
binding site – to stimulate ATP hydrolysis and/or support the structural 
rearrangements that occurs during Prp2-mediated ATP hydrolysis and release. This 
assumption was in line with previous studies which postulated the importance of the 
length of the intron downstream of the BPS for step 1 catalysis (Rymond, Torrey et al. 
(1987), Cheng (1994), Fabrizio, Dannenberg et al. (2009). In addition, cross-linking 
experiments demonstrated contacts of the essential Prp2 DEAH-box ATPase with this 
intron region (Teigelkamp, McGarvey et al. (1994). Thus, B
act
 represents a 
spliceosome prior to the final catalytic step mediated by Prp2. Therefore we suggest 
that one or more factors present in our purified spliceosomal C complex may be 
required for promoting step 1 (i.e. Cwc25) (Fabrizio, Dannenberg 2009).  
The proteomic analysis of C complexes showed that at least nine proteins are 
recruited at the time of C complex formation and step 1 catalysis, these factors are 
named the C complex proteins (Figure 4.2). One of them is Cwc25, an essential 
spliceosomal factor that was recently shown to promote the first step of splicing and 
suggested to bind at or near the branch site of the pre-mRNA after Prp2 action 
(Warkocki, Odenwalder et al. (2009), (Tseng, Liu et al. 2011). We found Cwc25 only 
with low peptide numbers in the C complex (Table 3.1), indicating that Cwc25 had 





dissociation (i.e. Prp16, Slu7 and Prp18, see below) have already entered (Ohrt, 
Odenwälder et al., manuscript submitted).  
If one compares our purified pre-catalytic, but activated B
act
 complex with the first 
step spliceosome C complex, it is obvious that this transition also entails a dramatic 
remodeling. Our first step spliceosome showed a lower S value (40S) than did the B
act
 
complex. This remodeling was also accompanied by a destabilization of Prp2 and its 
co-factor Spp2 as determined by the decrease of peptide numbers analyzed by MS 
(Table 3.1). Additionally we observed a decreased number of peptides for proteins 
belonging to the U2 associated SF3a and SF3b complexes. The SF3a/b proteins are 
required at early stages in the splicing cycle, but it is not yet clear whether they are 
required after step 1. We will discuss further the importance of the destabilization of 
the U2 SF3a/b proteins during the transition from complex B
act
 to C below, together 
with our dcFCCS data.  
The proteomic analysis of C complexes showed also a recruitment of spliceosomal 
factors which are known to act at later stages of the splicing reaction and include also 
the so-called “second step factors” that comprise Prp16, Slu7, Prp18 and Prp22 
(Umen and Guthrie (1995). Prp17 is also a second step factor but it is already present 
at the time of B
act
 complex formation, which is consistent with recent observation that 
Prp17 plays a role in step 1 of the splicing reaction (Sapra, Khandelia et al. 2008). 
Thus, Prp17 can be considered as a bona fide step 1 factor. Surprisingly, we also 
detected all members of the trimeric disassembly NTR complex (Ntr1, Ntr2 and 
Prp43) in our C complex preparations. The NTR plays a role at a later stage of the 
splicing cycle, during the disassembly of the spliceosome after completion of splicing. 
One explanation for the unexpected association of the NTR with the spliceosome is 
that the splicing machinery might initiate turnover of the stalled spliceosomes due to 
the mutation or the lack of the 3’SS in our pre-mRNA substrate (Pandit, Lynn et al. 
2006). 
In summary, the proteins present in complex C likely comprise the complete list of 
proteins required to maintain a functional RNP machine in which step 1 is catalyzed 
(Fig. 4.2) As the complete set of known step 2 factors is present in complex C, this 





mRNA substrate. The limited number of proteins recruited during the B
act
 to C 
transition revealed by this work has already offered the possibility of investigating 
step 1 and 2 catalysis in vitro using purified components of known composition 
(Warkocki, Odenwalder et al. 2009) and also gave us the opportunity of learning more 
about protein dynamics during catalytic activation and step 1 catalysis as revealed by 
dcFCCS in the second part of this work (Ohrt, Prior et al. 2012). 
 
4.6 Compositional dynamics correlate with structural changes 
Our EM analyses showed that the B, B
act
 and C complexes exhibit distinct typical 
shapes (Figure 4). Complex B images have triangular/rhombic shapes which are very 
similar to corresponding images obtained for human and Drosophila B complexes 
(Deckert, Hartmuth et al. 2006), (Herold, Will et al. 2009). In addition, structural 
features which were first described for the human complex (Boehringer, Makarov et 
al. 2004), like head, neck, stump and foot, are also discernible in the yeast B complex. 
This suggests that higher order interactions and the general spatial organization of 
spliceosomal subunits are also conserved among metazoans and yeast. The most 
evident difference between B complexes from yeast and man lies in the size of the 
head region, which is substantially smaller in yeast. The structural heterogeneity 
observed for complex B's head domain in other organisms (Boehringer, Makarov et 
al. 2004);(Deckert, Hartmuth et al. 2006), is also seen in the yeast complex, but here 
the degree of heterogeneity is less pronounced. B and B
act
 are structurally very 
different, in agreement with substantial differences in protein/RNA composition and 
the profound compositional remodeling during the B to B
act
 transition. Remodeling 
also leads to a change in sedimentation behavior – from 40 to 45S – during this 
activation step. 
Our EM studies indicated that there are profound structural differences also between 
the 2D class averages of Bact and C. This is also reflected in the S value which drops 
from 45S to 40S for the less compact appearing C complex. The reason for the 
observed structural differences were found only in later studies (Warkocki, 
Odenwalder et al. 2009) and result from remodeling event occurring concomitant with 
the transformation of the B
act





for 5'SS cleavage in complex C. Thus, consistent with mechanistic differences 
between B
act
 and C, their 2D structures suggest differences in their spatial 
organization. EM immunolabeling of spliceosomal components and 3D 
reconstructions may allow a more precise determination of the structural differences 
between B
act
 and C spliceosomes. 
 
4.7 Suitability of dual color Fluorescens Cross Correlation Spectroscopy 
(dcFCCS) for investigating spliceosomal protein dynamics 
With the experiments done in this work we demonstrated that dcFCCs is, in 
combination with the established in vitro reconstitution system of functional 
spliceosomes, a powerful approach to investigate dynamics of purified spliceosomes. 
For dcFCCS measurements, yeast spliceosomes were stalled before step 1 by using 
the temperature-sensitive mutant prp2-1 yielding a B
actΔPrp2
 spliceosome. It was 
shown by the work of Warkocki et al (2009) that highly purified B
actΔPrp2
 can be 
catalytically activated to form B* when supplemented with recombinant Prp2 and 
Spp2 splicing factors (Warkocki, Odenwalder et al. 2009). Purified B
actΔPrp2
 
complexes assembled on actin pre-mRNA labeled at its 5’ end with the red 
fluorescent dye Atto647N were used. Proteins were labeled in vivo by fusing the 
protein of interest with a fluorescent protein EGFP (enhanced green fluorescent 
protein) by genetic modification. As in any study involving the introduction of bulky 
labels, there was a risk of label-induced impaired behavior. In the system described 
here, neither the label on the pre-mRNA nor those on the various proteins impaired 
the activity of the spliceosomes examined. The resulting doubly fluorescent-labeled 
and purified spliceosomal complexes were analyzed before and after catalytic 
activation by Prp2 and were found to be stable under our dcFCCS conditions as 
demonstrated for Snu114-EGFP. Snu114 is known to bind to the spliceosome 
throughout the splicing cycle (Fabrizio, Laggerbauer et al. 1997) (Fabrizio, 
Dannenberg et al. 2009) and was therefore used as a ‘‘positive control’’ in our 
experiments. The dcFCCS results of our complexes were sufficiently reproducible 






4.8 Prp2-mediated transformation of the Bact into the B* complex 
substantially alters the binding affinity of several proteins at the catalytic 
core of the spliceosome 
Although the essential role of Prp2 in the catalytic activation of the spliceosome was 
established earlier, its mechanism of action has remained enigmatic (Kim and Lin 
(1996). The structural change the spliceosome undergoes upon Prp2-mediated, ATP-
dependent activation must be profound, given the substantial change in S value seen 
between the precursor B
actΔPrp2 
complex (45S) and the catalytically activated 
spliceosome B* (40S) (Kim and Lin (1996); Warkocki, Odenwalder et al. (2009). We 
expanded our MS data by dcFCCS showing that the binding affinity of at least seven 
proteins, i.e., the U2 SF3a/b proteins Prp11 and Cus1, the RES complex protein 
Bud13, Cwc24, Cwc27, Yju2, and Cwc25, is quantitatively and qualitatively altered 
by Prp2-mediated catalytic activation of the spliceosome. Due to their characteristics 
in their binding behavior, these proteins can be divided into three groups. The first 
group comprises Cwc24, Cwc27, and Bud13, which are tightly bound to the B
actΔPrp2
 
spliceosome and which dissociate almost completely (Cwc24 and Cwc27) or partly 
(Bud13), even under near-physiological conditions upon Prp2-mediated activation 
and conversion to the B* complex. The second group includes the SF3a/b proteins 
Prp11 and Cus1, whose binding to the spliceosome is weakened by the catalytic 
activation thus becoming salt-sensitive, such that they dissociate from the B* complex 
at higher salt concentrations, while staying associated with the B* spliceosome at 
non-stringent conditions (Fig. 3.18). The third group contains proteins whose binding 
to the spliceosome is enhanced during the B
act
 to B* transition and includes Yju2 
(which is recruited at the stage of the B
act
 complex and which is more weakly bound 
prior to catalytic activation) and Cwc25 (which before the transition was not bound at 
all and is thus recruited to B*). Both proteins are known to be required for the first 






4.9 Cwc24 functions in the generation of an active spliceosome but is not 
required for splicing catalysis per se 
There is little known about the function of Cwc24 and Cwc27 in splicing. Cwc27 
contains a peptidylprolyl isomerase and also has an evolutionarily conserved 
counterpart in the human spliceosome, NYCO-10 (Ohi, Link et al. (2002); Fabrizio, 
Dannenberg et al. (2009), but nevertheless, Cwc27 is not essential for the growth of S. 
cerevisiae under standard conditions (Winzeler, Shoemaker et al. (1999),Giaever, Chu 
et al. (2002). In contrast, Cwc24 is known to be essential for yeast growth, and it is 
needed for the splicing of the U3 snoRNA precursor in vivo (Goldfeder and Oliveira 
(2008). Our results that Cwc24 and Cwc27 dissociate almost quantitatively from the 
spliceosome during or after the Prp2-mediated catalytic activation of the spliceosome 
(Fig. 3.15) was the first indication that they are not required for catalysis of the 
splicing reaction per se. This fact led us to investigate the role of Cwc24 in splicing in 
more detail. The depletion and reconstitution experiments, done in our laboratory, 
confirmed that the presence of Cwc24 is necessary for splicing to proceed through the 
first catalytic step in vitro (Ohrt, Prior et al. 2012). Surprisingly, they also showed that 
Cwc24 is not required during the actual catalysis; catalytically activated B* 
complexes that had lost all of their Cwc24 were still able to perform the first catalytic 
step of splicing efficiently when complemented with the step 1 factor Cwc25 (Fig. 
3.14B). Thus, the function of Cwc24 must be to assist in the assembly or the 
maturation of the activated spliceosome B
act
. Consequently, we regard Cwc24 as an 
assembly factor for the B
act
 complex that is probably involved in generating the 
correct structure or conformation of the B
act
 complex. Therefore it will be interesting 
to find out which proteins of the B
act
 complex are direct interaction partners of Cwc24 
and whether it also binds to spliceosomal RNAs or the pre-mRNA.  
Earlier in this work, we showed that the proteins of the RES complex are recruited to 
the spliceosome at the time of the B complex and that it is stoichiometrically present 
in B
act
 (Table 3.1 and Figure 4.2). Our dcFCCS results demonstrate that the RES 
protein Bud13 loses its affinity for the B* complex. Previous studies showed that the 
RES complex is not essential for yeast viability, but is required for efficient splicing 
in vitro and in vivo. The work by Dziembowski et al. (2004) demonstrated that the 





nucleus (Dziembowski, Ventura et al. (2004). Our present results are consistent with 
the idea that the RES proteins remain associated with the spliceosome until Prp2-
mediated catalytic activation of the spliceosome and first step of catalysis to prevent 
the premature nuclear release of unspliced pre-mRNA. 
 
4.10 Sf3a/b proteins remain bound to the B* spliceosome under near-
physiological conditions, but their binding is reduced at high salt 
Our dcFCCS data revealed clearly that Prp2-mediated ATP hydrolysis affects the 
binding affinity of the SF3a/b complexes (Fig. 3.18). We demonstrated that 
representative proteins of the Sf3a/b complex, Prp11 and Cus1, remained bound to the 
spliceosome under physiological salt conditions (i.e. 75 mM KCl). However, a 
destabilization of their interaction with the B* complex could be analyzed by the loss 
of their binding affinity at higher salt conditions. In human B/B
act
 complex, several 
SF3a/b proteins bind to the pre-mRNA on both sides of the BS (Gozani, Potashkin et 
al. (1998), and a similar function may likely be ascribed to their counterparts in yeast. 
Indeed, Hsp155, the yeast homolog of human SF3b155, cross-links to pre-mRNA 
close to the BPS (McPheeters and Muhlenkamp (2003). Thus, the destabilization of 
proteins, losing their binding affinity upon Prp2-mediated ATP hydrolysis, could 
expose the BPS adenosine for nucleophile attack at the 5’SS phosphodiester bond, 
due to rearrangement of the spliceosome near the BPS.  
There are somewhat conflicting reports regarding the fate of the U2-associated SF3a/b 
proteins during catalytic activation. Our MS data showed that the U2 SF3a/b proteins 
were represented in similar quantities in B and B
act
, nevertheless, in the C complex 
their presence was reduced to 20%–30%. In the B* and C complexes, prepared from 
B
actΔPrp2
 by complementation in vitro, the same U2 proteins were found by MS to be 
similarly abundant in the B
actΔPrp2
, B*, and C complexes (Warkocki, Odenwalder et al. 
(2009). In a recent paper (Lardelli et al. 2010), it was reported that endogenous yeast 
C complexes arrested in vivo by the effect of a cold-sensitive Prp16 mutant and 
subsequently purified from whole yeast extracts contained virtually no U2 proteins. In 
the present work, we found that, under dcFCCS conditions (i.e., spliceosomes 





concentration), the U2 proteins Prp11 and Cus1 are not released either from complex 
B* or from complex C. We believe that the results shown here correspond most 
closely to physiological reality because dcFCCS allows spliceosomes to be 
investigated directly in solution and in equilibrium without requiring 
biochemical/physical perturbation of the sample. The differences described above 
could be due simply to the U2 proteins having an intermediate binding affinity after 
catalytic activation of the spliceosome so that their continued presence in B* and/or C 
complexes is sensitive to small changes in the spliceosome’s physical environment. 
Since in all cases, either truncated pre-mRNAs or mutated RNA helicases were used 
to arrest the spliceosome at the desired stage, it is also possible that, in extract, discard 
mechanisms are responsible for the removal of the U2 proteins from dead-end 
spliceosomal complexes. Very recently it was shown in our laboratory that the U2 
SF3a/b proteins remain bound to the spliceosome during the entire spliceosomal cycle 
and the U2 snRNP is released during disassembly of the spliceosome as an intact 
particle (Fourmann, Schmitzova et al. 2013). 
 
4.11 Prp2 action creates high-affinity binding sites for the step 1 factors Yju2 
and Cwc25 in the catalytically activated spliceosome 
Yju2 is one of the factors which needs the ATP-dependent Prp2-mediated activation 
of the spliceosome for stable integration. Of all the proteins studied here by dcFCCS, 
Yju2 has the lowest affinity for the B
actΔPrp2
 spliceosome and can be completely 
removed from it at 300 mM salt. After Prp2-mediated catalytic activation, the 
spliceosome’s binding affinity for Yju2 is strongly enhanced, and its association 
becomes largely salt-resistant. These results evidenced that Prp2 has to function 
before Yju2 to create a high-affinity binding site for stable integration. Thus, it is 
possible to conclude that the stable integration of Yju2 is Prp2-dependent. 
Additionally we demonstrated that the first step factor Cwc25 is recruited after Prp2 
has acted. No peptides were found for Cwc25 in our Bact complex preparations as 
revealed by MS analysis. However, via dcFCCS we clearly showed that after catalytic 






4.12 Substantial Prp2-mediated remodeling during catalytic activation of the 
spliceosome 
The ability to isolate and to purify spliceosomal complexes stalled at distinct stages of 
the splicing cycle and to characterize their proteome was a milestone towards the 
understanding of the ongoing processes at the core of the splicing machinery during 
its activation. We showed a dramatic change in the protein composition during the 
transition from the B
act
 to C complex, including the destabilization of the U2 proteins 
and RES complex as revealed by MS. Thus, to expand our MS data, we measured the 
effect of the catalytic activation on the binding strength of at least seven proteins in 
this first application of dcFCCS to functional spliceosomes. Of theses, Bud13, Prp11 
and Cus1, all belong to multiprotein complexes containing additional proteins. Bud13 
is a member of the RES complex, which comprises two additional proteins, Prp11 and 
Cus1 belong to the U2 snRNP associated multiprotein complexes SF3a/b which 
consist of two (SF3a) or six additional proteins (SF3b) (see Figure 4.2). The dcFCCS 
results from this work are in line with our MS data. Thus, we imply that the 
interaction of at least 17 proteins with the spliceosome is affected by the Prp2-
mediated catalytic activation of the spliceosome (Fig. 4.3). 
 
Figure 4.3: Schematic representations of the substantial remodelling the B
act 
spliceosome undergoes during the Prp2/ATP-mediated catalytic activation. 
Cwc24, Cwc27, the RES protein Bud13, Prp2 and Spp2 are released while the U2 SF3a/b proteins are 
destabilized by Prp2/ATP such that the BS adenosine becomes available for a nucleophile attack at the 
5' SS phosphodiester bond. At the same time high affinity binding sites are created for Yju2 and 






Based on our data we addressed the question whether Prp2 is the only 
ATPase/helicase responsible for these dramatic rearrangements at the catalytic core of 
the spliceosome. The MS analysis of B
actΔPrp2
 complexes from the work of Warkocki 
et al. (2009) showed a complete absence of the other helicases Prp5, Sub2 and Prp28, 
which are required for earlier steps of spliceosome assembly. The only spliceosomal 
helicase that is stoichiometrically present in the B
act
 complex is Brr2, which is known 
to trigger together with the GTPase Snu114 the precatalytic activation of the 
spliceosome by disrupting U4/U6 interaction (Bartels, Klatt et al. 2002); (Small, 
Leggett et al. 2006).  
It was recently shown that the obligate ATPase Brr2, together with Prp43, functions 
in the dissociation of the post-splicing complexes that contain the intron lariat (Arenas 
and Abelson 1997); (Small, Leggett et al. 2006), suggesting that Brr2 could also be 
involved in catalytic activation, together with Prp2. However, we demonstrated earlier 
that the Prp2-dependent shift in S value from ~ 45S to ~40S during catalytic 
activation takes place in the presence of all rNTPs (not only ATP) (Warkocki, 
Odenwalder et al. 2009). In this work we showed that, upon Prp2-mediated catalytic 
activation, the dissociation of individual proteins, such as Cwc24-EGFP, occurs in the 
presence of UTP with efficiency equal to that in the presence of ATP (Fig. 3.15). 
Based on our results we can exclude the possibility that Brr2 contributes to 
spliceosome remodeling during catalytic activation due to the fact that yeast Brr2 
hydrolyzes only ATP and no other rNTP, while Prp2 is rNTP unspecific (Kim, Smith 
et al. 1992). This would imply that Prp2 alone is responsible for the many changes in 
molecular interactions that take place during the transformation of B
act
 into the B* 
spliceosome.  
The assumption that Prp2 is alone responsible for the ongoing processes at the time of 
catalytic activation at the spliceosome’s core suggests a cascade of remodeling steps 
during the B
act
 to B* complex transition. One possible consideration for such a 
substantial remodeling model would be that Prp2 has only a single substrate and that 
only one protein is displaced from the network of intermolecular interactions in the 
B
act
 complex and that this process triggers all subsequent rearrangements. A possible 
Prp2 target could be Cwc24, as it is very stably bound in the B
act
 complex but loses its 





the recent demonstration of a direct interaction between Cwc24 and Cef1 is of interest 
(Goldfeder and Oliveira 2008). Cef1 is a core protein of the NTC complex, which acts 
as a major assembly platform, integrating and coordinating many molecular 
interactions in B
act
 and B* complexes (Tsai, Chow et al. 1999); (Hogg, McGrail et 
al.). An alternative primary target of Prp2 could be one of the U2 SF3a/b proteins, 
which are known to interact with the pre-mRNA near the BPS. We cannot entirely 
exclude, however, that Prp2 may act on a number of targets, altering in succession the 
binding affinities of various proteins. This question could potentially be answered by 
performing a time-resolved analysis of the dissociation of various proteins and by 
determining the number of ATP molecules that are hydrolyzed during the 
transformation of a B
actΔPrp2
 to a C complex.  
It is also unclear which RNA structure(s) in the spliceosome is/are the primary 
target(s) of Prp2/ATPase activity or whether Prp2 affects protein-protein interactions 
directly. Prp2 has been cross-linked to the region between the BPS and the 3’SS 
(Teigelkamp, McGarvey et al. 1994), raising the possibility that Prp2 modulates 
interactions between the BPS region and the U2 proteins. Alternatively, contact with 
this stretch of RNA might merely be required to stimulate Prp2/ATPase activity. It is 
also possible that Prp2/ATPase activity modulates the U2 RNA conformation during 
catalytic activation (Hilliker, Mefford et al. 2007); (Perriman and Ares 2007), which, 
in turn, could lead to the rearrangement of protein-RNA and protein-protein 
interaction at the catalytic core. Clearly, more information is needed about the direct 
contact sites of Prp2 on the B
act
 spliceosome and about the timing of the Prp2-
mediated structural changes of the spliceosome to understand this important and 
profound structural reorganization step. In conclusion, the studies described in this 
work show that our isolated and purified complexes are well suited for structural and 
biochemical investigations and that dcFCCS can contribute significantly to these 






5. Future perspectives 
Our recently established affinity-based methods allowed us to isolate and characterize 
yeast spliceosomal complexes at defined functional stages (Dannenberg et al, 2012). 
In addition, it gave us the opportunity to carry out an investigation of the poorly 
understood conformational rearrangements in the spliceosome's catalytic core that 
occur prior to and during/after step 1 catalysis, using several approaches described in 
detail in this work. For example, by applying fluorescence-spectroscopic methods 
such as dcFCCS (in collaboration with Prof. J. Enderlein, Univ. of Göttingen) coupled 
with an in vitro reconstitution system (Warkocki, Odenwalder et al. 2009), we 
investigated the dynamics of the spliceosome’s protein composition during catalytic 
activation by the RNA helicase/ATPase Prp2. We show that the binding affinity of a 
surprisingly high number of proteins is significantly changed during catalytic 
activation, suggesting remarkable Prp2-mediated structural rearrangements in the 
spliceosome’s catalytic core (Ohrt, Prior et al. 2012). We have already expanded our 
studies and followed structural changes and the kinetics of protein recruitment/release 
during step 2 catalysis by dcFCCS. Our data show that the step 2 factors Slu7 and 
Prp18 are needed to displace the step 1 factor Cwc25 from the spliceosome and that 
this displacement occurs immediately before step 2 catalysis and, in addition another 
RNA helicase/ATPase, Prp16, is involved (Ohrt et al., submitted). Thus, these studies 
have already paved the way for a deeper understanding of the action of Prp16, a 
crucial RNA helicase essential for step 2 catalysis. Additional studies including 
essential RNA helicases/ATPases required after step 2 catalysis, as for example Prp22 
and Prp43, will also be undertaken in the future, to follow structural changes and the 
kinetics of protein recruitment/release during their action by dcFCCS and FRET (with 
Prof. J. Enderlein).  
Additional main goals will also be to investigate molecular details of the 
transformation of the yeast Commitment complex to A complex and the pre-catalytic 
B to B
act
 complex, both of which involve dramatic structural rearrangements. For 
example, the latter rearrangement includes the displacement of all U4/U6 proteins and 
the stable integration of about 20 new proteins [i.e. the Prp19 (NTC) complex and the 
NTC-related proteins] into the newly formed B
act
 complex (Fabrizio et al., 2009). This 





expressed NTC and NTC-related proteins (in collaboration with Dr. Vlad Pena). With 
this system we will dissect the requirements for the Brr2-mediated dissociation of the 
U4/U6 base pairing which initiates activation and the role of proteins in restructuring 
the U6 and U2 snRNAs and in assembling the catalytic core RNP domain. 
Additionally, our isolated CC2 could be used for in vitro reconstitution of A 
complexes upon addition of purified U2 snRNPs and recombinant Prp5. 
In collaboration with Prof. H. Stark’s group, we have obtained a 3D Cryo-EM 
structure of the yeast B
act
 complex at 20-25 Å resolution. To learn more about the 
structural organisation of individual snRNPs, we will localise important proteins and 
RNA regions within the B
act
 complex by immunoelectron microscopy. Using 
genetically tagged proteins, it would now be possible to map the position of selected 
proteins (e.g., Cwc2, Prp2 and Prp19) in purified yeast B
act 
complexes, providing 
initial insight into the location of the spliceosome's catalytic centre. A second major 
focus will be to determine the spliceosome's 3D structure at higher resolution, which 
we will pursue mainly by a combination of single-particle electron cryomicroscopy 
(with Prof. H. Stark). Our EM studies will be conducted mainly on reconstituted and 
purified yeast spliceosomes – with the hope of isolating sufficient quantities of all of 
the interesting intermediates formed during spliceosome activation and catalysis – 
with the goal of obtaining cryo-EM structures with 10-15 Å resolution or even higher. 
In collaboration with Prof. H. Stark, our laboratory is currently testing a variety of 
methods, including the optimization of buffer and pH conditions and mild 
crosslinking procedures, to optimize stabilization and thus reduce conformational 
heterogeneity of spliceosomes. At the same time, we will extend our EM studies to 
locate specific proteins and RNA regions to other spliceosomal complexes (i.e. B and 
C). The topographical data obtained in this way, in combination with biochemical and 
cross linking data on the spatial organisation of RNAs and proteins, will be of great 
value for the interpretation of the 3D cryo-EM structures. With the availability of 3D 
cryo-EM maps of yeast spliceosomes at higher resolution in the near future, crystal 
structures of individual spliceosomal proteins can be fit into the 3D EM maps, and 
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7.1 List of abbreviations 
 
3’SS   3‘ splice site 
5’SS    5‘ splice site 
°C    degree celsius 
A    adenosine 
ADP    adenosine-5‘-diphosphate 
AMP-PCP   5-adenylyl methylenediphosphonate 
APS    ammonium peroxy sulfate 
ATP    adenosine-5‘-triphosphate 
bp    basepair 
BPS   branch point sequence 
C    cytosine 
CC   Commitment complex 
Ci    Curie 
CV   column volumes 
Da    Dalton 
dcFCCS  dual-color Fluorescence cross correlation spectroscopy 
DNA    deoxyribonucleic acid 
dNTPs   deoxynucleotide-5‘-triphosphates 
DTT    1,4- dithiothreitol 
EDTA   ethylendiamine-N, N, N‘, N‘-tetraacetic acid 
EM   Electron microscopy 
fmol    femtomole 
G    guanosine 
G-75/150  gradient buffer containing 75 mM or 150 mM KCl 
GDP    guanosine-5’-diphosphate 
GTP    gunosine-5’-triphosphate 
h    hour(s) 
kDa    kilo-Dalton 





Lsm    Like-Sm 
μ    micro 
μl    microliter 
μm    micrometer 
μM    micromolar 
M    molar 
min    minute 
ml    milliliter 
mM    milimolar 
mRNA   messenger RNA 
MS    mass spectrometry 
n    nano 
nM    nanomolar 
nmol    nmol 
NP-40   Nonidet P-40 
nt    nucleotide 
NTPs    nucleotide-5’-triphosphates 
OD    optical density 
PAA    poly-acrylamide 
PAGE   poly-acrylamide gel electrophoresis 
PCI    phenol-chloroform-isoamylalcohol 
PCR    polymerase chain reaction 
PEG    polyethylene glycol 
pmol    picomole 
pre-mRNA   pre-messenger RNA 
Prp    pre-mRNA processing 
RNA    ribonucleic acid 
RNP    ribonucleoprotein 
RT    room temperature 
S    Svedberg 
S. cerevisiae   Saccharomyces cerevisiae 
SDS    sodium dodecylsulfate 





snRNA   small nuclear ribonucleic acid 
snRNP   small nuclear ribonucleoprotein 
T    thymidine 
TBE    tris-borate-EDTA buffer 
TE    Tris-EDTA buffer 
TEMED   N, N, N’, N’-tetramethylethylendiamine 
Ts   temperature-sensitive 
U    uridine 
U snRNA   uridine rich small nuclear ribonucleic acid 
U snRNP   uridine rich small nuclear ribonucleoprotein 
UV    ultraviolet 
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